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Kwame Afari Appenteng, PhD 
University of Pittsburgh, 2009 
 
Prostate cancer incidence and mortality rates continue to be higher among African Americans 
than Caucasians. While psychosocial factors may explain some of the disparities, the role played 
by genetic differences in the two racial groups is not so clear.  Emerging evidence suggests an 
important role of chronic or recurrent inflammation in prostate carcinogenesis. Interleukin-1 (IL-
1) and IL-6 are inflammatory genes reported to be associated with prostate cancer risk. 
Interleukin-1 and IL-6 cytokines also decrease bone mineral density (BMD) by inducing 
osteoclasts to resorb bone matrix. We sought to determine if genotypes of IL-1A, IL-1B, IL-1RN, 
IL-6 and IL-6R were associated with prostate cancer risk, as well as with selected risk factors, in 
the two racial groups. 
We examined allele frequency distributions of polymorphisms in IL-1A, IL-1B, IL-1RN, 
IL-6 and IL-6R genes in a cross-sectional study of African American and Caucasian men ages 40 
to 80 years old. We also assessed the associations of genotypes of these inflammatory genes and 
the risk of prostate cancer in a case-control study of the two racial groups. Additionally, we 
evaluated the associations of bone mineral density and prostate cancer in our sample. We found 
racial differences in minor allele frequencies, as well as in the associations of single nucleotide 
polymorphisms of inflammatory genes IL-1 and IL-6 and prostate cancer. We also found 
associations of IL-1 and IL-6 genotypes and prostate cancer. Additionally, we found an inverse 
association of BMD and prostate cancer in both racial groups. Our findings support a growing 
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body of evidence that chronic or recurrent inflammation play an important role in prostate 
carcinogenesis, and the possibility of ethnic based differences in susceptibility. Understanding 
the role of IL-1 and IL-6 genes in the development of prostate cancer is of great public health 
significance because it will enable their possible use as biomarkers for early detection and 
prompt intervention, increase our understanding of the molecular biology of the disease, open up 
new avenues for prevention and treatment, as well as explain some of the observed disparities in 
the disease. 
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1.0  INTRODUCTION 
Prostate cancer incidence and mortality rates continue to be higher among African Americans 
than Caucasians. While psychosocial factors may explain some of the disparities, the role played 
by genetic differences in the two racial groups is not so clear.  Emerging evidence suggests an 
important role of chronic or recurrent inflammation in prostate tumorigenesis. Interleukin 1 (IL-
1) and IL-6 are inflammatory cytokines reported to be associated with prostate cancer risk. 
Additionally, these cytokines decrease bone mineral density by causing resorption of bone 
matrix via osteoclast activity. Several studies have reported an association between BMD and 
cancer of the breast, endometrium and prostate. These studies have primarily assessed BMD as a 
proxy measurement of a lifetime exposure of specific organs to sex-steroid hormones, among 
others. The molecular factors that contribute to racial disparities in prostate cancer risk are still 
unclear. The disease is initially androgen dependent but rapidly becomes androgen independent, 
and refractory to therapy. Inflammatory cytokines such as IL-6 have been reported to influence 
clinical outcome by mediating the transition from androgen dependence to androgen 
independence. There is a compelling role of chronic or recurrent inflammation in prostate cancer 
development based on genetic, histopathology, and epidemiologic studies. However, the role of 
IL-1 and IL-6 in prostate cancer risk and in explaining observed racial disparities in the disease 
are not clearly understood. 
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The main objective of the current study is to assess whether there are differences in allele 
frequencies of inflammatory cytokines IL-1 and IL-6 gene polymorphisms among African 
American and Caucasian men, which may partly explain the observed disparities in prostate 
cancer incidence and mortality rates between the two racial groups. It is also aimed at 
understanding whether BMD is associates with prostate cancer in the two racial groups. The 
aims of the current study therefore are to: 1) investigate allele frequencies of polymorphisms of 
IL-1 and IL-6 genes among African Americans and Caucasians, 2) determine whether genotypes 
of IL-1 and IL-6 are associated with prostate cancer in the two racial groups, and 3) determine if 
bone mineral density is associated with prostate cancer in African Americans and Caucasians.   
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2.0  REVIEW OF THE LITERATURE 
2.1 EPIDEMIOLOGY OF PROSTATE CANCER 
Prostate cancer is a major public health problem in the United States. It is the most common 
nonskin cancer, and the third leading cause of cancer related death among men in the United 
States1. According to the American Cancer Society, there will be approximately 186,320 new 
cases of prostate cancer in the United States in 2008; in the same year 28,660 men will die from 
the disease1. African Americans are more likely to be diagnosed with and die from the disease as 
are White Americans 2. Figure 2.1 shows age-adjusted prostate cancer incidence and mortality 
rates among AA and Caucasians men ages 50 years and older (1974 to 2004; constructed using 
SEER 9-registry data). While socioeconomic and hormonal differences are thought to be 
contributory factors 2-4, the role played by differences in sequence variants of cytokines in the 
inflammation pathway of these two populations have not been comprehensively examined as part 
explanation for these disparities.  
Recently research efforts have focused on the important role of inflammation in the 
pathogenesis of prostate cancer. Chronic or recurrent inflammation is known to increase the 
incidence of malignancies of the bladder, colon, endometrium, esophagus, liver, lung and 
pancreas 5-9. Similarly, evidence from epidemiologic, genetic, molecular biology and 
histopathology studies have suggested a compelling role of inflammation in the development of 
prostate cancer 10-13. The precise mechanism by which inflammation causes cancer is not clearly 
understood, but it is thought that chronic or recurrent inflammation, which may be a result of 
immunological conditions, recurrent microbial infections, or chemical irritation, trigger the 
production of inflammatory cytokine mediators and genotoxic reactive oxygen radicals that 
increase cell proliferation and promote tumorigenesis 14. The likelihood of developing cancer 
may then be dependent upon host response to this inflammatory cascade 15.  
 
SEER (9-registry) age-adjusted invasive prostate cancer incidence 
and mortality rates in U.S. Black and White males, 50+yrs (1974-2004)
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Figure 2.1: Prostate cancer incidence and mortality rates 
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Efforts by numerous investigators to identify genes in the inflammation pathway that may 
be involved in prostatic carcinogenesis have partly elucidated the role of a variety of important 
susceptibility genes and cytokines in prostate cancer pathogenesis 16-20. The interleukin-1 (IL-1) 
and IL-6 family of genes have been reported to be associated with prostatic tumorigenesis 21, 22. 
Sequence variants in the interleukin-1 receptor antagonist (IL-1RN) were reported to be 
associated with prostate cancer risk in a population-based study conducted in Sweden by 
Lindmark et al 21. Additionally, endogenous IL-1 has been reported to promote the invasiveness 
of malignant cells of the prostate by initiating and completing the process of angiogenesis 23. 
Interleukin-6 regulates the growth and differentiation of prostate carcinomas 24. Sivashanmugam 
et al have shown that IL-6 is involved in the initiation and progression of prostate cancer by 
mediating the lysophosphatidic acid-regulated cross-talk between stromal and epithelial cells of 
the prostate gland 25. The important role of IL-6 in this regard is evidenced by the fact that 
neutralization of IL-6 activity abrogates the conditioned medium (CM) induced mitogenic 
extracellular signal regulated kinase 1 and 2 (ERK) and signal transducer and activator of 
transcription 3 (STAT3) in LNCaP cells 25. Additionally, clinical studies have shown that 
elevated circulating plasma levels of IL-6 and its soluble receptor are associated with prostate 
cancer progression and metastasis 26-28.  
In addition to playing an active role in the initiation and progression of prostate cancer, 
IL-1 and IL-6 have been shown to influence bone mineral density 29, 30.  Both of these cytokines 
are known to decrease bone mineral density by resorption of bone matrix through osteoclast 
activity 31, 32. Furthermore, serum levels of IL-1 and IL-6 have been found to be associated with 
bone loss 33, 34. There are estrogen-dependent changes in the production of these two genes which 
potentially modify their bioactivity. As a result of  decreasing estrogen levels with age, the bone 
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resorption activity of  IL-1 and IL-6 increases thereby accelerating the rate of bone loss; however 
administration of hormone replacement therapy decreases the rate 29. In addition to estrogen, 
other hormones such as testosterone, parathyroid hormone, and insulin-like growth factor 1 
(IGF-1) are known to influence bone mineral density by regulating IL-1 and IL-6 related 
osteoclast activities 35-38. Moreover, these same factors, as well as others, such as high calcium 
intake, and low vitamin D levels, are considered risk factors for prostate cancer 35, 39-44.  
 To ascertain the long term effect of serum levels of  IL-1 and IL-6 on the pathogenesis of 
prostate cancer, there is the need to obtain serial measurements over many years, but this has 
been difficult, resulting in discrepant findings by various epidemiologic studies 26-28, 45. Since 
bone mass reflects a lifetime exposure to IL-1 and IL-6-related osteoclast activity, bone mineral 
density should serve as a possible surrogate marker for cumulative exposure to these pro-
inflammatory cytokines, as well as prostate cancer risk. 
2.2 PROSTATE CANCER BIOLOGY 
The prostate gland is part of the genitourinary system in men, and surrounds the neck of the male 
bladder and urethra46. It is partly glandular and partly muscular, and has ducts which open into 
the prostatic portion of the urethra. It measures approximately 3cm x 4cm x 2cm (the size of a 
walnut), and weighs about 20gm in adults46. The exact function of the prostate gland has not 
been fully defined; however, epithelial cells lining the prostatic glandular acini secrete fluid that 
becomes a component of seminal fluid47. Additionally, these luminal epithelial cells secrete 
7 
 
prostate specific antigen (PSA), a protease that cleaves seminal proteins likely to maintain the 
fluidity of seminal fluid47.  
2.2.1 Anatomy of the Prostate 
There are no true lobar structures in the adult prostate; the generally accepted zones are as 
described by McNeal, and consist of a peripheral zone representing 70% of the glandular bulk, a 
central zone which forms 20% of the glandular weight, a transitional zone of 5% of the gland, 
and a non-glandular anterior fibromuscular zone of stroma48, 49. The peripheral zone comprises 
all the apical and most of the subcapsular area, representing the region of cancer susceptibility. 
The central zone is thought to be of Wolffian ductal origin and less than 1% of all prostate 
cancers arise from this zone46. Most benign prostate hyperplasia (BPH) forms in the transitional 
zone11, which is located in a para-urethral position in the mid-prostate. Carcinoma in this region 
is uncommon (<20% of all cancers), although it represents isolated tumor formation noted 
histologically following transurethral prostate resection46.  The boundary between the transitional 
zone and the peripheral zone forms the basis of the ‘capsule’ morphologically noted between 
benign and malignant-bearing tissues46. The prostate rests on the pelvic diaphragm, and 
communicates with a complex network of blood supply and lymphatic drainage in the 
hypogastric region. This communication network explains the metastatic spread of prostatic 
carcinoma to the sacrum, ileum, and lumbar spine. 
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2.2.2 Histological Features 
Greater than 70% of prostate cancers are adenocarcinomas that arise from the peripheral zone50. 
Microscopic foci of latent prostate cancer are found commonly on autopsy, but may appear early 
in life51. Approximately 30% of men over 50 years of age have evidence of  latent disease, but 
because of the very slow growth rate of these microscopic tumors, many never develop to 
clinical disease50. In the normal prostate, each acinus consists of a layer of luminal columnar 
epithelial cells and a layer of basal cells, surrounded by stromal tissue, including smooth 
muscle47, 52. These acini are connected to each other, and form a ductal system that empties into 
the prostatic urethra. It is uncertain which cells are at risk of becoming cancerous, but it has been 
suggested that a cell with a phenotype that is intermediate between a stem cell and an epithelial 
cell is most likely to undergo neoplastic transformation53.  Foci of prostate cancer typically 
consist of a lining of tumor cells surrounded by a lumen. These acini are often small and have 
lost the characteristic papillary infoldings of an acinus, and the component tumor cells have large 
nuclei47. Once these cells become cancerous, they undergo architectural changes, the extent of 
which can be described by a histologic grading system referred to as the Gleason scoring system. 
2.2.3 Grading 
Grading is used to evaluate the aggressiveness of malignant neoplasm, and is based on the idea 
of cell differentiation. Differentiation refers to the extent to which cells resemble comparable 
normal cells. Well –differentiated tumors are composed of cells resembling the mature normal 
cells, poorly differentiated tumors have unspecialized cells46. The Gleason system is the most 
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widely used classification, and it evaluates the architecture of the neoplasia and its relation to the 
stroma. It defines five patterns and considers a primary (or predominant) and a secondary (or 
least –abundant) pattern, thereby defining a total score or sum ranging from 2 to 10. Typically a 
Gleason score of seven or greater is considered to be histologically poorly differentiated. 
2.3 RISK FACTORS 
There are many risk factors for prostate cancer; these include age, race, androgens, family 
history,  diet, obesity, sexually transmitted infections, vitamin D deficiency, and benign prostatic 
hyperplasia47. The strength of association of each of these risk factors with prostate cancer varies 
from one risk factor to another, as shown in Table 2. Brief discussions of a few of the strong risk 
factors are discussed below, other risk factors are incorporated in subsequent text. 
2.3.1 Age 
Age is the strongest factor influencing the development of prostate cancer; clinical disease rarely 
occurs before age 40 years46, and the incidence increases markedly after age 60 years50.  
2.3.2 Race 
There are wide disparities in prostate cancer incidence and mortality rates in the United States. 
African-Americans have approximately twice the incidence and mortality rates as Caucasians54. 
Additionally, African-Americans appear to develop the disease at an earlier age50. Prostate 
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cancer incidence and mortality rates for Asian/Pacific Islander, American Indian/Alaskan Native, 
or Hispanic are substantially lower than those for Caucasians54. 
2.3.3 Family history 
Prostate cancer risk increases between two- and threefold in men with a first degree relative 
(brother or father) in whom the disease was diagnosed at an early age55. The risk is even higher 
with increasing number of first degree relatives with the disease56. The role of inheritance in the 
development of prostate cancer is further buttressed by findings of twin studies which have 
shown higher concordance for prostate cancer diagnosis among monozygotic than dizygotic 
twins 57. 
2.3.4 Androgens 
Men who have diminished androgen production due to castration, hypogonadism, or enzyme 
defects of androgen metabolism, such as 5-alpha reductase, have minimal risk for prostate 
cancer58. In a prospective cohort study, Gann et al reported that high pre-diagnosis levels of 
plasma testosterone was associated with prostate cancer, and an inverse trend was seen with 
increased levels of sex hormone-binding globuline59.  
2.3.5 Etiologic model 
Figure 2.2 shows a proposed etiologic model which integrates host and environmental factors 
relevant to the current research that may be involved in the development of prostate cancer. In 
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this model polymorphisms of inflammatory cytokines such as IL-1 and IL-6, which may be 
determined by race, influences cytokine concentration as well as an individual’s susceptibility to 
infection, which may include sexually transmitted diseases (STDs). Infection of the prostate by a 
pathogen, whether viral or bacterial, causes cell damage and results in prostate inflammation, as 
well as elevation of cytokine levels. This process may be mediated by cytokine gene 
polymorphisms. Chronic or recurrent prostate injury and inflammation may result in the 
formation of proliferative inflammatory atrophy (PIA) lesions, and subsequently prostatic 
intraepithelial neoplasia (PIN), and prostate cancer. Race and age are established risk factors of 
prostate cancer. Levels of hormones such as androgens and estrogens are influenced by race and 
age. These sex steroid hormones are known to be associated with prostate cancer risk, but also, 
they are known to influence bone health. High androgen levels, for example, are associated with 
high BMD. On the other hand the inflammatory cytokines IL-1 and IL-6 decrease BMD by 
inducing osteoclasts to resorb bone. Therefore, BMD reflects long term interplay of opposing 
factors: those such as sex steroid hormones which cause bone formation, and others such as 
cytokines which cause bone resorption.  Since the prostate gland is chronically under the 
influence of these sex steroid hormone and cytokines, BMD may therefore serve as a surrogate 
marker of long term exposure of the prostate gland to these hormones and cytokines.   
Race
Genetic polymorphisms
 inflammatory cytokines
(IL-1 / IL-6)
Hormones
BMD
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Figure 2.2 : Proposed etiologic model 
2.4 PROSTATE CANCER DEVELOPMENT AND PROGRESSION 
Androgens are believed to contribute to the development and progression of prostate cancer47. 
Androgen-dependent tumors can be successfully treated with androgen ablation therapy; 
however, the cancer eventually recurs as an androgen independent tumor and is no longer 
responsive to treatment60. Therefore, the progression from androgen-dependence to androgen-
independence is a very important component of prostate cancer development. Recent studies 
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have shown that androgen-independent activation of the androgen receptor mediates the 
progression of prostate cancer in the absence of androgen60, 61. Interleukin-6 is a pro-
inflammatory cytokine that has been shown to regulate prostate cancer growth and to activate 
androgen receptor-dependent gene expression in the absence of androgen60, 61. Indeed, the 
important role of inflammatory cytokines in the development of cancer is not limited to the 
prostate gland, but to several other cancers5, 8, 62.  
2.4.1 Inflammation and Cancer 
Chronic or recurrent inflammation is known to increase the incidence of malignancies of the 
bladder, colon, endometrium, esophagus, liver, lung and pancreas5-9. Even though infectious 
agents and environmental conditions are involved in several of these cancers, inflammation often 
increases cancer development even further by collaborating with environmental conditions such 
as dietary derived toxins63.  It has been suggested that inflammatory cells and cytokines found in 
tumors are more likely to contribute to tumor growth, progression, and immunosuppression than 
they are to mount an anti-tumor effect 6.   
The exact mechanism by which inflammation causes cancer is unclear, but it is thought to 
comprise a complex series of events involving the innate and adaptive immune systems 14, 62, 64-
66. Activated phagocytic inflammatory cells of the innate immune system are known to release 
highly reactive chemical compounds, which includes superoxides, hydrogen peroxide, singlet 
oxygen and nitric oxide, which causes oxidative or nitrosative damage to DNA in the epithelial 
cells, or react with other cellular components such as phospholipids, thereby initiating a free-
radical chain reaction67.  These events result in host epithelia cell damage or death, and in order 
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for the epithelium to maintain its barrier function, resident progenitor and/or stem cells undergo 
cell division to replace the damaged or dead cells. Epithelial cells that undergo DNA synthesis in 
the setting of these DNA damaging agents are at an increased risk of mutation67. 
One mechanism by which inflammatory cells aid disease progression is by migration 
through the extracellular matrix resulting from the release of proteolytic enzymes. Facilitation of 
epithelial cell invasion into the stromal and vascular compartments ultimately results in the 
metastasis of tumor cells 64, 65.  In another mechanism, the disruption of cytokine production and 
regulation, including cytokine deficiencies, leads to increased inflammation and cancer, whether 
in response to an infectious agent or to chemical carcinogens 68. Additionally, cell-mediated anti-
tumor immune surveillance mechanisms can be dampened by certain immune responses, thereby 
averting an immune reaction against the tumor that could potentially eliminate the cancer 69.  
The important role of oxidant and nitrosative stress in prostate carcinogenesis is 
evidenced by epidemiologic data which has shown that consumption of certain dietary 
antioxidants is associated with reduced prostate cancer risk.  For example, several 
epidemiological studies have correlated low selenium with an increased risk of prostate cancer 70-
73. Additionally, a randomized, placebo controlled clinical trial of selenium supplementation for 
the prevention of recurrent nonmelanoma skin cancer (the Nutritional Prevention of Cancer 
Study) showed a decrease in incident prostate cancer (overall RR 0.51, 95% CI 0.29-0.87), 
especially in men with low selenium levels at study entry74, 75. Inflammatory cells are also known 
to secret cytokines that promote epithelial cell proliferation and stimulate angiogenesis23, 76. In 
human multiple myeloma the malignant cells are home to the bone marrow where they stimulate 
stromal cells to secrete the inflammatory cytokines IL-1, IL-6 and TNF. The cytokines stimulate 
myeloma cell growth and promote resistance to therapy 77. In mouse models of metastasis, 
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treatment with IL-1RN significantly decreases tumor development. This suggests that local 
production of IL-1 aids in the development of metastasis, because IL-1RN is known to inhibit the 
actions of IL-178. Furthermore, mice deficient in IL-1B were found to be resistant to the 
development of experimental metastasis 79. 
2.4.2 Inflammation and Prostate Cancer 
The role of inflammation in the development of prostate cancer has been examined by several 
epidemiologic studies through the assessment of the association between prostatitis, and sexually 
transmitted infections with the disease 80-85.  Additionally, genetics and molecular pathology 
studies have increased current understanding of the role of inflammation in prostate 
carcinogenesis 57, 86-90.  Much of the evidence has arisen from studies which assessed the use of 
nonsteroidal anti-inflammatory drugs (NSAIDS) in prostate cancer, but results have been 
inconsistent91-96. 
2.4.3 Prostatitis and prostate cancer 
Prostatitis manifests clinically with symptoms of dysurea, perineum pain, painful ejaculation, 
and urinary frequency 97. It may be classified as acute or chronic based upon National Institute of 
Health (NIH) consensus classification 98.  In this classification, there are four distinct categories 
of prostatitis namely: acute bacterial, chronic bacterial, chronic prostatitis/chronic pelvic pain 
syndrome and asymptomatic inflammatory98. This classification was instituted in 1999 by the 
NIH in an effort to better formalize the diagnostic criteria of prostatitis 98. Acute bacterial 
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prostatitis is usually caused by Escherichia coli (E. coli)99, whereas chronic prostatitis may be 
caused by several other organisms including E. coli 100, 101.   
 Even though several epidemiologic studies have reported an association between 
prostatitis and prostate cancer 80-85, there are a number of factors which makes the exact role of 
inflammation difficult to study: first, the incidence of prostatitis is uncertain. While the incidence 
of prostatitis in men aged 40 years and over is between 5-10% there are many men with the 
condition who are asymptomatic102. Moreover, men with symptomatic prostatitis are diagnosed 
with prostate cancer more frequently due to increased frequency of biopsy103, 104. Finally, the 
offending pathogen is often unknown in many cases of symptomatic prostatitis105, 106.  These 
findings appear to imply that host inflammatory responses rather than the cause of the 
inflammation (infectious agent or chemical compounds) leads to cancer development. 
2.4.4 Sexually transmitted infections (STI) and prostate cancer 
An association between sexually transmitted infections and prostate cancer has been reported by 
several epidemiologic studies; while some of these studies relied on self-report107, 108, others 
were based on serologic markers107, 109-111 and prostate tissue112, 113.The direction and strength of 
association noted by these studies may be confounded by various factors: the case control 
studies, and also those which assessed STI status based on interviewing and self-report were 
subject to interviewer and recall bias. Also, the use of antibiotics to treat common STI such as 
gonorrhea, Chlamydia, and syphilis is likely to markedly reduce the incidence of prostatitis 
caused by these agents. Moreover, infectious agents with oncogenic properties, such as human 
papillomavirus (HPV) may influence prostate carcinogenesis independent of inflammation 13. 
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Nevertheless the odds of developing prostate cancer in men with a history of gonorrhea or 
syphilis increases from 1.6 to 3.3 with three or more episodes of gonorrhea107, indicating that 
recurrent inflammation may be mediating development of the disease. 
2.4.5 Molecular pathology 
There are certain characteristic features of the molecular pathogenesis of prostate cancer which 
highlight the role inflammation in the development of the disease: these include the somatic 
inactivation of gluthathione S-transferase pi gene (GSTP1) and the strong possibility that 
(proliferative inflammatory atrophy) PIA lesions are prostate cancer precursors114-116. 
Gluthathione is a tripeptide with antioxidant properties, whose conjugation to various reactive 
chemical species, including oxidants is catalyzed by the enzyme gluthathione S-transferase 
(GST)116. Silencing of GSTP1 transcription accompanies somatic CpG island hypermethylation; 
this results in the loss of GSTP1 expression, and is almost always accompanied by the 
development of prostate cancer116.  Expression of GSTP1 is typically induced to high levels at 
sites of prostatic inflammation and loss of GSTP1 expression is characteristic of prostatic 
intraepithelial neoplasia (PIN) lesions and prostatic carcinoma115, 116. 
2.4.5.1 Proliferative inflammatory atrophy 
Proliferative inflammatory atrophy (PIA) is a term used to describe focal prostate lesions 
comprised of prostate epithelial cells which are atrophic but have a high proliferative index116. 
These cells show many signs of stress, which include the induction of GSTP1 and 
cyclooxygenase-2 (COX-2) expression, as well as features of cells thought to be intermediate in 
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the differentiation between basal epithelial cells and columnar cells53, 116-118. PIA lesions are 
often found near early adenocarcinoma lesions119 and high grade prostatic intraepithelial 
neoplasia (PIN), which are precursor cancer lesions120. Furthermore, GSTP1  CpG island 
hypermethelation, which is present in 90% of prostate cancer cases, has been found in 6.3% of 
PIA lesions121. Loss of GSTP1 function has the tendency to mark the transition between PIA 
lesions and PIN lesions; which is consistent with the possibility that compromised defenses 
against inflammatory oxidants may initiate carcinogenesis of the prostate114. 
2.4.6 Genetics 
Of all human cancers, prostate cancer has been reported to show the greatest hereditability risk 57, 
86-88. The role played by genetics in the development of prostate cancer has been suggested by 
segregation analyses and linkage studies of familial prostate cancer, which have hinted at 
specific prostate cancer susceptibility genes; as well as by twin studies which have compared 
prostate cancer incidence between monozygotic and dizygotic twins57, 86, 122, 123. However, the 
molecular pathogenesis of prostate cancer displays a great deal of heterogeneity between 
individuals as well as within the affected organ124. Currently, the identified somatic gene 
abnormalities associated with prostate cancer are very diverse, implying that there is not a single 
dominant molecular pathway required for prostate cancer development114, 124. Besides somatic 
genes, numerous germline prostate cancer susceptibility genes have been identified125-127.  
Support for the role of inflammation in the pathogenesis of prostate cancer is further buttressed 
by linkage and association studies of genes encoding factors involved in infection response, 
19 
 
oxidant defense enzymes, and inflammatory cytokines. These include RNASEL, MSR1, MnSOD, 
hOGG1, IL-1, and IL-6. 
2.4.6.1 RNASEL 
Ribonuclease L (RNASEL) is a gene in the innate immune system which encodes a widely 
expressed latent endoribonuclease that is involved in interferon-inducible RNA degradation 
pathway128. It is activated upon viral infection and has been reported by some studies as a 
candidate prostate cancer susceptibility gene17, 18, 128, but not by others129.  A study by Carpten et 
al found that variant RNASEL alleles Glu256X and Met1Ile encoded defective enzymes and were 
linked to prostate cancer in certain families18. The Arg462Gln allele also encodes a defective 
RNASEL enzyme which has three times less enzymatic activity than the wildtype130. Casey et al 
reported that the fraction of prostate cancer in the population attributable to the Arg462Gln 
RNASEL allele was approximately 13%130. Rokman et al noted a higher risk of familial but not 
sporadic prostate cancer for Gln homozygotes131.  Furthermore, a recent study by Urisman et al 
identified a novel gammaretrovirus named Xenotropic MuLV-related virus (XMRV) in stromal 
cells of 40% of prostate cancer patients homozygous for the R462Q variant of RNASEL132.  The 
exact mechanism by which defects in an interferon inducible RNA degradation pathway causes 
prostate cancer is not certain, but is thought to result in decreased interferon-alpha antiviral 
activity and deficiencies in induction of apoptosis 133. Shea et al reported no significant 
association between RNASEL or RNASEL-inhibitor polymorphisms and prostate cancer risk in 
the Afro-Caribbean population129. 
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2.4.6.2 MRSI 
The macrophage scavenger receptor-1 (MSR1) is a macrophage plasma membrane spanning 
protein that is capable of binding a variety of ligands, including bacterial lipoteichoic acid, as 
well as oxidized high-density lipoprotein and low density lipoprotein in the serum134. The MSR1 
gene is located on 8p22, an area of frequent allelic loss in prostate cancer 19, 134. Rare germline 
MSR1 mutations have been linked to prostate cancer susceptibility in some families at high risk 
for prostate cancer 19. In addition, the nonsense mutation Arg293X has been detected in 
approximately 3% of men with sporadic prostate cancer compared to 0.4% of unaffected men 
(p=0.047)19. A population case-control study of African American men found the Asp174Tyr 
MSR1 allele in 6.8% of prostate cancer cases and 3.6% in non-cases (p=0.14)20. The exact 
mechanism by which defects in macrophage function might lead to prostate cancer is not clearly 
understood, however, mice models show vulnerability to Listeria monocytogenes, 
Staphylococcus aureus, E. coli, and Herpes simplex virus type 1134-136. 
2.4.6.3 MnSOD 
Manganese superoxide dismutase (MnSOD) encodes a mitochondrial enzyme that protects cells 
against oxidative damage137. Reactive oxygen species produced during chronic inflammation and 
other mechanisms involving oxidative stress are thought to play an important role in prostate 
carcinogenesis137. Superoxide dismutases are located in several human organs, including the 
prostate gland 138, 139. In the Alpha-Trocopherol, Beta-Carotene Prevention Study, the Ala16Val 
allele of MNSOD was associated with an increased risk of prostate cancer (OR 1.72, CI 0.96-
3.08 for AlaVal homozygotes)140. Variants of hoGG1, another gene involved in repair of 
oxidative genome damage, were found to be associated with increased prostate cancer risk 141. 
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2.4.7 NSAIDS and Aspirin use and Prostate Cancer 
Several recent studies have evaluated the association of aspirin and NSAIDs use and prostate 
cancer risk91, 93, 94, 142-144. Overall, the results of these studies show that aspirin and NSAIDS have 
a protective effect against prostate cancer; however, there are apparent inconsistencies.  The 
retrospective studies conducted in Canada and France found no significant association between 
NSAID use and the risk of prostate cancer whereas the prospective studies conducted in the U.S. 
found significant associations. A possible explanation for the lack of association in the 
retrospective studies may be detection bias. Participants who use NSAIDS on a regular basis for 
many years are likely to be health conscious people who also receive frequent medical care, and 
are therefore more likely to be screened for prostate cancer.  Detection bias may also account for 
the observed reduction in advanced cases of prostate cancer among aspirin users as these patients 
are more likely to be diagnosed at the early stage of the disease. This is because regular and long 
term aspirin use is likely to be a result of physician prescription, and patients under routine 
physician care are more likely to be screened for prostate cancer, leading to early detection. The 
prospective studies conducted in the U.S all showed a statistically significant protective effect of 
aspirin and NSAID against prostate cancer, except for the study by Leitzmann et al. They 
reported a protective effect only for those with metastatic disease who took aspirin for a 
minimum of 22 days each month, but this was not statistically significant. Besides the studies 
conducted by Perron et al and Jacobs et al, none of the other studies appears to have directly 
addressed the effect of dosage and duration of NSAIDS/aspirin use in relation to prostate cancer.  
Perron’s study utilized information from the Quebec health insurance system database, Regie de 
l’assurance maladie du Quebec (RAMQ), which keeps detailed prescription medication 
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reimbursement records of residents of Quebec aged 65 years and older.  It was a well powered 
study, and had access to detailed exposure data, and reported a stronger inverse association for 
larger doses of aspirin, but only among those who used it for 4 years or more. However, because 
the study relied on database information it could not account for non-prescription NSAIDS or 
aspirin use, a factor which could have influenced the results. The study by Jacobs et al was a well 
powered prospective study which obtained detailed dosing and duration information, and found 
an inverse association among participants who used at least 30 pills of aspirin or NSAIDS each 
month for a minimum of 5 years. Roberts et al also found an inverse association, which increased 
with age, but they did not address the effect of dosing. Also, like other prospective studies, 
information on the use of aspirin and other NSAIDS were obtained at study beginning only, 
however, reported aspirin/NSAIDS use may change over the course of a study, and this can 
potentially result in misclassification.  In spite of these pitfalls, there is overwhelming evidence 
from these studies that the use of aspirin and other NSAIDS reduces the risk of prostate cancer, 
thus buttressing the role of inflammation in prostate carcinogenesis. 
2.5 INFLAMMATORY CYTOKINES AND PROSTATE CANCER 
2.5.1  INTERLEUKIN-6 (IL-6) 
The IL-6 gene is located on chromosome 7p21145. It contains four introns and five exons, and 
encodes a precursor protein consisting of 212 amino acids with two intrachain disulphide bridges 
and a 28-residue hydrophobic signal sequence, which has a molecular mass of 21-28 kDa145, 146. 
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The gene is expressed in diverse cell types including fibroblasts, endothelial cells, keratinocytes,  
monocytes,  macrophages, T-cells and B-cells, and a variety of tumor cells including the prostate 
gland147. IL-6 is not constitutively produced under normal circumstances, but its expression is 
readily induced in response to several stimuli, such as, viral infections, exposure to 
lipopolysaccharides, and to other cytokines including IL-1, TNF-alpha, platelet-derived growth 
factor, IL-3 and granulocyte macrophage-colony stimulating factor148-152. Both protein kinase C- 
and cAMP-dependent signal transduction pathways are involved in IL-6 gene induction151, 153. 
Interleukin-6 is involved in regulating immune and inflammatory responses154. In 
addition to inducing terminal differentiation of B-cells it synergizes with IL-1 in activating T-
cells by inducing IL-2 responsiveness, and enhances the differentiation of cytotoxic T 
lymphocytes from thymic precursors146, 155, 156. It has a central role in the acute-phase response, 
acting on hepatocytes to increase the synthesis of acute-phase proteins (haptoglobin, fibrinogen, 
C-reactive protein,etc) and reducing the secretion of albumin and transferein157. It also 
contributes to the body’s defenses by increasing the body temperature and stimulating the release 
of adrenocoticotropin hormone158-160. Other functions include: impairs natural killer cell 
function; induces bone resorption; stimulates osteoclast formation; induces experimental cancer 
cachexia; induces platelet-derived growth factor in blood vessels; enhances proliferation of 
vascular smooth muscle; negative inotropic effect on cardiac myocites; enhances secretion of 
chorionic gonadotrophin from trophoblasts154. 
2.5.1.1  Interleukin-6 receptors 
Interleukin-6 receptors are found in a wide variety of cell types including epithelial cells, neural 
cells, fibroblasts, hematopoietic cells, neural cells, B and T cells, macrophages and prostate146. 
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The IL-6 receptor consists of two molecules, an 80-kDa IL-6 binding protein (alpha chain), and a 
130-kDa signal transducer, gp130 (beta-chain)161, 162.   Cytokine receptors lack intrinsic kinase 
activity, therefore the IL-6R must interact with another molecule that is capable of recruiting 
secondary intracellular messengers. Binding of IL-6 with IL-6R triggers the association of IL-6R 
with 2 copies of a 918-amino acid transmembrane protein known as gp130163. Binding of IL-6R 
and gp130 stabilizes the interaction between receptor and ligand, resulting in an apparent 
increase in binding activity163.  
2.5.1.2 Intracellular Signal Transduction 
The first step in the intracellular signal transduction cascade is the homodimerization of gp130, 
which is triggered by IL-6/IL-6R binding leading to recruitment and activation of non-receptor 
protein tyrosine kinases. Activation of 2 distinct pathways then occur: 
1) The Janus Kinase (JAK) – signal transducers and activators of transcription (STAT) 
pathway. 
2) The mitogen-actvated protein kinase (MAPK) pathway. 
2.5.1.3 The JAK-STAT transduction pathway 
The Janus kinase (JAK) family of kinases contain both a kinase and a pseudokinase domain in 
series164. Once activated, this family of kinases phosphorylates and activates STAT transcription 
factors, particularly STAT3, which then moves into the nucleus to activate transcription of genes 
containing STAT3 response element.  A series of intracellular events may lead to activation of 
the MAPK pathway. MAPK in turn activates other downstream factors, including additional 
transcription factors such as serum response factors (SRF). These factors respond to many other 
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signaling pathways, but together they regulate a variety of complex promoters and enhancers that 
respond to IL-6 and other signaling factors. Besides the JAK-STAT and MAPK transduction 
pathways IL-6 is thought to mediate cellular activities through other pathways such as the 
phosphatidylinositol 3-kinase pathway165. 
2.5.1.4 Interleukin-6 and disease 
In 1987 Hirano et al demonstrated the possible involvement of the deregulated expression of the 
IL-6 gene in polyclonal B-cell abnormalities in patients with cardiac myxoma166. Since then, 
much evidence has shown that deregulation of IL-6 production could be involved in a variety of 
diseases, including autoimmune, inflammatory and malignacies146. Polymorphisms of IL-6 have 
been shown to be associated with various cancers, such as cervical, oral, colorectal, ovarian 
cancer, prostate cancer and plasmacytoma22, 167-171.   
The attention of investigators were drawn to the role of IL-6 in prostate cancer 
development based on observations by that the disease transitioned from an androgen-dependent 
tumor, initially responsive to androgen ablation therapy, to an untreatable androgen independent 
tumor60. In-vitro studies by Siegall et al showed that the androgen-independent cell lines DU145 
and PC3 and the androgen-dependent cell line LNCaP expressed IL-6R on their surfaces, and all 
three cell lines were susceptible to a chimeric Pseudomonas exotoxin-IL-6 toxin. Susceptibility 
was mediated by IL-6R as cytotoxic activity was blocked in the presence excess human 
recombinant IL-6172. Since then, the expression of mRNA for IL-6R and the gp130 signal 
transducer has been confirmed in human prostate cancer by other investigators172-174.  
Furthermore, recent in-vitro studies have shown that IL-6 initiates and promotes prostate 
tumorigenesis by mediating cross-talk between stromal and epithelial cell of the prostate25.  
26 
 
Sivashanmugam et al used a co-culture cell assay to identify messangers involved in the 
cross-talk between human prostate stromal PS30 and epithelial LNCaP cells. After stimulation 
with lisophosphatidic acid (LPA), the mitogenic extracellular signaling regulated kinase (ERK) 
signaling pathway in PS30 were activated, but not LNCaP25. Co-culture of PS30 and LNCaP 
cells resulted in the activation ERK in LNCaP that was further increased in response to LPA. 
When animals were implanted with a mixture of both PS30 and LNCaP tumor cells, they 
developed larger tumors with higher frequencies compared to LNCaP cells alone.  Protein 
analysis demonstrated that treatment of the PS30 cells with LPA induced synthesis of IL-6. By 
antibody neutralization experiments, it was determined that IL-6 is responsible for the LPA-
induced mitogenic signaling and growth of the LNCaP cells. A major finding of this study was 
that activation of G protein-coupled receptors (GPCRs) expressed in prostate stromal cells 
induced the secretion of factors that promoted mitogenic signaling of epithelial cells. Therefore, 
GCPRs regulate the cross-talk between stromal and epithelial prostate cells, which plays an 
important role in the initiation and progression of prostate cancer. Interleukin-6 is a major 
mitogenic growth factor secreted from PS30 cells in response to stimulation with the GPCR 
ligand LPA25. Other in-vitro studies have indicated that IL-6 induces the progression of prostate 
tumor epithelial cells175, 176. Additionally, several investigators have reported elevated serum 
levels of   IL-6 upon progression of prostate cancer to androgen independence26.   
2.5.1.5 Serum interleukin-6 and prostate cancer 
The correlation between serum IL-6 levels and clinical features of prostate cancer has been 
evaluated by several studies. Twillie et al reported elevated serum IL-6 levels in 47%  of 73 
patients with advanced hormone refractory prostate cancer177. They measured IL-6 
27 
 
concentrations in the ejaculate plasma of healthy men, in primary culture of prostate epithelial 
cells, in human prostate cancer cell line cultures and in severe combined immunodeficiency 
mouse xenografts and in the plasma of 73 men with metastatic adenocarcinoma of the prostate, 
and reported that elevated IL-6 levels are strongly correlated with objective measures of 
morbidity177. Drachenberg et al assessed the potential of serum IL-6 levels as a marker of 
disease in 407 men including 15 controls. They found significantly higher IL-6 levels in 
patients with clinically evident hormone-refractory prostate cancer compared to normal 
controls, as well as those with prostatitis, BPH, localized, and recurrent disease (p<0.01)178.  
Wise et al showed that serum IL-6 levels, and that of other cytokines IL-4 and IL-10 were 
significantly higher among patients with hormone refractory prostate cancer compared to those 
with hormone-controlled disease (p=0.02, 0.01, an 0.0001 respectively)179. Nakashima et al 
evaluated the prognostic significance of serum IL-6 levels in 74 prostate cancer patients: 23 
stage A, 14 stage B, and 37 stage C. They found that serum IL-6 was significantly correlated 
with clinical stage of prostate cancer; moreover, a serum IL-6 concentration of >7 pg/ml was 
associated with a clinically poorer survival in stages C and D (p=0.024)180.  
Another study by Shariat et al assessed plasma IL-6 and soluble IL-6R levels in 44 
healthy patients without cancer, 19 men with prostate cancer metastatic to regional lymph nodes, 
and 10 men with bone-scan proved metastatic prostate cancer. They reported that IL-6 and 
soluble IL-6R concentrations were significantly higher in patients with bony metastases 
compared to those with only node-positive disease (p<0.001), and in those with nodal metastases 
compared to organ confined disease and healthy controls (p=0.042 and 0.034 respectively). In 
another cohort of 120 consecutive patients presenting for radical prostatectomy, they found that 
IL-6 and soluble IL-6R concentrations were associated with a Gleason sum on final histology of 
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>7(p=0.042 and 0.034) and with prostatic tumor volume (p=0.048 and 0.043).  On multivariate 
analysis the preoperative concentration of soluble IL-6R but not IL-6 predicted postoperative 
biochemical progression (p<0.040), and also preoperative levels were highest in those with 
aggressive disease181. In a recent study by Michalaki et al, serum levels of IL-6 and TNF-alpha 
were found to correlate with clinicopathological features in 80 prostate cancer patients and 30 
controls. Serum IL-6 levels in patients with metastatic disease (9.3+/- 7.8 pg/ml) were higher 
than those in patients with localized disease ((1.3+/-0.8 pg/ml, p<0.001). The levels of both 
cytokines correlated with the extent of disease26.    
The findings of the aforementioned studies have been consistent in their report of a 
correlation between serum IL-6 levels and the clinical features of prostate cancer; however, 
elevated serum IL-6 levels may be reflective of the body’s inflammatory response to prostate 
cancer, rather that a cause of the disease. Therefore, the results of these studies may not be 
interpreted as necessarily confirming a pathogenic role for IL-6 in prostate carcinogenesis.  
 Besides serum IL-6 levels, a few recent studies have examined the relationship between 
IL-6 gene polymorphisms and prostate cancer risk, but with mixed result 12, 182-184. Sun et al 
tested for an association between sequence variants of IL-6 in 1,383 cases and 780 controls who 
participated in the Cancer prostate in Sweden study185. They reported no significant association 
between 6 SNPs and prostate cancer risk. This study was well powered due to its large sample 
size, but was limited by the number of tagging SNPs (total of 6) examined. In addition, the study 
population was homogeneous (all Swedish males), therefore the results may not apply to other 
races, such as African Americans who are known to have the highest rates of prostate cancer. 
Contrary to the findings of Sun et al, Tan et al. reported that the -174G to C polymorphism of  
the IL-6 gene was associated with an overall increased risk of advanced prostate cancer184. In a 
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retrospective analysis of 95 prostate cancer patients, they reported that the distribution of the 
GC/CC genotype was significantly different between patients with stage T3-T4 tumors compared 
to those with stage T1-T2 (p < 0.001)184.  They also reported that IL-6-174G to C polymorphism 
was strongly associated Gleason score (p<0.001).  Additionally, this genotype was reported to be 
significantly associated with vascular invasion, seminal vesicle involvement, capsular invasion, 
recurrent disease, and serum PSA elevation. This study was comprised of 89% Whites, 6% 
Blacks, and 5% other; however there was no stratification of the analyzed data by race, therefore 
the extent to which race/ethnicity influences IL-6 gene polymorphism, and subsequently prostate 
cancer morbidity in the study population could not be ascertained from the results. Furthermore, 
there was low power due to the small sample size. Nonetheless, this study successfully 
demonstrated a strong association of the -174G>C polymorphism of the IL-6 gene with prostate 
cancer aggressiveness and recurrence, suggesting that genetic differences in the IL-6 gene could 
be linked to prostate cancer morbidity.   
In another study, Michaud et al examined SNPs in the genes encoding IL-6, IL-1B, IL-8 
and IL-10 in 503 prostate cancer cases and 652 controls enrolled in the Prostate, Lung, 
Colorectal and Ovarian Cancer (PLCO) screening trial, to evaluate their possible role of genetic 
susceptibility within the inflammatory pathway in relation to prostate cancer182.  A total of seven 
SNPs were evaluated in the four cytokines (IL-6, IL-1B, IL-8 and IL-10), which included one 
SNP each in IL-6 and IL-8; two SNPs in IL-1B and three SNPs in IL-10. They reported no 
association between these seven SNPs and prostate cancer risk. Findings were similar even after 
stratifying prostate cancer cases by stage and grade, as well as adjusting for NSAID use182. This 
study had a large number of cases, and the nested case-control design reduced potential bias, 
however, the number of SNPs examined was too few to draw a conclusion. For example, only 
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one SNP in the IL-6 gene was examined; it is possible that other unmeasured SNPs in this and 
the other genes may be associated with prostate cancer. Furthermore, the PLCO is a screening 
trial, and prostate cancer is often detected early with PSA screening, therefore the results of this 
study may not be generalizable to men who are less likely to be screened and are diagnosed at a 
later stage in the disease. 
Zheng et al evaluated 9,275 SNPs in 1,086 genes of the inflammation pathway to assess 
their association with prostate cancer among enrollees in the Cancer Prostate in Sweden study. 
They first conducted an exploratory stage analysis in 200 familial cases and 200 unaffected 
controls, followed by a confirmatory stage analysis of 1,223 cases and 676 controls selected 
randomly from the Cancer Prostate in Sweden study. After the exploratory stage analysis 26 
SNPs including IL-6R were identified for confirmatory analysis in a larger group. Selection was 
based on the most significant p-value, allele frequency in controls similar to the reference group 
(CEPH- Utah residents with ancestry from northern and western Europe), when multiple SNPs 
within a gene were found to be significant only the most significant one was chosen. The 
confirmatory analysis resulted in three SNPs that were significantly associated with prostate 
cancer risk. One of these SNPs, cytokine receptor like factor-1 (CRLF1) was suggested to be a 
subunit of a cytokine receptor complex, and its mRNA was upregulated by several genes 
including IL-6186.   
This study was comprehensive in the number of SNPs analyzed, and had a large sample 
size to conduct both exploratory analysis in familial prostate cancer cases, as well as a 
confirmatory analysis in non-familial cases. It also provided an objective support for an 
association between prostate cancer and multiple modest-effect genes in the inflammatory 
pathway.  However, the findings of the study are limited to Swedish men, and may not be 
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generalizable to other populations, such as African Americans, who are reported to have the 
highest prostate cancer incidence and mortality rates in the world. 
 A few population-based studies have assessed the relationship between IL-6 
polymorphisms and prostate cancer risk. Two of these studies were based on a homogenous 
Swedish population, and the other two were conducted in the U.S.  Overall these studies reported 
inconsistent findings. Furthermore, none of the studies was specifically conducted to 
comprehensively evaluate racial differences in cytokine gene (IL-1 and IL-6) polymorphisms as 
part explanation for the disparities in prostate cancer risk in African Americans compared to 
Caucasians.   
2.5.2 Interleukin-1 (IL-1) 
The IL-1 family of cytokines are comprised of two signaling agonists IL-1 alpha (IL-1A) and IL-
1 beta (IL-1B), and the IL-1 receptor antagonist (IL-1RN) 187. In spite of low sequence homology 
but high structural similarity, IL-18 is now widely accepted as the fourth member of the IL-1 
family187.  Besides these primary members, there are several other genes which have currently 
been accepted as members of the interleukin-1 superfamily based on structural similarity, but 
whose exact properties have not yet been ascertained; these have been assigned a new 
nomenclature using the expression IL-1F reflecting their being part of a family of related ligands 
188. Members of the IL-1 family are produced by a wide variety of cells, including blood 
monocytes, tissue macrophages, dendritic cell, B-lymphocytes and NK cell188. 
 With the exception of IL-18, which resides on chromosome 11, all three known primary 
members of the IL-1 family are located within a 350 kb span on the q arm of chromosome 2189. 
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IL-1A, IL1-B and IL-1RN share less than 25% identity with each other but bind to a common 
signaling receptor; however, IL-18 shares approximately 18% identity with the other members of 
the IL-1 family and binds to a distinct receptor190. Each of these primary members of the IL-1 
family is initially synthesized as a precursor molecule without a signal peptide. The N-terminal 
amino acids are then removed by special proteases, resulting in ‘mature’ peptides188. For 
example, the 31 kDa precursor form of IL-1B is biologically inactive and requires cleavage by a 
specific intracellular cysteine protease called IL-1B converting enzyme (ICE). ICE, which is also 
termed capsace-1, cleaves the IL-1B and IL-18 precursors resulting in the mature form of IL-1B 
molecule (17.5 kDa) and of IL-18 molecule (18 kDa) 191. 
IL-1 and its related family members are primarily proinflammatory cytokines, and are 
known to initiate cyclooxygenate type 2 (COX-2), type 2 phospholipase A and inducible nitric 
oxide synthase (iNOS) in inflammation187. This accounts for the large amount of prostaglandin-
E2 (PGE-2), platelet activating factor and nitric oxide (NO) produced by cells exposed to IL-1 or 
in animals or humans injected with IL-1188. Additionally, IL-1 promotes the infiltration of 
inflammatory and immunocompetent cells into extravascular space by increasing the expression 
of adhesion molecule-1 (ICAM-1) on mesenchymal cells and vascular-cell adhesion molecule-1 
(VCAM) on endothelial cells188.   Interleukin-1 facilitates angiogenesis by increasing the 
expression of vascular endothelial growth factor; thereby promoting tumor metastases and blood 
vessel supply23.  
2.5.2.1 Interleukin-1 receptors 
There are two primary IL-1 receptors, IL-1 receptor type 1 (IL-1RI) and IL-1 receptor type 2 (IL-
1RII); as well as one accessory receptor protein (IL-1R-AcP)188. The IL-1RI is an 80 kDa 
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glycoprotein which has three Ig-like domains on its extracellular segment, and a Toll-homology 
domain in the cytoplasm segment192, 193. The Toll- homology domain of the IL-1R is necessary 
for signal transduction193. Interleukin-1 signal transduction is initiated by binding of IL-1 to one 
chain on the IL-1RI, and the formation of a heterodimer with a second, different receptor chain, 
termed IL-1 receptor accessory protein (IL-1R-AcP)194. The formation of the heterodimer of the 
IL-1RI with the IL-1R-AcP results in the physical approximation of the Toll homology domains 
of each chain in the cytoplasmic segments and initiates signal transduction188. Of the three 
primary IL-1 family members (IL-1A, IL-1B and IL-1RN), IL-1B has the lowest affinity for the 
cell bound form of IL-1RI. It has an even lower affinity for the soluble form. IL-1RN has the 
highest binding affinity, and a slow, nearly irreversible off-rate to the cell bound IL-1RI188.  
The IL-1RII functions as a negative or ‘decoy’ receptor195 . Its extracellular segment has 
three typical Ig-like domains, which includes a transmembrane segment and a short cytoplasmic 
domain which contains 29 amino acids in humans 196, 197. The short cytoplasmic domain is 
unable to initiate signal transduction since there is no Toll-homology domain, therefore, when 
IL-1 binds to the cell membrane, IL-1RII does not signal197. The binding affinity of IL-1 to the 
type II receptor is greatest for IL-1B, followed by IL-1A and IL-1RN respectively198 . The 
function of the type II receptor as a decoy receptor is based on the binding affinity of IL-1B to 
the cell surface form of this receptor, which prevents the ligand to form a complex with the type 
I receptor and accessory protein195. Additionally, the decoy receptor forms a trimeric complex of 
the IL-1B ligand with the type II receptor and the accessory protein, which serves to deprive the 
functional receptor type I of the accessory chain199. 
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2.5.2.2 Signal transduction 
Interleukin-1 binding causes activation of two kinases IRAK-1 (IL-1 Receptor Associated 
Kinase-1) and IRAK-2. IRAK-1 activates and recruits TNF associated factor-6 (TRAF-6) to the 
IL-1 receptor complex. TRAF-6 in turn activates two pathways, one leading to activation of 
nuclear factor kappa beta (NF-kB) and another leading to c-jun activation200. A series of 
intracellular events results in the induction of cyclooxygenase-2 (COX-2) expression by IL-1, 
which occurs through the p38 and p42/44 MAP kinase pathways201.  
2.5.2.3 Interleukin-1 and prostate cancer 
The role of IL-1 in prostate carcinogenesis has been evaluated by assessing the effect of p38 
activation on cell proliferation202. Ricote et al conducted immunohistochemical and Western blot 
analysis on 94 prostate samples comprised of normal, BPH and prostate cancer tissues. They 
reported that overexpression of p38 in BPH, and more intensely, in prostate cancer, enhances cell 
proliferation202. Furthermore,   changes in the expression patterns of members of the IL-1 family 
have been reported as relating to prostate cancer progression202-205. Evaluation of 82 prostatic 
tissues to determine the relationship between these changes and prostate cancer progression 
showed that high expression levels of IL-1A and IL-1RI in epithelial cells of BPH and prostate 
cancer samples were involved in cell proliferation; and that the loss of immune-expression of IL-
1B and IL-1RN was a characteristic feature of prostate cancer compared with normal prostate 
sample and BPH203. Interactions of sequence variants of genes in the inflammation pathway, 
including IL-1, have been found to be associated with prostate cancer risk 12, 183, 206.  In a recent 
case-control study, Sun et al analyzed 11 single nucleotide polymorphisms (four in IRAK1 and 
seven in IRAK4) among 1,383 newly diagnosed prostate cancer patients and 780 population 
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controls in Sweden. They reported that synergistic effects between variants IRAK4-7987 CG/CC 
and Toll-like receptor 6-1-10(TLR6-1-10) conferred an excess prostate cancer risk (OR=9.68, 
p=0.03)183 .  Lindmark et al evaluated the association between sequence variants of the IL-1RN 
gene and prostate cancer risk in a large population-based case-control study in Sweden21. They 
reported that the most common haplotype (ATGC) was significantly associated with prostate 
cancer (haplotype – specific p-value = 0.009). Furthermore, the association was strengthened in 
cases with advanced disease.  The findings of this study provided additional support for a role of 
chronic inflammation in the development of prostate cancer. It had a large sample size, with 
DNA samples being available from over 1380 histologically characterized cases and 779 
controls. Furthermore, the full clinical spectrum of prostate cancer was well represented, with 
over 40% of the cases having advanced disease.  However, test for Hardy-Weinberg equilibrium 
(HWE) revealed that the genotype frequencies of one of the haplotype tagging SNPs (rs315951) 
deviated significantly from expected proportions among prostate cancer cases; which may be a 
result of genotyping errors, selection bias, or population stratification. A third study by Michaud 
et al182 which examined genetic polymorphisms of IL-B and prostate cancer risk (discussed 
above) reported no significant association, but the findings were based on the analysis of only 
two SNPs in the IL-1B gene.  
To date, only three population-based studies (all of which are case-control) have 
examined the association of polymorphisms in the IL-1 gene and prostate cancer risk21, 182, 185 , 
and the findings have been inconsistent. There is some suggestion from two of these studies21, 183 
that the inflammatory cytokine IL-1 plays an important role in prostate cancer risk among 
Swedish males. It is uncertain whether polymorphisms in this cytokine have the same effect in 
African Americans and/or White Americans.  A comprehensive analysis of polymorphisms in 
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this cytokine among these two latter populations may help to elucidate the role of this gene in 
prostate cancer risk in these two racial groups.     
The most salient and relevant properties of IL-1 in inflammation are the initiation of 
COX-2, type 2 phospholipase A and inducible nitric oxide (iNOS)188. This accounts for the large 
amounts of prostaglandin-E2 (PGE2), platelet activating factor and nitric oxide (NO) produced 
by cells exposed to IL-1188. Use of aspirin and other NSAIDs has been shown to be associated 
with reduced risk of colon cancer; and aspirin use has been shown to reduce the risk of colorectal 
polyp recurrence207, 208. There are indications from laboratory studies that NSAIDS might also 
influence prostate carcinogenesis, including inhibition of prostate cancer growth and metastases 
in rodent models209.  
2.6 HORMONES AND PROSTATE CANCER 
2.6.1 Androgens 
The important effect of sex hormones on the prostate is underscored by the fact that the two 
peaks of prostatic growth are marked by periods of sex hormone increases: the first being 
puberty when there is rise in androgen level, while the second peak begins around age 50 years, 
when there is an increase in the estrogen to androgen ratio210, 211.  Testosterone is the principal 
circulating androgen secreted by the Leydig cells of the testis212. Approximately 1-2% of the 
total testosterone in the serum circulates as free testosterone; most of the circulating testosterone, 
however, are bound to two proteins (sex hormone-binding globulin and albumin)213.  Free 
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testosterone enters the prostate gland though passive diffusion, where it is converted to 
dihydrotestosterone (DHT); this reaction is catalyzed by the membrane bound enzyme, steroid 5 
alpha-reductase (SRD5A)214. Two isoenzymes have been described, SRD5A1 and SRD5A2, the 
latter being the predominant enzyme in the prostate215. After DHT is formed it binds to the 
intracytoplasmic androgen-receptor, forming a receptor-androgen complex, which is translocated 
to the nucleus216.  The binding of this complex to DNA results in increased protein synthesis, 
which eventually leads to cell proliferation216. 
2.6.2 Androgen levels and prostate cancer risk 
Testosterone and its potent metabolite dihydrotestosterone (DHT) are essential for the normal 
growth of the prostate, and may play a role in the development of prostate cancer. This is due to 
the observation that conditions which results in diminished androgen production such as 
castration, pre-puberty, hypogonadism, or enzyme defects of androgen metabolism, such as 5-
alpha reductase, almost never results in prostate cancer 58, 217, 218. Additionally, there are 
indications from recent epidemiologic studies to suggest that elevated circulating levels of 
testosterone are associated with prostate cancer risk59, 219, 220.  In a prospective cohort study, 
Gann et al found that high plasma levels of testosterone before diagnosis were associated with 
increased risk of PC; and an inverse trend with levels of sex hormone globuline59. Another study 
by Ross et al showed that young African American men have higher circulating testosterone 
levels than their White counterparts and suggest that these higher levels could promote cancer 
growth, leading to observed higher rates of cancer in African American men 221. However, other 
investigators have found no such association40, 222, 223.   Besides androgen levels, it has also been 
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suggested that genetic defects in the androgen receptor gene, which results in shorter glutamine 
(CAG) repeat lengths is associated with prostate cancer risk 224, 225.  
2.6.3 Androgen receptor (AR) 
The human AR gene locus resides on the long arm of the X chromosome and belongs to the 
super-family of ligand binding transactivation factors226. This receptor mediates the actions of 
testosterone and DHT in androgen-responsive tissues227. Alterations of the AR gene in prostate 
cancer can result in a wider array of activating steroids and non-steroid ligands228, 229. A unique, 
polymorphic polyglutamine stretch encoded by (CAG)nCAA and polymorphic polyglycine 
sequence sequence encoded by (GGN)n, are present in the human AR terminus, in addition to 
polyanaline and polyproline amino acid repeats230. Within the normal population, the number of 
glutamine repeats varies from 9-33 residues and the glycine stretch ranges between 16 and 27 
residues231.  Acidic polyproline and polyglutamine sequence motifs are thought to result in a 
transcriptional activation function when present in various proteins. Fewer numbers of glutamine 
residues in this region of the AR are associated with higher levels of gene transactivation than 
are longer repeat lengths232. Additionally, genetic variations in the length of the polyglutamine 
stretch have been implicated in the progressive nature of prostate cancer 224, 225, and in the 
neuromuscular degenerative disease known as spinal bulbar muscular atrophy or Kennedy’s 
disease 233.  
In prostate cancer, the more transcriptionally active AR with fewer polyglutamine repeat 
residues is thought to be associated with higher incidence, higher grade, and faster progression of 
the disease, whereas in Kennedy’s disease, abnormally long repeats exceeding 40 glutamine 
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residues are associated with neuronal degeneration227. The mean number of CAG repeats in 
African-Americans is approximately 20, compared with 22 in White Americans234, 235.  A series 
of epidemiologic studies have suggested that the increased risk of developing prostate cancer in 
African-Americans is related to a reduced frequency of CAG repeats in this polpulation224, 225, 236, 
237.   
2.6.4 Steroid 5 alpha-reductase type II (SRD5A2) 
There are two isoforms of the steroid 5 aplha-reductase enzyme (SRD5A1 and SRD5A2), each of 
which contains 5 exons, have 50% identity of their nucleotide sequences, and are encoded by 
different genes238.  The human type 1 isoform is present at low levels in the prostate but is the 
predominant isozyme in the skin and liver. It is encoded by a gene on the short arm of 
chromosome 5238. The SRD5A2 is located on the short arm of chromosome 2 and catalyzes the 
conversion of testosterone to the more bioactive compound, dihydrotestosterone. 
Dihydrotestosterone, has a greater affinity for the androgen receptor, which results in greater 
transactivation of androgen responsive genes239. Molecular defects in SRD5A2 are responsible 
for reduced serum and tissue DHT and inadequate virilization of the urogenital sinus and 
external genitalia observed in some infants with male pseudohermaphroditism due to deficiency 
of steroid 5 alpha- reductase enzyme240. 
A study by Reichardt et al which evaluated the distribution of a dinucleotide repeat in 
African Americans, non-Hispanic Caucasians, and Asians found more polymorphisms in this 
marker than previously reported; with some alleles being specific to African Americans241. A 
subsequent study by the same group which analyzed mutations in SRD5A2 reported one amino 
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acid substitution, V89L, which replaced valine at codon 89 with leucine242.  This substitution 
was a germline DNA polymorphism, and was noted to reduce SDR5A2 activity in vitro. The 
substitution is common among Asians and is thought to partly explain the low risk for prostate 
cancer in this group242. 
Inhibition of SRD5A2 has been shown to reduce the risk of prostate cancer243. The drug 
finasteride inhibits SRD5A2 activity, thereby blocking the conversion of testosterone to DHT244. 
Finasteride markedly suppresses serum DHT levels, and causes a major decrease in prostate 
epithelium, most pronounced in the fibromuscular  and glandular components of the prostate 
gland245.  In the Prostate Cancer Prevention Trial (PCPT) finasteride was found to be 
chemopreventive against prostatic carcinogenesis: prostate cancer was detected in 18.4% of men 
randomized to the finasteride group as opposed to 24.4% in the placebo group. This was a 24.8% 
relative risk reduction in the prevalence of prostate cancer during the trial (p<0.001)243.  These 
results prompted the early termination of the trial 15 months before the anticipated completion 
date. However, the trial also reported higher-grade disease among men in the finasteride arm of 
the study compared to controls, but it is uncertain if this finding was related to histologic or 
sampling artifact in the study243.   
2.6.5 Growth factors 
Several factors such as insulin-like growth factor-1 (IGF1), epidermal growth factor (EGF), 
keratinocyte growth factor (KGF), and transforming growth factors (TGF)-alpha and -beta, and 
their respective receptors have been reported as being expressed by prostate cancer cells, even 
though they are not produced by normal prostate epithelium246, 247. These factors are important in 
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the stromal epithelial cross-talk. Insulin-like growth factor-1 is thought to promote prostate 
tumorigenesis by stimulating cell proliferation and decreasing apoptosis246.  
In a nested case-control study of men in the Northern Sweden Health and Disease cohort 
study, Stattin et al reported an increased risk of prostate cancer in men with elevated plasma 
levels of IGF-1. They found this relation to be strongest among young men, which is suggestive 
of an early involvement of IGF-1 in the disease process246. In another nested case-control study 
of men in the Physicians’ Health Study, Chan et al found a strong positive association between 
IGF-1 levels and prostate cancer risk248. This association was noted to be independent of baseline 
prostate specific antigen (PSA) levels. Keratinocyte growth factor has also been reported as 
being involved in the development and progression of prostate cancer, in addition to other human 
malignancies249. It has been shown that in the early stages of the disease, prostate cancer cells 
produce their own KGF, which serves as a growth advantage. But in later stages of the disease, 
the KGF receptor is not expressed anymore on these cancer cells.  
2.7 BONE MINERAL DENSITY AND PROSTATE CANCER 
2.7.1 Bone Formation 
Bone formation begins as a cartilage framework which is converted to bone by endochondrial 
ossification in the long bones and vertebra; and membranous bone formation adjacent to 
cartilage in flat bones250. The primary constituents of bone are organic materials (35%) and 
inorganic materials (65%) by weight. The organic material is mostly collagen, and gives bone its 
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flexibility, whereas the inorganic materials are comprised of the minerals calcium and phosphate 
which forms a calcium phosphate crystal known as hydroxyapatite Ca10(PO4)6(OH)2 250.  During 
childhood there is periosteal apposition and endosteal resorption, which results in enlargement of 
the marrow cavities (modeling)251. However, at puberty there is both periosteal and endosteal 
apposition, resulting in rapid increase in bone mass. Towards the end of puberty, there is 
epiphyseal closure, due to influence of estrogen, after which modeling activity decreases251. The 
exact age at which bone mass peaks differs between the axial and appendicular skeleton, and 
between males and females, but is generally thought to be around age 30 years, after which 
begins to decline252. However, removal and replacement of portions of bone continues 
throughout life (remodeling)253.  Remodeling compensates for endosteal bone loss and 
weakening of skeletal structures: it is a complex process initiated by activation, a process which 
involves hormones, inflammatory factors, and stromal cells of osteoblast lineage. Bone 
remodeling is under the control of several factors, including parathyroid hormone (PTH), 
calcitonin, thyroxine, estrogen, androgens, growth hormones, vitamin-D, glucoccorticoids, 
insulin, prostaglandins, and cytokines253. An imbalance in remodeling whereby bone resorption 
exceeds bone formation results in low bone mineral density254. Bone mineral density (BMD) 
refers to the average concentration of mineral per unit area of bone255. Measurement of BMD 
primarily assesses bone calcium content, and is often used to diagnose osteoporosis255.  Very low 
BMD results in osteoporosis and may be largely due to excessive osteoclastogenesis, mediated 
by IL-1, IL-6 and TNF-alpha256-258. 
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2.7.2 Techniques for measuring bone mineral density 
            There are a variety of techniques for measuring BMD; these include single-energy x-ray 
absorptiometry (SXA); dual energy x-ray absorptiometry (DXA); peripheral densitometry; 
quantitative computed tomography (QCT); radiographic absorptiometry (RA); and quantitative 
ultrasound (QUS). Single x-ray absorptiometry uses a single x-ray energy beam for 
measurement, and a water bath to simulate soft tissue thickness. DXA scans utilize two x-ray 
beams: one at a higher energy level and the other at a lower energy level, soft tissue absorption 
is subtracted, and then the absorption of each beam by bone is used in calculating BMD255, 259. 
Peripheral DXA refers to dual x-ray absorptiometry measured at peripheral sites255. 
Radiographic absorptiometry compares the density of proximal phalanges to a wedge of 
aluminum of known densities placed on the film alongside the hand. It is used to measure bone 
density from cortical thickness260. The quantitative computed tomography scan provides three 
dimensional volumetric measurements of bones reported in mg/cc. It uses a conventional CT 
scanner with a calibration phantom, and measures both trabecular and cortical bone density, and 
is able to isolate trabecular bone for mineral content evaluation255. QUS assesses bone density 
and structure quantitatively by transmitting ultrasonic waves through bone. It is commonly used 
to assess bone density of the heel and shin. Of these techniques, the DXA is the most commonly 
used to measure BMD, and is often employed in obtaining BMD of the spine, hip, and total 
body255. 
A key measurement issue that needs to be considered when assessing BMD in 
epidemiologic studies is determining the site to be measured. Deciding whether to measure 
peripheral or central BMD depends on purpose of the study, cost considerations, age of 
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participants, expected precision and available technology. Medication use also needs to be taken 
into consideration because treatment produces smaller changes in peripheral measurements 
compared to spine or hip bone mineral density. 
2.7.3 Bone mineral density and prostate cancer 
Hormones such as estrogen, testosterone, parathyroid hormone, and insulin-like growth factor 1 
(IGF-1) are known to influence bone mineral density29, 35-38. Furthermore, these same factors, as 
well as others, such as high calcium intake, and low vitamin D levels, are considered risk factors 
for prostate cancer 35, 39, 41-44. A few epidemiologic studies have assessed BMD as a surrogate 
marker of a lifetime prostatic exposure to these various factors, but results have been mixed261-
263. Bunker et al found an increased risk of prostate cancer with increasing BMD among men 
aged 60-79 years in a cross-sectional study of 1,725 Afro-Caribbean men who were being 
screened for cancer in the Tobago Prostate Survey261.  In this study, prostate cancer risk among 
participants in the highest quartile of BMD was double that of those in the lowest quartile, 
independent of age and body mass index (OR 2.12, 95% CI 1.21-3.71, P for trend = 0.004). 
These results were consistent with the findings of the cohort analyses by Zhang et al262, which 
assessed the relationship of bone mass and subsequent prostate cancer risk in 1,012 Caucasian 
men in the Framingham study. There were 100 incident cases in the Framingham study, most of 
which were diagnosed at an older age (median age 75.2 years). Cortical bone mineral densities of 
the metacarpal bones were obtained at a mean participant age of 61 years. There was an 
increased incidence of prostate cancer in the two higher age-specific quartiles compared to the 
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lowest quartile. The risk ratio for men in the highest quartile compared to the lowest was 1.6 
(95% CI 0.9-3.0, P for trend =0.06)262.  
Contrary to the findings of these two studies, Farhat et al. found a statistically significant  
inverse association between BMD and prostate cancer in a cohort study of 4,597 men aged 65 
years and older, with no prior history of prostate cancer that were followed for an average of 5.2 
years264.  Similarly, Nelson et al found an inverse association of BMD and prostate cancer risk in 
94 men followed prospectively in the First National Health and Nutrition Examination Survey 
(NHANES I) Epidemiologic follow-up Study (NHEFS), but the results were not statistically 
significant263. BMD of the hand was measured at a mean age of 49 years, after which participants 
were followed for approximately 19 years for diagnosis of prostate cancer. The rate ratio for men 
in the highest quartile compared to the lowest was 0.72 (95% CI 0.38-1.38, P trend = 0.37)263. A 
key methodological difference that might explain the discrepant results of the NHANES study 
compared to the Tobago and Framingham studies was BMD data analysis. Whereas the 
Framingham study employed age-specific BMD quartiles, the Tobago study based the quartiles 
upon two broad age categories (45-59 years and 60-79 years).  In the NHANES study BMD 
quartiles were calculated across all age groups. Additionally, the NHANES cohort were enrolled 
at a much younger age (mean age 49 years), and may not have been followed long enough for 
prostate cancer to develop (total follow-up time was 19 years).  
2.7.4 Interleukin-1 and IL-6 and bone mineral density    
 The major factor driving low BMD is an imbalance in bone resorption which exceeds bone 
formation; this occurs due to excessive bone resorption ability of osteoclasts.  Interluekin-1 and 
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IL-6 play a central role in bone turnover by stimulating osteoclastogenesis, a key factor 
responsible for increasing bone resorption30. Functional polymorphisms of IL-1 and IL-6 have 
been reported to be associated with bone mineral density38, 257, 265-268. Kim et al examine the 
relation between IL-1 and IL-1RN polymorphisms and BMD in 202 postmenopausal Korean 
women. They reported that women carrying the A2 allele of the IL-1 RN gene had a significantly 
lower BMD than those without the allele, and the A2 allele was more common in osteoporotic 
women than in those without osteoporosis265 Nemetz et al reported that the presence of the IL1B-
511 allele was associated with significantly lower Z scores and a higher risk of osteopenia  and 
osteoporosis in patients with irritable bowel disease268.      
Moffett et al evaluated the relationship between the IL-6 G-174C polymorphism and 
BMD, the rate of decline in BMD, and the risk of fracture in 3376 Caucasian women aged 65 
years and older among participants in the Study of Osteoporotic fractures (SOF) 257. They 
reported the lowest BMD of the proximal and distal radius among women with the G/G 
genotype, intermediate in heterozygotes, and highest in women with the C/C genotype (p < 
0.05). In addition, women with the C/C genotype experienced a slower rate of decline in total hip 
and femoral neck BMD compared with the G/G genotype (p < 0.05)257.  In another study 
Lorentzon et al investigated the IL-6 G-174C polymorphism in relation to BMD during and after 
puberty in 90 teenage males, and reported that participants with the CC genotype had a higher 
BMD of the femoral neck and lumbar spine, compared to those with the GG genotype (p < 
0.5)38. These findings of an association between IL-6 gene polymorphisms and low BMD have 
been corroborated by several other studies30, 267, 269-271. A study by Ota et al in which 192 sibling 
pairs of Japanese women from 136 families were genotyped for microsatellite polymorphisms in 
or near IL-6, IL-6R, calcium-sensing receptor (CASR), and matrix Gla protein (MGP) genes, 
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found that the IL-6 locus was linked to a decrease in BMD ( T value for all women = -2.0405; 
postmenopausal women = -2.406; p values <.05).  
To ascertain the long term effect of serum levels of  IL-1 and IL-6 on the pathogenesis of 
prostate cancer, there is the need to obtain serial measurements over many years, but this has 
been difficult, resulting in discrepant findings by various investigators 26-28, 45. Since bone mass 
reflects a lifetime exposure of bone to IL-1 and IL-6, bone mineral density should serve as a 
possible surrogate marker for cumulative exposure of the prostate to these inflammatory 
cytokines.  
2.8 SIGNIFICANCE 
 
The molecular factors that contribute to prostate cancer risk as well as racial disparities in 
morbidity and mortality are not clearly understood. Evidence from epidemiologic, genetic, 
molecular biology and histopathology studies suggest a compelling role of chronic or recurrent 
inflammation in the development of prostate cancer. The disease is initially androgen dependent 
but rapidly becomes androgen independent, and refractory to therapy. Inflammatory cytokines 
such as IL-6 have been reported to influence clinical outcome by mediating the transition from 
androgen dependence to androgen independence. However, the role of IL-1 and IL-6 in prostate 
cancer risk and in explaining observed racial disparities in the disease are not clearly understood. 
Understanding how these various factors influence prostate carcinogenesis is of great public 
health significance because it will enable their use for early identification of those at increased 
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risk of the disease. This may result in early detection of the disease, and prompt intervention. 
Additionally, it will increase our understanding of the molecular biology of the disease, which 
may open up new avenues for prostate cancer prevention and treatment. It may also help to 
explain some of the observed racial disparities in prostate cancer risk.  
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3.1 ABSTRACT 
Objective: To assess allele frequencies of inflammatory cytokines IL-1A, IL-1B, IL-1RN, IL-6 
and IL-6R gene polymorphisms among African American and Caucasian men.  
Methods: We conducted a cross-sectional study of 286 African-American (AA) and Caucasian 
men ages 40-80y who were controls in the Cancer and Prostate Study (CAPS) and enrolled 
between 2001 and 2006. Tagging single nucleotide polymorphisms (tagSNPs) and putative 
functional SNPs in IL-1A, IL-1B, IL-1RN, IL-6 and IL-6R were selected using HapMap, 
Haploview and FastSNP. Genomic DNA was extracted from whole blood, and genotyping was 
conducted using on the Sequenom iPLEX gold. We conducted descriptive analysis on all 
subjects. We used the allele chi-square test to compare minor allele frequencies between AA and 
Caucasians in SAS/Genetics 9.2.  
Results: Genotyping information was successfully obtained on 53 SNPs in 5 genes in the 
inflammation pathway for 59 AA and 227 Caucasians controls. There were significant MAF 
differences (p < 0.05) in at least 50% of the SNPs in each of the 5 genes between the two racial 
groups. 
Conclusion: Minor allele frequencies were significantly different in 50% or more SNPs in each 
of the five inflammatory genes, between AA and Caucasians.  
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3.2 INTRODUCTION 
Inflammatory cytokines are important mediators of the immune system, and play a major role in 
the development of various diseases8, 9. Single nucleotide polymorphisms (SNPs) at the 
regulatory regions of cytokine genes are associated with modification of protein expression, and 
have been reported to influence morbidity170, 184, 272, 273. It has been suggested that as a result of 
genetic heterogeneity, individual response to immune system insults, which is a result of 
differences in patterns of cytokine expression, may differ from one person to another274. Thus 
host response is a major component of chronic or recurrent inflammatory state15. The interleukin-
1 (IL-1) and interleukin-6 (IL-6) family of genes promote inflammation and have been associated 
with prostatic carcinogenesis 21, 22, 26. Sequence variants in the interleukin-1 receptor antagonist 
(IL-1RN) and IL-6 have been reported to be associated with prostate cancer21, 184. It has been 
suggested that ethnicity is strongly associated with cytokine gene polymorphisms, and is 
subsequently an important determinant  of differences in disease susceptibility and morbidity in 
various racial groups274.    
The purpose of this study is to determine whether allele frequencies of pro-inflammatory 
cytokines IL-1 and IL6 are the same or different in African American and Caucasian men.  Our 
hypothesis is that allele frequencies of IL-1A, IL-1B, IL-1RN, IL-6 and IL-6R are different in 
African American compared to Caucasian men. 
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3.3     MATERIALS AND METHODS 
3.3.1 Study Sample 
Subjects in the current study were controls from an existing prostate cancer case-control study 
known as the Cancer and Prostate Study (CAPS). Briefly, the Cancer and Prostate Study (CAPS) 
was a case-control study designed to assess the individual and joint associations of bone mineral 
density (BMD) and sex hormone gene polymorphisms in prostate cancer risk. Enrollment into 
CAPS started in December of 2001 and was completed in January of 2006, and included 
Caucasian and African American (AA) men aged 40 to 80 years. Cases were men with recently 
diagnosed prostate cancer (within 3 months of enrollment into the study; confirmed diagnosis 
based on pathology report). Controls were men without a history of prostate cancer. All 
participants in CAPS gave informed consent. The study was approved by the institutional review 
boards (IRB) of the University of Pittsburgh and the University of Alabama at Birmingham. 
Potential enrollees were excluded if they used glucocorticoids (>6 months); used 
testosterone (>3 months); had a history of hyper- or hypothyroidism, hyperparathyroidism, renal 
disease or bone disease. Other exclusion criteria included bilateral hip replacement; kidney 
transplant; previous diagnosis of prostate cancer or any other cancer besides basal and squamous 
cell skin cancer; evidence of bone metastases among prostate cancer cases; and PSA levels above 
3.0 ng/ml among controls. Controls were frequency matched to cases by age and race. 
Participants in CAPS were recruited from Pittsburgh and Alabama. In Pittsburgh, 
recruitment was conducted at two sites: The University of Pittsburgh Medical Center (UPMC), 
and the Veterans Administration Medical Center (VA). Recruitment in Alabama was conducted 
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at the University of Alabama in Birmingham (UAB) Medical Center. A total of 593 Caucasian 
and African American men were enrolled in CAPS. Controls from Pittsburgh numbered 253, and 
were recruited from the local community, as well as from University of Pittsburgh employees, by 
sending out flyers. Controls were frequency age-matched to cases. Majority of the controls were 
from the ongoing Prostate, Lung, Colorectal, and Ovarian study (PLCO). A total of 10 
participants were recruited from the VA Medical Center in Pittsburgh, comprising of 3 cases and 
7 controls.  
In Alabama, information about the CAPS study was advertised in the UAB Reporter. 
Additionally, flyers were sent out to local residents and University of Alabama employees, and 
brochures were placed in waiting rooms of Birmingham area urologist offices. Forty-four 
community-based controls were enrolled at the UAB Medical center, majority of who were from 
the ongoing PLCO trial. Other control enrollees included UAB employees, as well as local 
Birmingham residents who responded to advertisements and flyers. The total number of subjects 
(controls) in the current study is therefore 286, comprising 59 AA and 227 Caucasians.  
An interviewer administered standardized questionnaire was used to collect demographic 
and prostate cancer risk factor information. Whole blood, height and weight measurements, bone 
mineral density (BMD, Hologic DEXA) were obtained at a single clinic visit. Samples were 
stored in a -70oC freezer in the Department of Epidemiology in the Graduate School of Public 
Health at the University of Pittsburgh.  
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3.3.2 Selection of Single Nucleotide Polymorphisms  
Single Nucleotide Polymorphisms (SNPs) of IL-1A, IL-1B, IL-1RN, IL-6 and IL-6R were 
selected using two web-based programs – HapMap Phase 1 and 2 (HapMap Data Rel 22/phase II 
April 07, on NCBI B36 assembly, dbSNP b126) and Functional Analysis and Selection Tool for 
Single Nucleotide Polymorphisms (FastSNP).  Information on HapMap and FastSNP is available 
to the public online, and the programs can be downloaded free of charge at the respective 
websites:  http://www.hapmap.org and http://www.fastsnp.ibms.sinica.edu.tw. 
HapMap was used to obtain SNP information per gene for Caucasians (CEU) and Blacks 
(Yoruba-YRI) separately, and the information was downloaded into Haploview. The Tagger 
approach was used in Haploview to select tagSNPs for CEU and YRI separately, at a minor 
allele frequency (MAF) of at least 10%, and a pair-wise correlation (r2 of 0.80 or greater). This 
procedure identified a total of 51 tagSNPs in both racial groups. To complement the list of SNPs 
obtained from HapMap, we ran the five candidate genes through FastSNP, resulting in the 
identification of 2 additional potentially functional SNPs, bringing the total number of SNPs for 
genotyping analysis to 53. 
3.3.3 Laboratory assay 
Genomic DNA was isolated from EDTA anticoagulated whole blood by standard methods using 
the Puregene kit (Gentra Systems). Genotyping was carried out on the Sequenom platform. 
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3.3.3.1 Sequenom i-PLEX Gold SNP Assay 
Primer Design:  Three primers were designed for each locus of interest using Mass Array Assay 
Design version 3.1 (Sequenom Inc., San Diego, CA).  The two amplification primers flanked the 
polymorphic site to provide for sample amplification, while the single MassExtend primer lay 
immediately adjacent to allow for allelic discrimination via single base extension.  Assay Design 
software determined pooling of primer sets to optimize multiplex reactions.  Mass modifications 
are incorporated in the design of the MassExtend primers to maximize the mass differential 
between primers of different loci within a given multiplex pool.   
Sample Amplification: Target loci were amplified within the samples by multiplex 
polymerase chain reaction (PCR) in 1X PCR buffer (Qiagen) containing 3.5 mM MgCl2, 25 mM 
dNTPs, 500 nM each forward and reverse amplification primer within the multiplex pool and 2.5 
U HotStar Taq (Qiagen).  PCR conditions were: 95
o
C for 15 minutes for taq activation followed 
by 45 cycles of 94
o
C for 20 seconds, 56
o
C for 20 seconds and 72
o
C for 1 minute.  A single 
extension for 1 minute at 72
o
C completed the PCR reaction. Deoxyribonucleotide triphosphates 
(dNTPs) and primers were removed by incubation with 0.5 U shrimp alkaline phosphotase (SAP) 
at 37
 o
C for 40 minutes. SAP was inactivated by incubation at 87
 o
C for 5 minutes.   
MassExtend:  Excess MassExtend primers corresponding to the loci represented by the 
amplification primers used were pooled.  Higher mass primers were added at a higher 
concentration to adjust for signal drop off during spectra acquisition.  Single base extension was 
carried out in 0.2X iPLEX buffer plus, 1X termination mix (containing mass modified 
termination nucleotides), 1X iPLEX enzyme and primers at 0.84 μM, 1.04 μM and 1.25 μM as 
appropriate to the relative mass of the primer.   A double cycle amplification program performed 
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40 cycles of denaturation at 94
 o
C for 5 seconds followed by 5 cycles of 52
o
C for 5 seconds, 80
 
o
C for 5 seconds, back to 94
 o
C for a total of 200 cycles.  A final extension at 72
 o
C for 3 minutes 
completed the amplification.  Clean resin and water was added to the MassExtend reaction 
products.  Samples were incubated in clean resin at room temperature with mixing for 5 minutes 
and centrifuged at 3200 x g for 5 minutes. 
NanoDispense, Spectra acquisition and analysis: Samples were dispensed to a 
SpectraChip using the MassArray Nanodispenser according to manufacturer’s instructions.  
Spectra chips were loaded into the MassArray analyzer and spectra acquired for each sample.  
MassArray Typer software used the known mass of the MassExtend primers to identify each 
locus, and the increase caused by each distinct nucleotide to identify the alleles present in the 
sample.  
Whenever appropriate, alleles that were not automatically identified by the computer 
software were directly read and assigned by the operator. We observed 100% concordance rates 
in two randomly replicated samples. Centre d’Etude du Polymorphisme Humain (CEPH) 
positive controls and water negative controls were included in two 96 well plates as part of 
quality control measures. For 52 of 53 SNP assays we were able to obtain genotyping results for 
over 97% of subjects analyzed. One SNP assay (rs11265613) produced a genotype result in 94% 
of subjects tested.  
3.3.4 Data Analysis  
We analyzed our data in SAS/Genetics version 9.2. There were 304 controls in CAPS. From this 
number 18 subjects were excluded due to lack of sufficient samples for genotyping, or low call 
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rates.  The total number of controls included in our analysis is 286. Genotype frequencies 
observed among AA controls were consistent with HWE, as per the allele test in SAS/Genetics 
9.2. Two IL-1RN loci (rs3181052 and rs4252019) and two IL-6R loci (rs4393147 and rs7518199) 
departed from HWE among Caucasian controls (0.024 < P < 0.050, exact test).  
We conducted race-specific descriptive analyses on all  286 subjects included in our 
analyses for the following risk factors: age (years), height (cm), weight (kg), body mass index 
(kg/m2), personal history of benign prostatic hypertrophy (BPH) or prostatitis (“yes” or “ no”), 
family history of prostate cancer (“yes” or “no”), and history of regular aspirin or  non-steroidal 
anti-inflammatory drugs (NSAIDs) use (“yes” or “no”). Regular aspirin or NSAIDs use was 
defined as taking these medications at least five to seven days per week for the twelve months 
preceding enrollment into the study. 
Our reference minor allele frequencies for Blacks and Whites were based on genotyping 
information provided by HapMap on YRI and CEU populations respectively. In the HapMap 
project 30 sets of samples from two parents and an adult child (trio) were obtained from the 
Yoruba people of Ibadan, Nigeria for genotyping analyses. The project also collected samples 
from 30 trios in the United States, who were residents of Utah (CEU population), with northern 
and western European ancestry by the Centre d’Etude du Polymorphisme Humain (CEPH). 
Genotyping information is available to the public for free download at: http://www.hapmap.org .  
We downloaded the YRI and CEU genotyping data provided by HapMap. We excluded 
offspring genotyping information, bringing the total HapMap sample included in our analyses to 
Yoruba (n=60), and CEU (n = 60). This sample served as the HapMap references for each of our 
racial groups. We assessed allele frequencies in our reference groups using SAS/Genetics 
version 9.2.   
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In our controls we characterized race-specific distributions of the variant allele at each 
locus based on the rare allele observed in our White control group using the allele Chi-square 
test. We compared race-specific allele frequencies at each locus between our control groups 
(observed) and the HapMap sample (reference). Our assessment of a significant minor allele 
frequency difference between the observed and reference group at each locus, was based on the 
allele test (p<0.05). Additionally, we compared minor allele frequencies at each locus between 
our Black and White control groups. 
 
 
 
 
 
 
 
 
 
 
 
59 
 
3.4 RESULTS 
Selected characteristics of our control subjects are shown in Table 3.1. A total of 286 men who 
enrolled in CAPS and whose blood samples were satisfactorily genotyped were included in our 
analyses. There were 59 AA and 227 Caucasian controls, mean age in the total study sample 
were 61.1 ± 7.1 years. Caucasians were slightly taller than AA, but weighed less and also had a 
lower body mass index (BMI); however, these differences were not statistically significant.  A 
significantly higher proportion of Caucasians had a history of benign prostatic hypertrophy 
(BPH) than AA, but there was no significant difference in the proportion of controls with a 
family history of prostate cancer between the two racial groups 
A list of IL-1A, IL-1B, IL-1RN, IL-6 and IL-6R SNPs that were genotyped is shown in 
Table 3.2. Genes are ordered according to chromosome and SNPs by position across the 
respective genes. Genotyping information on 53 SNPs in 5 genes in the inflammation pathway 
are shown for 286 AA and Caucasian control subjects (Table 3.3). Race-specific minor allele 
frequency (MAF) comparisons between observed and reference Black and White groups are 
shown in Table 3.3. There was 1 SNPs in our AA control group in which data was unavailable in 
the reference group (IL-1A-rs20540), therefore, the total number of SNPs available for 
comparison between the Black observed vs. reference group was 52. Similarly, among Whites, 
there were 2 SNPs in our control group in which data was unavailable in the reference group (IL-
1A-rs20540, IL-6R-rs-7549338); therefore, the total number of SNPs available for comparison in 
the White observed vs. reference group was 51. We noted that there were 6 significant (P<0.05) 
MAF differences between the observed vs. reference groups in Blacks, compared to no 
significant differences in Whites.  Graphs comparing MAF in observed vs. reference groups in 
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Blacks and Whites are shown in Figures 3.1 and 3.2. As illustrated in these figures there were 
greater numbers of significant differences in MAF between the reference vs. observed group in 
Blacks, compared to Whites. Race-specific control group allele frequency and HWE test results 
are shown in Table 3.3. 
Table 3.4 shows comparisons of MAF in AA and Caucasian control subjects. Significant 
differences in MAF between AA and Caucasian were observed in 64% of all SNPs genotyped. 
Of SNPs showing significant differences, 79% were highly significantly different (p<0.01) 
between the two racial groups. In each of the 5 genes we observed 50% or more markers with 
significant MAF differences between the two racial groups (IL-1A, 50%; IL-1B, 60%; IL-1RN, 
63%; IL-6, 71%; and IL-6R, 68%). A lesser proportion of AA controls (0.229) carried the variant 
allele (A) at IL-1A-rs17561 than Caucasians (0.278), but the difference was not statistically 
significant (Table 3.4). The GG genotype of this particular marker up-regulates the protein 
encoded by the IL-1A gene, and was found more commonly among AA controls (61%) than 
Caucasian controls (53%). Similarly, a lesser proportion of AA controls (0.169) than Caucasians 
(0.223) carried the variant allele at IL-1-B-rs1143634, but the difference was not statistically 
significant (Table 4). The (C) allele at this locus up-regulates IL-1B secretion, and was carried 
more commonly by AA controls (83%) compared to Caucasians control (80%).   
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3.5 DISCUSSION 
We compared MAFs of inflammatory gene markers between AA and Caucasian controls. We 
found significant differences in the distribution of variant alleles at several IL-1A, IL-1B, IL-1RN, 
IL-6 and IL-6R loci in the two racial groups. We made race-specific comparisons of MAF of IL-1 
and IL-6 gene markers between observed and HapMap reference groups and found that 
approximately 12% of MAFs were significantly different in our Black comparison group, but 
none in our White comparison group. These differences may reflect greater admixture in the 
African American population compared to Caucasians, and is an important consideration in 
disease susceptibility275, 276. Cytokine gene polymorphisms have been reported to influence 
disease susceptibility, severity and clinical outcome184, 277. Racial differences in the distribution 
of inflammatory marker allele frequencies have been reported to influence allograft rejection, 
and in rheumatoid arthritis development and response to treatment 274, 278-280.    
In this study, there were significant MAF differences between the two racial groups in 
50% of IL-1A, 60% of IL-1B and 63% of IL-1RN SNPs. These differences may underlie some of 
the disparities in clinical outcome noted between the two racial groups. Interleukin-1A and IL-1B 
up-regulate the division of immune cells, as well as promote cell growth, differentiation and 
migration188. They also inhibit apoptosis and induce angiogenesis, thereby promoting tumor 
growth23, 188. Their action, however, is inhibited by the binding of the IL-1RN to the IL-1 
receptor. Interleukin-1 and its related family members are primarily inflammatory cytokines, and 
are known to initiate cyclooxygenate type 2 (COX-2), type 2 phospholipase A and inducible 
nitric oxide synthase (iNOS) in inflammation187.  
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The GG polymorphism at IL-1A-rs17561 produces an alanine-to-serine amino acid 
substitution at codon 114 of the IL-1 cytokine protein and has been associated with an increased 
risk of atopy281.  In a recent study which compared differences in cytokine gene polymorphisms 
among healthy primiparous African American (N = 179) and Caucasian (N = 396) women 
seeking prenatal care prior to 20 weeks’ gestation in Pittsburgh, Pennsylvania, Ness et al 
reported that the up-regulating GG genotype at IL-1A-4845 (IL-1A-rs17561) was found in 59.7% 
of AA women compared to Caucasian women (47.3%)282. In the current study the GG genotype 
was found in 61% of AA men compared to 53% Caucasians. The (C) allele at IL-1B-rs1143634 
has been associated with an increased secretion of IL-1B in activated macrophages in vitro283. 
Ness et al reported that the (C) allele at IL-1B-3597 (rs1143634) was found in 86% of AA 
women compared to 77% in Caucasians282. In the current study the (C) allele was found in 
approximately 83% of AA men compared to 80% of Caucasians. We extend the findings of Ness 
et al by studying a greater number of inflammatory markers, and by focusing on AA and 
Caucasian men.  IL-1A-rs20540 is a putatively functional SNP, involved in splicing regulation 
(http://www.fastsnp.ibms.sinica.edu.tw). The exact functions of the other IL-1 SNPs are not 
clearly known, but they are candidates with biological plausibility, being that they are clustered 
in highly conserved genomic regions in different vertebrate species (http://genome.ucsc.edu).  
Of the IL-6 gene SNPs evaluated in this study 71% of IL-6 and 68% of IL-6R MAFs were 
significantly different between AA and Caucasians. Due to the pleiotropic nature of IL-6 such 
differences in MAFs could result in disparities in disease development, progression and 
treatment response between the two racial groups.  Interleukin-6 is involved in regulating 
immune and inflammatory responses154. In addition to inducing terminal differentiation of B-
cells it synergizes with IL-1 in activating T-cells by inducing IL-2 responsiveness, and enhances 
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the differentiation of cytotoxic T lymphocytes from thymic precursors146, 155, 156. It has a central 
role in the acute-phase response, acting on hepatocytes to increase the synthesis of acute-phase 
proteins (haptoglobin, fibrinogen, C-reactive protein) and reducing the secretion of albumin and 
transferein157. It also contributes to the body’s defenses by increasing the body temperature and 
stimulating the release of adrenocoticotropin hormone158-160. Other functions include impairment 
of natural killer cell function, induction of bone resorption via stimulation of osteoclast 
formation, and induction of experimental cancer cachexia. IL-6 also induces platelet-derived 
growth factor in blood vessels, enhances proliferation of vascular smooth muscle, and has a 
negative inotropic effect on cardiac myocites.154.  
Attention to the role of IL-6 in the pathogenesis of prostate cancer was drawn by the 
observation that the disease transitioned from an androgen-dependent tumor, initially responsive 
to androgen ablation therapy, to an untreatable androgen independent tumor60. In-vitro studies by 
Siegall at al showed that the androgen-independent cell lines DU145 and PC3 and the androgen-
dependent cell line LNCaP expressed IL-6R on their surfaces, and all three cell lines were 
susceptible to a chimeric Pseudomonas exotoxin-IL-6 toxin. Susceptibility was mediated by IL-
6R as cytotoxic activity was blocked by excess human recombinant IL-6172. Since then, the 
expression of mRNA for IL-6R and the gp130 signal transducer has been confirmed in human 
prostate cancer by several investigators172-174.  Furthermore, recent in-vitro studies have shown 
that IL-6 initiates and promotes prostate tumorigenesis by mediating cross-talk between stromal 
and epithelial cell of the prostate25. 
IL-6R -rs28730736 is a putatively functional SNP (missense), and is involved in splicing 
regulation (http://www.fastsnp.ibms.sinica.edu.tw). The variant allele of this SNP was carried by 
15% of AA controls in our study, but was absent in our Caucasian controls, who were 100% 
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homozygous for the common allele. Two IL-6 loci (rs1554606 and rs2069845) were in strong 
pair-wise LD (r2=0.99) in Caucasians. Greater than a third of the IL6R SNPs evaluated in this 
study were in strong linkage disequilibrium with each other (r2 ≥ 0.90). While we are not certain 
of the exact functions of these SNPs, several of them appear to be candidates with biological 
plausibility, because they are clustered in highly conserved genomic regions in different 
vertebrate species (http://genome.ucsc.edu). 
Our study had several limitations. Our tag SNP panel was based on Phase II of the 
International HapMap project, and may not have captured a more comprehensive set of tag SNPs 
as provided in Phase III of the HapMap project. We studied a limited number of inflammatory 
markers, even though the true assessment of differences in MAFs may involve a larger number 
of inflammatory markers, and include others in areas of the genome outside our tag region. We 
also relied on self reporting of race, even though there is admixture among African Americans. 
In spite of these limitations, our study has several strengths. It is one of the first to 
directly perform a three-way comparison of MAFs in AA vs. YRI of West Africa, AA vs. 
Caucasians, and Caucasians vs. CEU of Utah within the context of a comprehensive set of 
inflammatory cytokines.  Such a comparison adds breadth and depth to our understanding of the 
heterogeneity of allele frequency distributions in the population, and the basis for predisposition 
or susceptibility to certain diseases.  It identified two putatively functional inflammatory markers 
(IL-1A-rs20540 and IL-6R- rs28730736) with variant alleles found in African Americans, but not 
Caucasians, that may or may not be associated with prostate cancer, but have not as yet been 
reported in the literature in relation to the disease. Beyond reporting similar findings as previous 
studies, the current study demonstrated that there are differences in allele frequency distributions 
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of markers of inflammation in the two racial groups that may contribute to disparities in 
inflammation mediated diseases.  
Even though we do not know the exact functions of all the SNPs in this study there is the 
possibility AA carry a greater proportion of alleles that up-regulate pro-inflammatory cytokines 
compared to Caucasians thereby leading to differentially poor clinical outcomes in AA. Future 
studies may want to consider examining a wide variety of markers which up-regulate pro-
inflammatory cytokines in these two groups, as well as those with marginal effect on prostate 
cancer and other diseases in order to determine susceptibility. Understanding the differences in 
allele frequencies of IL-1 and IL-6 gene is of great public health significance because it is the 
first step in understanding the basis for some of the observed disparities in the disease between 
the two racial groups. It will also enable their possible use as biomarkers for early detection and 
prompt intervention, as well as increase our understanding of the molecular biology of the 
disease. 
 
 
 
 
 
 
 
 
 
 3.6 TABLES AND FIGURES 
Table 3.1 : General characteristics of control subjects 
African Americans Caucasians All subjects
Mean SD N Mean SD N p-value Mean SD N
Age in years 61.1 9.8 59 61.1 6.2 227 0.9514 61.1 7.1 286
Height (cm) 174.7 5.3 59 176 6.3 227 0.0784 175.9 6.1 286
Weight (kg) 92 17.1 59 90.6 15.5 227 0.5775 90.9 15.8 286
BMI (kg/m2) 30 5 59 29.1 4.4 227 0.2058 29.3 4.5 286
Father or brother with history of prostate cancer N (%) N (%) p-value N (%)
   Yes 3 5.1 10 4.4 0.8234 13 4.6
   No 56 94.9 217 95.6 273 95.4
Personal medical history of BPH or prostatitis
   Yes 10 16.9 128 56.4 <.0001 138 48.2
   No 49 83.1 99 43.6 148 51.8
BMI - Body mass index
BPH - Benign prostatic hyperplasia  
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Chromosome Gene SNP identification number
Chr1 IL-6R rs4845617 rs6427641 rs11265610 rs12083537 rs1386821 rs4075015 rs4601580 rs4845618
rs7549338 rs7518199 rs4553185 rs4393147 rs4537545 rs4845626 rs28730736 rs11265618
rs10159236 rs4329505 rs4509570 rs2229238 rs4072391 rs4379670
Chr2 IL-1A rs3783590 rs2856836 rs17561 rs20540 rs2856838 rs1609682 rs3783526 rs2856837
Chr2 IL-1B rs1143643 rs1143634 rs1143633 rs3136558 rs1143630
Chr2 IL-1RN rs3181052 rs1794066 rs1794067 rs2071459 rs432014 rs380092 rs452204 rs4252019
rs315955 rs315951 rs9005
Chr7 IL-6 rs2069837 rs2069840 rs1554606 rs2069842 rs1548216 rs2069843 rs2069845
Genes are odered by chromosome.  SNPs are presented by position across the gene. SNPs (N=51) were selected from HapMap/Haploview
               using the Tagger approach, MAF > 0.8, r2 > 0.1 .  Two additional SNPs were selected from FastSNP
Chr - Chromosome; SNP - Single nucleotide polymorphism; IL-1A - Interleukin-1A; IL-1B - Interleukin-1B;
IL1RN - Interleukin-1 receptor antagonist; IL-6 - Interleukin-6; IL-6R - IL-6R
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Table 3.2 :SNPs included in genotyping analysis 
Table 3.3 : Control group allele frequency and Hardy-Weinberg Equilibrium (HWE) test result, by race 
Gene variant Allele [1] Observed Reference Observed Reference
IL1A
rs3783590 A 0.093 0.229 0.005 * 1.0000 0.002 0.000 0.613 1.0000
rs2856836 C 0.229 0.133 0.056 0.4574 0.278 0.308 0.506 0.6204
rs17561 T 0.229 0.133 0.056 0.4778 0.278 0.308 0.506 0.6204
rs20540 T 0.051 1.0000 0.000
rs2856838 T 0.364 0.358 0.922 0.7784 0.388 0.400 0.805 0.7846
rs1609682 C 0.203 0.183 0.695 1.0000 0.336 0.292 0.362 1.0000
rs3783526 A 0.042 0.008 0.094 0.0862 0.333 0.292 0.394 1.0000
rs2856837 T 0.254 0.183 0.186 1.0000 0.278 0.308 0.506 0.6192
IL1B
rs1143643 A 0.195 0.150 0.359 0.4314 0.339 0.392 0.284 0.0724
rs1143634 T 0.169 0.100 0.116 0.6616 0.202 0.223 0.623 0.8440
rs1143633 A 0.237 0.178 0.261 0.1582 0.338 0.397 0.242 0.0566
rs3136558 C 0.136 0.153 0.5760 0.187 0.323 0.8322
rs1143630 A 0.288 0.254 0.563 0.5388 0.064 0.040 0.361 1.0000
IL1RN
rs3181052 A 0.153 0.217 0.203 0.6122 0.082 0.119 0.213 0.0446 *
rs1794066 G 0.390 0.475 0.185 0.2744 0.398 0.390 0.868 0.8834
rs1794067 A 0.288 0.183 0.057 0.7470 0.308 0.271 0.433 0.5346
rs2071459 T 0.161 0.283 0.023 * 0.6304 0.082 0.119 0.218 0.0506
rs432014 C 0.203 0.175 0.576 0.6744 0.308 0.271 0.433 0.5252
rs380092 T 0.703 0.833 0.017 * 0.7504 0.275 0.314 0.403 0.8770
rs452204 A 0.491 0.600 0.094 0.3052 0.396 0.390 0.895 0.8928
rs4252019 T 0.364 0.592 0.000 * 0.7878 0.090 0.127 0.231 0.0240 *
rs315955 C 0.138 0.108 0.489 1.0000 0.000 0.000
rs315951 C 0.407 0.533 0.051 1.0000 0.240 0.263 0.610 1.0000
rs9005 A 0.254 0.175 0.136 0.1738 0.335 0.305 0.540 0.5582
Allele [3] HWE [4] Allele [3] HWE [4]
Black White
Allele frequency [2] Allele frequency [2]
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Table 3.3 (continued)  
Gene variant Allele [1] Observed Reference Observed Reference
IL6
rs2069837 G 0.144 0.158 0.759 0.3240 0.073 0.067 0.820 0.3314
rs2069840 G 0.127 0.169 0.360 0.2108 0.347 0.317 0.529 0.4596
rs1554606 T 0.356 0.267 0.143 0.3988 0.445 0.542 0.059 0.8898
rs2069842 A 0.042 0.102 0.078 0.0840 0.000 0.000
rs1548216 C 0.169 0.217 0.357 0.3512 0.018 0.000 0.157 1.0000
rs2069843 A 0.093 0.175 0.064 0.3968 0.018 0.017 0.943 1.0000
rs2069845 G 0.347 0.300 0.434 0.2658 0.444 0.542 0.057 1.0000
IL6R
rs4845617 A 0.379 0.373 0.919 0.5776 0.383 0.397 0.793 0.5618
rs6427641 G 0.703 0.730 0.664 1.0000 0.423 0.396 0.5868
rs11265610 C 0.272 0.356 0.168 0.7324 0.000 0.000
rs12083537 G 0.280 0.233 0.413 0.3502 0.203 0.136 0.112 0.3052
rs1386821 C 0.110 0.092 0.636 0.1208 0.185 0.167 0.642 0.3800
rs4075015 A 0.110 0.042 0.046 * 1.0000 0.423 0.458 0.486 1.0000
rs4601580 T 0.570 0.608 0.553 0.4246 0.415 0.508 0.068 0.2150
rs4845618 G 0.542 0.575 0.612 0.7930 0.434 0.508 0.145 0.1380
rs7549338 C 0.297 0.417 0.053 0.5490 0.421 0.2764
rs7518199 C 0.186 0.100 0.057 0.3988 0.410 0.347 0.218 0.0392 *
rs4553185 C 0.578 0.508 0.286 0.2848 0.430 0.492 0.227 0.1304
rs4393147 T 0.103 0.042 0.066 0.4820 0.410 0.345 0.202 0.0398 *
rs4537545 T 0.644 0.692 0.436 0.7700 0.421 0.339 0.107 0.1704
rs4845626 T 0.475 0.442 0.610 0.5968 0.167 0.158 0.812 1.0000
rs28730736 A 0.153 0.167 1.0000 0.000 0.000
rs11265618 T 0.407 0.383 0.711 0.7880 0.170 0.158 0.769 1.0000
rs10159236 A 0.220 0.115 0.038 * 0.7230 0.161 0.109 0.174 1.0000
rs4329505 C 0.415 0.467 0.424 1.0000 0.159 0.158 0.995 0.8040
rs4509570 G 0.500 0.614 0.081 1.0000 0.242 0.328 0.061 0.7250
rs2229238 T 0.161 0.208 0.347 1.0000 0.196 0.258 0.136 0.8350
rs4072391 T 0.263 0.336 0.220 0.1832 0.196 0.254 0.165 0.8324
rs4379670 T 0.161 0.192 0.535 1.0000 0.196 0.242 0.271 0.8386
1. Rare allele observed in white control group
2. Reference allele frequency obtained from HapMap or EntrezSNP database
3. Observed vs. reference allele frequency (allele test), with asterisk (*) to indicate p<0.05
4. Hardy-Weinberg-Equilibrium p-value, exact method (5000 permutations), with asterisk (*) to indicate p < 0.05
Black White
Allele frequency [2] Allele frequency [2]
Allele [3] HWE [4] Allele [3] HWE [4]
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 Table 3.4 : Allele frequencies in Black and White control subjects 
Gene variant Allele Freq N Freq N
IL1A
rs3783590 A 0.093 59 0.002 227 ***
rs2856836 C 0.229 59 0.278 227
rs17561 T 0.229 59 0.278 227
rs20540 T 0.051 59 0.000 227 ***
rs2856838 T 0.364 59 0.388 227
rs1609682 C 0.203 59 0.336 225 **
rs3783526 A 0.042 59 0.333 227 ***
rs2856837 T 0.254 59 0.278 227
IL1B
rs1143643 A 0.195 59 0.339 227 **
rs1143634 T 0.169 59 0.202 225
rs1143633 A 0.237 59 0.338 226 *
rs3136558 C 0.136 59 0.187 227
rs1143630 A 0.288 59 0.064 227 ***
IL1RN
rs3181052 A 0.153 59 0.082 226 *
rs1794066 G 0.390 59 0.398 226
rs1794067 A 0.288 59 0.308 227
rs2071459 T 0.161 59 0.082 225 *
rs432014 C 0.203 59 0.308 227 *
rs380092 T 0.703 59 0.275 224 ***
rs452204 A 0.491 58 0.396 227
rs4252019 T 0.364 59 0.090 227 ***
rs315955 C 0.138 58 0.000 227 ***
rs315951 C 0.407 59 0.240 225 ***
rs9005 A 0.254 59 0.335 227
Black White Allele 
test [1]
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            Table 3.4 (continued) 
Gene variant Allele Freq N Freq N
IL6
rs2069837 G 0.144 59 0.073 227 *
rs2069840 G 0.127 59 0.347 226 ***
rs1554606 T 0.356 59 0.445 227
rs2069842 A 0.042 59 0.000 225 ***
rs1548216 C 0.169 59 0.018 227 ***
rs2069843 A 0.093 59 0.018 227 ***
rs2069845 G 0.347 59 0.444 223
IL6R
rs4845617 A 0.379 58 0.383 227
rs6427641 G 0.703 59 0.423 227 ***
rs11265610 C 0.272 57 0.000 214 ***
rs12083537 G 0.280 59 0.203 227
rs1386821 C 0.110 59 0.185 227
rs4075015 A 0.110 59 0.423 227 ***
rs4601580 T 0.570 57 0.415 224 **
rs4845618 G 0.542 59 0.434 227 *
rs7549338 C 0.297 59 0.421 227 *
rs7518199 C 0.186 59 0.410 227 ***
rs4553185 C 0.578 58 0.430 227 **
rs4393147 T 0.103 58 0.410 227 ***
rs4537545 T 0.644 59 0.421 227 ***
rs4845626 T 0.475 59 0.167 227 ***
rs28730736 A 0.153 59 0.000 225 ***
rs11265618 T 0.407 59 0.170 227 ***
rs10159236 A 0.220 59 0.161 227
rs4329505 C 0.415 59 0.159 227 ***
rs4509570 G 0.500 59 0.242 227 ***
rs2229238 T 0.161 59 0.196 227
rs4072391 T 0.263 59 0.196 227
rs4379670 T 0.161 59 0.196 227
1. Allele test p-value, p<0.001***, p<0.01**, p<0.05*
2. Hardy-Weinberg-Equilibrium p-value, exact method (5000 permutations), with asterisk (*) to indicate p < 0.05
Black White Allele 
test [1]
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Figure 3.1: SNP by SNP comparison of allele frequencies observed in Black control  
group (N=59) and calculated for the HapMap YRI reference population (N=60 mother- 
father pairs). Reference and observed allele frequencies for SNPs shown red differ  
significantly (allele test, p-value <0.05). 
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Figure 3.2: SNP by SNP comparison of allele frequencies observed in White control  
group (N=227) and calculated for the HapMap CEU reference population (N=60 mother- 
father pairs). Reference and observed allele frequencies for SNPs shown red differ  
significantly (allele test, p-value <0.05). 
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4.1 ABSTRACT 
Objective: To assess association of common polymorphisms in inflammatory genes interleukin-
1A (IL-1A), IL-1B, IL-1RN, IL-6 and IL-6R and risk of prostate cancer in African American (AA) 
and Caucasian men.  
Methods: We conducted a matched case-control study of 558 African-American (AA) and 
Caucasian men ages 40-80y who enrolled in the Cancer and Prostate Study (CAPS) between 
2001 and 2006. A total of 53 single nucleotide polymorphisms (SNPs) were selected using 
HapMap, Haploview and FastSNP. Genomic DNA was extracted from whole blood, and 
genotyping was done using Sequenom iPlex Gold.  
Results: Genotyping information was successfully obtained on 53 SNPs for 113 AA (54 cases 
and 59 controls) and 445 Caucasians (218 cases and 227 controls). Three IL-1RN SNPs 
(rs452204, rs425019, and rs9005) were associated with a personal history of BPH or prostatitis 
in AA, but not in Caucasian controls. Three IL-1B SNPs (rs1143643, rs1143633 and rs1143630) 
were significantly associated with a family history of prostate cancer in Caucasian, but not in AA 
controls. IL-1RN-rs432014, IL-1RN-rs9005, and IL-6R-rs4845626 were significantly associated 
with prostate cancer in AA in the dominant model. Three IL-1RN SNPs (rs3181052, rs2071459, 
and rs4252019) were associated with prostate cancer in Caucasians in the dominant model. We 
identified two putative functional SNPs (1L-1A-rs20540 and IL-6R-rs28730736) whose variant 
alleles are carried by AA, but not by Caucasians.  
Conclusion: We found statistically significant prostate cancer associations of two IL-1RN SNPs 
in AA, three IL-1RN SNPs in Caucasians, and one IL-6R in AA.   
 
76 
 
4.2 INTRODUCTION 
Prostate cancer is a major public health problem in the United States. It is the most common 
nonskin cancer, and the second leading cause of cancer related death among men in the United 
States1. According to the American Cancer Society, there will be approximately 186,320 new 
cases of prostate cancer in the United States in 2008; in the same year approximately 28,660 men 
will die from the disease.1 African Americans (AA) are twice as likely to be diagnosed with and 
die from the disease as are White Americans 2. Socioeconomic and hormonal differences are 
thought to be contributory factors 2-4, however, the role played by differences in sequence 
variants of genes in the inflammation pathway of these two racial groups have not been 
comprehensively examined as part explanation for these disparities.  
Chronic or recurrent inflammation is known to increase the incidence of malignancies of 
the bladder, colon, endometrium, esophagus, liver, lung and pancreas 5-9. Similarly, evidence 
from epidemiologic, genetic, molecular biology and histopathology studies have suggested a 
compelling role of inflammation in the development of prostate cancer 10-13.  The precise 
mechanism by which inflammation causes cancer is currently not clearly understood, but it is 
thought that chronic or recurrent inflammation, which may be a result of immunological 
conditions, recurrent microbial infections, or chemical irritation, trigger the production of 
inflammatory cytokine mediators and genotoxic reactive oxygen radicals that increase cell 
proliferation and promote tumorigenesis 14. The likelihood of developing cancer may then be 
dependent upon precise host response to this inflammatory cascade 15.  
The interleukin-1 (IL-1) and interleukin-6 (IL-6) family of genes promote inflammation, 
and have been reported to be associated with prostatic tumorigenesis 21, 22. Sequence variants in 
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the interleukin-1 receptor antagonist (IL-1RN) have been reported to be associated with prostate 
cancer risk in a population-based study conducted in Sweden 21. Additionally, endogenous IL-1 
has been reported to promote the invasiveness of malignant cells of the prostate by initiating and 
completing the process of angiogenesis 23. Interleukin-6 regulates the growth and differentiation 
of prostate carcinomas 24, and has been shown in laboratory studies to be involved in the 
initiation and progression of prostate cancer by mediating the lysophosphatidic acid-regulated 
cross-talk between stromal and epithelial cells of the prostate gland 25. Additionally, clinical 
studies have shown that elevated circulating plasma levels of IL-6 and its soluble receptor are 
associated with prostate cancer progression and metastasis 26-28.  
Even though prostate cancer incidence and mortality rates have been reportedly higher in 
African Americans than Caucasians for several decades1, the molecular factors that contribute to 
these racial disparities are still unclear. The disease is initially androgen dependent but rapidly 
becomes androgen independent, and refractory to therapy.  Inflammatory cytokines have been 
reported to influence clinical outcome of prostate cancer by mediating the transition from 
androgen dependence to androgen independence60. Evidence from epidemiologic, genetic, 
molecular biology and histopathology studies have suggested a compelling role of chronic or 
recurrent inflammation in the development of prostate cancer10-13, 126. The role of inflammatory 
genes IL-1 and IL-6 in prostate cancer risk and in explaining observed racial disparities in the 
disease are not clearly understood. However, cytokine gene polymorphisms have been reported 
to be strongly associated with ethnicity274, and these differences have been suggested to partly 
explain the apparent influence of ethnicity on disease outcome, such as allograft rejection274 . 
The purpose of this study is to determine if genotypes of polymorphisms in inflammatory genes 
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IL-1A, IL-1B, IL-1RN, IL-6 and IL-6R are related to prostate cancer risk in African American and 
Caucasian men.  
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4.3 MATERIALS AND METHODS 
4.3.1 Study sample 
Participants in the current study were selected from an existing prostate cancer case-control 
study known as the Cancer and Prostate Study (CAPS). Briefly, CAPS was a case-control study 
designed to assess the individual and joint associations of bone mineral density (BMD) and sex 
hormone gene polymorphism with prostate cancer. Enrollment into CAPS started in December 
of 2001 and was completed in January of 2006, and included Caucasian and African American 
(AA) men aged 40 to 80 years. Cases were men with recently diagnosed prostate cancer (within 
3 months of enrollment into the study; confirmed diagnosis based on pathology report). Controls 
were men without a history of prostate cancer. All participants in CAPS gave informed consent. 
The study was approved by the institutional review boards (IRB) of the University of Pittsburgh 
and the University of Alabama at Birmingham. 
Potential enrollees were excluded if they used glucocorticoids (>6 months); used 
testosterone (>3 months); had a history of hyper- or hypothyroidism, hyperparathyroidism, renal 
disease or bone disease. Other exclusion criteria included bilateral hip replacement; kidney 
transplant; previous diagnosis of prostate cancer or any other cancer besides basal and squamous 
cell skin cancer; evidence of bone metastases among prostate cancer cases; and PSA levels above 
3.0 ng/ml among controls. Controls were frequency matched to cases by age and race. 
Participants in CAPS were recruited from Pittsburgh and Alabama. In Pittsburgh, 
recruitment was conducted at two sites: The University of Pittsburgh Medical Center (UPMC), 
and the Veterans Administration Medical Center (VA). Recruitment in Alabama was conducted 
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at the University of Alabama in Birmingham (UAB) Medical Center. A total of 593 Caucasian 
and African American men were enrolled in CAPS. There were a total of 244 cases recruited at 
UPMC, all of who were referrals from one institution-based urology practice. Patients at this 
practice were mostly community-based residents from Pittsburgh, many of who were referred for 
specialty care by their primary care physicians.  All recruited cases from this urology practice 
underwent radical prostatectomy within 3 months of diagnosis. The urologist personally 
informed potential subjects about the study for the first time during their second post-operative 
follow-up visit. Interested men were then referred to the CAPS research team at UPMC for 
further study details and enrollment information. Controls from Pittsburgh numbered 253, and 
were recruited from the local community, as well as from University of Pittsburgh employees, by 
sending out flyers. Controls were frequency matched by age and race to cases. Majority of the 
controls were from the ongoing Prostate, Lung, Colorectal, and Ovarian study (PLCO). A total of 
10 participants were recruited from the VA Medical Center in Pittsburgh, comprising of 3 cases 
and 7 controls.  
In Alabama, information about the CAPS study was advertised in the UAB Reporter. 
Additionally, flyers were sent out to local residents and University of Alabama employees, and 
brochures were placed in waiting rooms of Birmingham area urologist offices. Urologists at three 
community-based urology practices informed potential case subjects about the study, and then 
referred interested parties to an on-site study recruiter from UAB Medical Center, who provided 
detailed information about the study. A total of 42 cases were enrolled at UAB Medical Center, 
which included 41 referrals from the three community-based urology practices and one subject 
who was referred by word of mouth from another study participant. Forty-four community-based 
controls were enrolled at the UAB Medical center, majority of who were from the ongoing 
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PLCO trial. Other control enrollees included UAB employees, as well as local Birmingham 
residents who responded to advertisements and flyers. The total number of CAPS subjects 
eligible for the current study was therefore 593, comprising 122 AA and 471 Caucasians.  
An interviewer administered standardized questionnaire was used to collect demographic 
and prostate cancer risk factor information. Whole blood, height and weight measurements, bone 
mineral density (BMD, Hologic DEXA) were obtained at a single clinic visit. Samples were 
stored in a -70oC freezer in the Department of Epidemiology in the Graduate School of Public 
Health at the University of Pittsburgh. 
4.3.2 Selection of Single Nucleotide Polymorphisms 
Single Nucleotide Polymorphisms (SNPs) in IL-1A, IL-1B, IL-1RN, IL-6 and IL-6R were selected 
using two web-based programs – HapMap Phase 1 and 2 (HapMap Data Rel 22/phase II April 
07, on NCBI B36 assembly, dbSNP b126) and Functional Analysis and Selection Tool for Single 
Nucleotide Polymorphisms (FastSNP).  HapMap and FastSNP information is available to the 
public online, and the programs can be downloaded free of charge at the respective websites:  
http://www.hapmap.org and http://www.fastsnp.ibms.sinica.edu.tw. 
HapMap was used to obtain SNP information per gene for Caucasians (CEU) and Blacks 
(Yoruba-YRI) separately, and the information was downloaded into Haploview. The Tagger 
approach was used in Haploview to select TagSNPs for CEU and YRI separately, at a minor 
allele frequency (MAF) of at least 10%, and a pair-wise correlation (r2 of 0.80 or greater). This 
procedure identified a total of 51 TagSNPs in both racial groups. Haploview information is 
available to the public online, and the program can be downloaded free of charge at: 
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www.broad.mit.edu/haploview/haploview-downloads . To compliment the list of SNPs obtained 
from Haploview, we ran the five candidate genes through FastSNP, resulting in the identification 
of 2 additional potentially functional SNPs, bringing the total number of SNPs for genotyping 
analysis to 53. 
4.3.3 Laboratory Assay 
Genomic DNA was isolated from EDTA anticoagulated whole blood by standard methods using 
the Puregene kit (Gentra Systems). Genotyping was carried out on the Sequenom platform.  
4.3.3.1 Sequenom i-PLEX Gold SNP Assay 
Primer Design:  Three primers were designed for each locus of interest using Mass Array Assay 
Design.  The two amplification primers flanked the polymorphic site to provide for sample 
amplification, while the single MassExtend primer lay immediately adjacent to allow for allelic 
discrimination via single base extension.  Assay Design software determined pooling of primer 
sets to optimize multiplex reactions.  Mass modifications are incorporated in the design of the 
MassExtend primers to maximize the mass differential between primers of different loci within a 
given multiplex pool.   
Sample Amplification: Target loci were amplified within the samples by multiplex 
polymerase chain reaction (PCR) in 1X PCR buffer (Qiagen) containing 3.5 mM MgCl2, 25 mM 
dNTPs, 500 nM each forward and reverse amplification primer within the multiplex pool and 2.5 
U HotStar Taq (Qiagen).  PCR conditions were: 95
o
C for 15 minutes for taq activation followed 
by 45 cycles of 94
o
C for 20 seconds, 56
o
C for 20 seconds and 72
o
C for 1 minute.  A single 
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extension for 1 minute at 72
o
C completed the PCR reaction. Deoxyribonucleotide triphosphates 
(dNTPs) and primers were removed by incubation with 0.5 U shrimp alkaline phosphotase (SAP) 
at 37
 o
C for 40 minutes. SAP was inactivated by incubation at 87
 o
C for 5 minutes.   
MassExtend:  Excess MassExtend primers corresponding to the loci represented by the 
amplification primers used were pooled.  Higher mass primers were added at a higher 
concentration to adjust for signal drop off during spectra acquisition.  Single base extension was 
carried out in 0.2X iPLEX buffer plus, 1X termination mix (containing mass modified 
termination nucleotides), 1X iPLEX enzyme and primers at 0.84 μM, 1.04 μM and 1.25 μM as 
appropriate to the relative mass of the primer.   A double cycle amplification program performed 
40 cycles of denaturation at 94
 o
C for 5 seconds followed by 5 cycles of 52
o
C for 5 seconds, 80
 
o
C for 5 seconds, back to 94
 o
C for a total of 200 cycles.  A final extension at 72
 o
C for 3 minutes 
completed the amplification.  Clean resin and water were added to the MassExtend reaction 
products.  Samples were incubated in clean resin at room temperature with mixing for 5 minutes 
and centrifuged at 3200 x g for 5 minutes. 
NanoDispense, Spectra acquisition and analysis: Samples were dispensed to a 
SpectraChip using the MassArray Nanodispenser according to manufacturer’s instructions.  
Spectra chips were loaded into the MassArray analyzer and spectra acquired for each sample.  
MassArray Typer software used the known mass of the MassExtend primers to identify each 
locus, and the increase caused by each distinct nucleotide to identify the alleles present in the 
sample.  
Whenever appropriate, alleles that were not automatically identified by the computer 
software were directly read and assigned by the operator. We observed 100% concordance rates 
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in two randomly replicated samples. Centre d’Etude du Polymorphisme Humain (CEPH) 
positive controls and water negative controls were included in two 96 well plates as part of 
quality control measures. For 52 of 53 SNP assays we were able to obtain genotyping results for 
over 97% of subjects analyzed. One SNP assay (rs11265613) produced a genotype result in 94% 
of subjects tested.  
4.3.4 Data Analysis 
We analyzed our data in SAS/Genetics version 9.2. We excluded 31 study subjects due to lack of 
sufficient sample for genotyping. Four additional subjects were excluded due to low call rates 
(<85%), bringing the total number of subjects excluded from our analysis to 35.  Therefore the 
total number of subjects included for analysis in the current study is 558, comprising 113 AA 
and 445 Caucasians. Genotype frequencies observed among AA controls were consistent with 
HWE. Two IL-1RN loci (rs3181052 and rs4252019) and two IL-6R loci (rs4393147 and 
rs7518199) departed from HWE among Caucasian controls (0.024 < P < 0.050, exact test).  
We conducted race-specific descriptive analyses, by case-control status, on all 558 
subjects included in our analyses for the following risk factors: age (years), height (cm), weight 
(kg), body mass index (kg/m2), personal history of benign prostatic hypertrophy (BPH) or 
prostatitis (“yes” or “ no”), family history of prostate cancer (“yes” or “no”), and history of 
regular aspirin or  non-steroidal anti-inflammatory drugs (NSAIDs) use (“yes” or “no”). Family 
history of prostate cancer was defined as a father, brother or half brother with a history of 
prostate cancer. Regular aspirin or NSAIDs use was defined as taking any of these medications 
at least five to seven days per week for the twelve months preceding enrollment into the study.  
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To determine whether differences existed between subjects included (n=558), and those excluded 
(n=35) from our analyses, we performed descriptive analyses comparing these two groups using 
the chi-square test for categorical variables, and the t-test for continuous variables.  
In our control groups, we characterized race-specific distributions of individuals  
homozygous or heterozygous for  the variant allele at each locus, for the following risk factors: 
age (years), height (cm), weight (kg), body mass index (kg/m2), hip bone mineral density (BMD, 
gm/cm2), personal history of benign prostatic hypertrophy (BPH) or prostatitis (“yes” or “ no”),   
and family history of prostate cancer (“yes” or “no”), using the chi-square test for categorical 
variables, and the t-test for continuous variables.  
We compared genotype frequencies at each locus by case-control status, according to 
race, using the chi-square test. Our analyses of the association of each inflammatory gene marker 
and prostate cancer were based on genotype and trend chi-square tests. We assumed a dominant 
model of inheritance to evaluate the magnitude of association (OR, and 95% CI) between 
genotype and prostate cancer. Race- and age- stratified conditional logistic regression models 
(unadjusted and adjusted) were fitted to assess the association of each marker and prostate 
cancer, by race, and for all subjects.  Age stratification was based on the following age categories 
(40-54y, 55-59y, 60-64y, and 65-80y). Each conditional logistic regression model was adjusted 
for  the following risk factors individually: personal history of BPH or prostatitis, family (father, 
brother, or half brother) history of prostate cancer, BMI ( based on race-specific tertile cutpoints 
in the control groups: Blacks – 27.8 and 32.0 kg/m2;  Whites – 26.83 and 30.59 kg/m2 ), and 
BMD (based on race-specific tertile cutpoints in the control groups: Blacks – 1.005 and 1.124 
gm/cm2;  Whites – 0.972 and 1.070 gm/cm2 ). Race-specific haplotype blocks were constructed 
for IL-1A, IL-1B, IL-1RN, IL-6 and IL-6R genes in Haploview 4.1284.  Definition of haplotype 
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blocks were based on pairwise measures of linkage disequilibrium (LD) as calculated by 
Haploview285.  Loci in strong LD were combined into haplotypes. Race-specific distributions of 
haplotype frequencies and their corresponding p-values were generated by Haploview, for each 
gene, by case-control status.  
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4.4 RESULTS 
Selected subject characteristics are shown in Table 4.1. A total of 558 men who enrolled in 
CAPS and whose blood samples were satisfactorily genotyped were included in our analyses. 
There were 113 AA (54 cases and 59 controls), and 445 Caucasians (218 cases and 227 
controls). Controls had a slightly higher body mass index (BMI) than cases, and were also 
slightly older, but these differences were not statistically significant.  A first degree relative with 
a history of prostate cancer was significantly associated with prostate cancer in both races. A 
personal medical history of benign prostatic hyperplasia (BPH) or prostatitis was statistically 
significantly higher among AA cases than controls, however, among Caucasians, it was 
statistically significantly lower in cases than controls. 
A list of IL-1A, IL-1B, IL-1RN, IL-6 and IL-6R SNPs that were genotyped is shown in 
Table 4.2. Genes are ordered according to chromosome and SNPs by position across the 
respective genes. Genotyping results for the 53 SNPs are shown for 558 AA and Caucasian 
subjects (Tables 4.3 to 4.5, and in the Appendix Tables A1.1 to A1.5). Race-specific 
distributions of control subjects with one or two copies of the variant allele at each locus are 
categorized by selected risk factors:  personal history of prostatitis or BPH, and family history of 
prostate cancer distributions are shown in Tables 4.3 and 4.4. Figures 4.1 to 4.5 show race-
specific haplotype block organization and corresponding haplotype frequencies for IL-1A, IL-1B, 
IL-1RN, IL-6 and IL-6R. Appendix Tables A1.1 to A1.5 show race-specific distributions of 
control subjects homozygous or heterozygous for the variant allele at each of the 53 loci in 
relation to the following risk factors: age, height, weight, BMI, and BMD. 
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4.4.1 IL-1 genes and selected risk factors in controls 
A personal history of BPH or prostatitis was significantly less common among AA controls 
heterozygous or homozygous for the variant alleles at three IL-1RN SNPs (rs452204, rs425019, 
and rs9005) compared to AA controls homozygous for the common allele (Table 3). African 
American controls heterozygous or homozygous for the variant (T) allele at IL-1A-rs20540 
weighed significantly less, and had a significantly lower BMI than non-carriers (Tables A1.3 and 
A1.4). No other significant associations were observed between IL-1 genes and selected risk 
factors in AA controls.  
A family history of prostate cancer was significantly more common among Caucasian 
controls heterozygous or homozygous for the variant alleles at three IL-1B SNPs (rs1143643, 
rs1143633 and rs1143630) compared to Caucasian controls homozygous for the common allele 
(Table 4.4). Two of these SNPs (rs1143643 and rs1143633) were in linkage disequilibrium (LD) 
with each other (r2=0.97) (Fig. 4.2). Caucasian controls heterozygous or homozygous for the 
variant allele (T) at IL-1A-rs2856838 had a significantly lower mean hip BMD than non-carriers 
(Table A1.5).  No other significant associations were observed between IL-1 genes and selected 
risk factors in Caucasian controls.  
4.4.2 Associations of IL-1 markers and prostate cancer 
A greater proportion of AA cases (0.72) than controls (0.61) were homozygous for the common 
allele (G) at IL-1A-rs17561, but the difference was not statistically significant (Table 4.5). In 
Caucasians a slightly lesser proportion of cases (0.5) than controls (0.53) were homozygous for 
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the common allele at IL-1A-rs17561, but the difference was not statistically significant (Table 
4.5). The GG genotype of this particular marker up-regulates the protein encoded by the IL-1A 
gene. The common allele (C) at IL-1-B-rs1143634 was not significantly associated with prostate 
cancer in AA or Caucasians (Table 4.5). However, the (C) allele at this locus up-regulates IL-1B 
secretion, and was carried more commonly by AA controls (83%) compared to Caucasians 
control (80%). IL-1-B-rs1143634 was in strong pair-wise linkage disequilibrium with IL-1-B-
rs1143633 in Caucasians, Figure 4.2.   
Among AA increasing doses of the variant alleles were significantly associated with 
prostate cancer at two IL-1RN loci (rs432014 and rs9005, Table 4.5). In the dominant inheritance 
model the variant alleles of both of these SNPs were associated with a significantly decreased 
risk of prostate cancer in AA (Table 4.5).  In Caucasians, increasing doses of the variant alleles 
at three IL-1RN loci (IL-1RN-rs3181052, IL-1RN-rs2071459 and IL-1RN-rs4252019 were 
significantly associated with prostate cancer (Table 4.5). The variant alleles at each of these loci 
were significantly associated with an increased risk of prostate cancer in Caucasians (Table 4.5). 
IL-1RN-rs2071459 was in linkage disequilibrium with IL-1RN-rs3181052 (r2=0.92), Figure 4.3. 
Alleles from both of these SNPs were part of an IL-1RN haplotype (AGGTT). This haplotype 
was found more commonly in Caucasian prostate cancer cases (11.7%) than controls (8.1%), but 
the difference was not statistically significant (p = 0.765), Figure 4.3. 
4.4.3 IL-6 genes and selected risk factors in controls                                                       
A family history of prostate cancer was significantly less common among AA controls 
heterozygous or homozygous for the variant alleles at IL-6R-rs1554606 (Table 4.4) compared to 
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non-carriers. However, among AA controls, a significantly greater proportion of individuals 
heterozygous or homozygous for the variant allele at IL-6R-rs4393147 had a family history of 
prostate cancer compared to non-carriers (Table 4.4). Five IL-6R SNPs were significantly 
associated with anthropometric measures in AA controls heterozygous or homozygous for the 
variant alleles compared to non-carriers: weight (rs4845617 and rs11265610, Table A1.3), BMI 
(rs11265610 and rs4537545, Table A1.4), and BMD (rs4537545, Table A1.5). No other 
associations of IL-6 or IL-6R SNPs and selected risk factors were observed in AA controls. 
Caucasian controls heterozygous or homozygous for the variant allele at two IL-6 loci 
(rs1554606 and rs2069845) had a significantly higher mean BMD than non-carriers (Table 
A1.5).  These two SNPs were in strong pair-wise LD (r2=0.99), Figure 4.5. Seven IL-6R SNPs 
(rs4845618, rs7549338, rs4553185, rs4845626, rs11265618, rs10159236 and rs4329505) were 
all significantly associated with BMD in Caucasian controls heterozygous or homozygous for the 
variant alleles compared to non-carriers, (Table A1.5). Four of these SNPs   (rs4845626, 
rs11265618, rs10159236 and rs4329505) were in pair-wise LD with each other (r2 ≥ 0.90). No 
other IL-6 or IL-6R loci were associated with selected risk factors. 
4.4.4 Associations of IL-6 markers and prostate cancer 
Increasing doses of the variant allele (T) at IL-6R-rs4845626 was associated with decreased 
prostate cancer risk in AA (Table 4.5).  Individuals heterozygous or homozygous for the variant 
allele had a protective effect against prostate cancer in the dominant inheritance model, 
compared to non-carriers (Table 4.5).  No other statistically significant associations of IL-6 
markers and prostate cancer were noted in our dominant inheritance model in either race.   
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4.5 DISCUSSION 
We examined the associations of IL-1 and IL-6 gene polymorphisms and the risk of prostate 
cancer in AA and Caucasians. The current study was undertaken because recent studies have 
reported mounting evidence for potential associations of sequence variants of these pro-
inflammatory genes and prostate cancer21, 24 . Moreover, prostate cancer incidence and mortality 
rates have been consistently higher among AA than Caucasians for several decades1, 54. 
Furthermore, racial differences in immune modulating genes are well documented 277, and it has 
been suggested that such differences may influence disparities in clinical outcome between AA 
and Caucasians274. We sought to determine if genotypes of IL-1A, IL-1B, IL-1RN, IL-6 and IL-6R 
were associated with prostate cancer risk, as well as with selected risk factors, in the two racial 
groups. We found racial differences in the associations of SNPs of pro-inflammatory genes IL-1 
and IL-6 and prostate cancer, as well as with selected risk factors. Our findings support a 
growing body of evidence that chronic or recurrent inflammation play an important role in 
prostate carcinogenesis10-13, and the possibility of ethnic based differences in susceptibility. 
In the current study, several IL-1 SNPs were observed to be associated with prostate 
cancer, and also with selected risk factors. Interleukin-1A and IL-1B up-regulate the division of 
immune cells, as well as promote cell growth, differentiation and migration188. They also inhibit 
apoptosis and induce angiogenesis, thereby promoting tumor growth. Their action, however, is 
inhibited by the binding of the IL-1RN to the IL-1 receptor. Interleukin-1 and its related family 
members are primarily inflammatory cytokines, and are known to induce the release of 
cyclooxygenase-2 (COX-2), type 2 phospholipase A and inducible nitric oxide synthase  in 
inflammation187. This accounts for the large amount of prostaglandin-E2 (PGE-2), platelet 
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activating factor and nitric oxide  produced by cells exposed to IL-1 or in animals or humans 
injected with IL-1188. Additionally, IL-1 promotes the infiltration of inflammatory and 
immunocompetent cells into extravascular space by increasing the expression of adhesion 
molecule-1 on mesenchymal cells and vascular-cell adhesion molecule-1 on endothelial cells188.   
Since host response to inflammation (chronic or recurrent) is known to influence cancer 
development15, race or ethnicity based differential immune responses to inflammation may 
translate to differential cancer development in the given groups.   
 The GG polymorphism at IL-1A-rs17561 produces an alanine-to-serine amino acid 
substitution at codon 114 of the IL-1 cytokine protein and has been associated with an increased 
risk of atopy281.  In a recent study which compared differences in cytokine gene polymorphisms 
among healthy primiparous African American (N = 179) and Caucasian (N = 396) women 
seeking prenatal care prior to 20 weeks’ gestation in Pittsburgh, Pennsylvania, Ness et al 
reported that the up-regulating GG genotype at IL-1A-4845 (IL-1A-rs17561) was found in 59.7% 
of AA women compared to Caucasian women (47.3%)282. In the current study the GG genotype 
was found in 61% of AA men compared to 53% Caucasians. The (C) allele at IL-1B-rs1143634 
has been associated with an increased secretion of IL-1B in activated macrophages in vitro283. 
Ness et al reported that the (C) allele at IL-1B-3597 (rs1143634) was found in 86% of AA 
women compared to 77% in Caucasians282. In the current study the (C) allele was found in 
approximately 83% of AA men compared to 80% of Caucasians.     
We observed significant racial differences in the distribution of variant alleles of IL-1 and 
IL-6 SNPs (IL-1A 50%, IL-1B 60%, IL-1RN 64%, IL-6 71% and IL-6R 68%) in the current study. 
The extent to which these differences influenced prostate cancer risk in our cases is unclear, but 
we observed, for instance, that while a personal medical history of benign prostatic hypertrophy 
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(BPH) or prostatitis was significantly higher in AA cases than controls, it was significantly lower 
in Caucasian cases than controls (Table 4.1). A personal medical history of prostatitis has been 
reported by several studies to be associated with an increased risk of prostate cancer83, 84. We 
also observed noteworthy differences in the markers of association between the AA and 
Caucasians. The three IL-1RN SNPs (rs452204, rs4252019 and rs9005) that were associated with 
a personal history of BPH or prostatitis in controls showed significance exclusively in AA, 
whereas IL-1B SNPs (rs1143643, rs1143633 and rs1143630) showed significant associations 
with a family history of prostate cancer that were observed exclusively in Caucasian controls. IL-
1B-rs1143643 is involved in splicing regulation, and was in strong LD with rs11436633 (r2=97) 
in Caucasains. While we are not certain of the functional significance of all of the other markers, 
we find their polarizing racial predilection very striking. The variant allele of IL-1A-rs20540 was 
observed only in AA (5% of controls).  Caucasians were 100% homozygous for the common 
allele. IL-1A-rs20540 is a putatively functional SNP, involved in splicing regulation. No 
significant association of this marker and prostate cancer was observed in the dominant 
inheritance model. To our knowledge, this marker has not been reported in the literature as being 
associated with prostate cancer to date. 
Two IL-1RN SNPS (rs432014 and rs9005) were significantly associated with prostate 
cancer in AA. Three SNPs at IL-1RN (rs3181052, rs2071459 and rs425019) were significantly 
associated with prostate cancer in Caucasians in our dominant model. Two of these SNPs 
(rs3181052 and rs2071459) were in strong linkage disequilibrium (r2=0.97). The exact functions 
of these SNPs are not clearly known, but they are candidates with biological plausibility, being 
that they are clustered in highly conserved genomic regions in different vertebrate species 
(http://genome.ucsc.edu). Two IL-1RN haplotypes that were significantly associated with 
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prostate cancer in AA subjects (GG and AC) provided a protective effect against the disease; 
however, the single IL-1RN haplotype (TCG) that was significantly associated with prostate 
cancer in Caucasians increased the risk of disease.  We were unable to document an association 
of IL-1RN-rs315951 and prostate cancer, as reported by Lindmark et al21. In their study, 
rs315951 was one of four SNPs that formed a common haplotype which was strongly associated 
with prostate cancer21. 
Interleukin-1 is one of the most potent inducers of COX-2, which plays a key role in the 
inflammatory process188.  Aspirin and NSAIDs are known to exert their anti-inflammatory 
properties by selectively inhibiting the release of COX-2. We observed a high prevalence of 
ASA or NSAIDs use in our Caucasian subjects compared to AA. Among our controls 51% of 
Caucasians and 27% of AA used ASA or NSAIDs regularly. Similarly, in our cases 46% of 
Caucasians and 30% of AA used ASA or NSAIDs on a regular basis. Several population studies 
have reported a reduction in prostate cancer risk by regular use of ASA or NSAIDs91, 94, 144. If the 
pattern of ASA or NSAIDs use among men in our study in any way reflects the patterns of use 
among men in the general population, then this may imply that there is greater attenuation of the 
disease in Caucasians than AA from regular ASA or NSAIDs use, and may partly explain the 
differences in prostate cancer rates between the two racial groups.  
 IL-6R-rs4845626 showed the most significant association with prostate cancer 
(Ptrend=0.0022). The variant allele (T) at this marker was 3 times more likely to be carried by AA 
in our study than Caucasians. Individuals heterozygous or homozygous for the variant allele at 
this marker had a protective effect against prostate cancer compared to non-carriers, even after 
adjusting for a personal history of BPH or prostatitis in our conditional logistic regression model. 
The variant allele of another IL-6R SNP rs28730736 was carried by 15% of AA controls in our 
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study, but was absent in our Caucasian controls, who were 100% homozygous for the common 
allele. This is a functionally relevant SNP (missense), and is involved in splicing regulation. To 
our knowledge, this marker has not been reported in the literature as being associated with 
prostate cancer, to date. Among AA, one of the most commonly occurring haplotypes was IL-
6R-CC (Figure 4.5, block 4), and was associated with an increased risk of prostate cancer. The 
haplotype with the most significant association with prostate cancer was IL-6R-GG (Figure 4.5, 
block 2). This haplotype was found in AA, but it provided a protective effect against the disease. 
In the current study, we did not directly genotype IL6-174 (rs1800795), however one of the 
SNPs we genotyped, IL-6-rs1554606 was in pair-wise linkage disequilibrium with IL-6-174 
(r2=0.90). The *G allele of IL-6-174 up-regulates the production of IL-6 and has been reported 
by some studies to be carried more commonly by AA than Caucasians274, 282.   
We were unable to document an association of IL-6R-rs4329505 and prostate cancer, as 
reported by Zheng et al12. In their study of 9,275 SNPs in 1,086 genes in the inflammation 
pathway, IL-6-rs432905 was identified as one of 26 SNPs which were strongly associated with 
prostate cancer in the first stage of the study, but not in the confirmatory stage, where only three 
other SNPs showed association12. 
Interleukin-6 is involved in regulating immune and inflammatory responses154. In 
addition to inducing terminal differentiation of B-cells it synergizes with IL-1 in activating T-
cells by inducing IL-2 responsiveness, and enhances the differentiation of cytotoxic T 
lymphocytes from thymic precursors146, 155, 156. It has a central role in the acute-phase response, 
acting on hepatocytes to increase the synthesis of acute-phase proteins (haptoglobin, fibrinogen, 
C-reactive protein,etc) and reducing the secretion of albumin and transferein157. It also 
contributes to the body’s defenses by increasing the body temperature and stimulating the release 
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of adrenocoticotropin hormone158-160. Other functions include: impairment of natural killer cell 
function; induction of  bone resorption; stimulation of osteoclast formation; induction 
experimental cancer cachexia; induction of platelet-derived growth factor in blood vessels; 
enhancement of proliferation of vascular smooth muscle; negative inotropic effect on cardiac 
myocites; enhancement of secretion of chorionic gonadotrophin from trophoblasts154.  
Attention to the role of IL-6 in the pathogenesis of prostate cancer was drawn by the 
observation that the disease transitioned from an androgen-dependent tumor, initially responsive 
to androgen ablation therapy, to an untreatable androgen independent tumor60. In-vitro studies by 
Siegall at al showed that the androgen-independent prostate cancer cell lines DU145 and PC3 
and the androgen-dependent cell line LNCaP expressed IL-6R on their surfaces, and all three cell 
lines were susceptible to a chimeric Pseudomonas exotoxin-IL-6 toxin. Susceptibility was 
mediated by IL-6R as cytotoxic activity was blocked by in the presence excess human 
recombinant IL-6172. Since then, the expression of mRNA for IL-6R and the gp130 signal 
transducer has been confirmed in human prostate cancer by several other investigators172-174.  
Furthermore, recent in-vitro studies have shown that IL-6 initiates and promotes prostate 
tumorigenesis by mediating cross-talk between stromal and epithelial cell of the prostate25. 
In the current study, we observed associations of IL-6 and IL-6R and several prostate 
cancer risk factors. Interleukin-6 and IL-6R were significantly associated height and weight in 
AA, but not Caucasians (Appendix, Tables A1.2 and A1.3). While tall stature has been reported 
by some studies as being associated with an increased risk of prostate cancer286-288, the 
association of weight and prostate cancer is not so clear. Additionally, of the 11 SNPs that 
showed associations with BMD two were IL-6 markers and the other eight were IL-6R markers 
(Appendix, Table A1.5). Several of these SNPs were in strong linkage disequilibrium with each 
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other in Caucasians. BMD has been reported by several studies to be associated with prostate 
cancer261, 263, 264. With the exception of IL-6R-rs4845618, all statistically significant associations 
of IL-6 SNPs with BMD in our study were observed exclusively in Caucasians.  
Our study had several limitations. We relied on self reporting of race, even though there 
is an approximately 7-20% admixture among African Americans, which may tend to decrease 
our observed race-specific associations. Our tag SNP panel was based on Phase II of the 
International HapMap project, and may not have captured a more comprehensive set of tag SNPs 
as provided in Phase III of the HapMap project. In spite of our best efforts to include a 
comprehensive set of markers in our study, there is always the possibility of excluding markers 
of true association.   
In spite of these limitations, our study has several strengths. It is one of the first to 
directly assess prostate cancer risk in AA and Caucasian men within the context of a 
comprehensive set of inflammatory cytokines.  It evaluated the associations of the inflammatory 
cytokines and commonly reported risk factors of prostate cancer in the two racial groups. It 
identified two putative functional SNPs (IL-1A-rs20540 and IL-6R- rs28730736) in which variant 
alleles were observed in AA, but not Caucasians. These two SNPs have not been previously 
reported in the literature as being associated with prostate cancer. Prostate cancer is a very 
complex disease, whose development may involve a combination of numerous risk factors under 
a wide variety of conditions. Therefore no given risk factor (s) may explain all the variability in 
the disease, and its susceptibility. We believe however, that the racial predilection of some of the 
makers identified in our study should prompt further investigation into the roles of some of these 
inflammatory cytokines in the development of the disease in both racial groups.  
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In conclusion, we found racial differences in the associations of inflammatory genes IL-1 
and IL-6 and prostate cancer, as well as with selected risk factors. These findings suggest 
differences in response to inflammation which may be ethnic or race based. Our findings also 
support a growing body of evidence that chronic or recurrent inflammation plays an important 
role in the development of prostate cancer10-13. The differences in genotype and haplotype 
frequencies between the two racial groups in themselves may not mean much if the variants 
involved are nonfunctional. Even though we are not certain of the exact functions of several of 
the SNPs that showed significant associations with prostate cancer in the current study, we are of 
the opinion that a number of them might be potentially functional, because they cluster in highly 
conserved regions of the genome in several vertebrate species. There is the possibility that the 
higher rates of prostate cancer in AA compared to Caucasians may be due to differential up-
regulation of cytokines that promote or sustain inflammation in AA compared to Caucasians.  
Future studies may want to consider examining the function of some of the SNPs identified in 
this study to be significantly associated with prostate cancer. Additionally, future studies may 
include a wide variety of markers which up-regulate pro-inflammatory cytokines in these two 
groups, as well as those with marginal effect on prostate cancer in order to determine 
susceptibility. Results from this study also suggest the need to closely examine the IL-1RN, as 
well as the IL-6R including its alpha- (gp80) and beta- (gp130) subunits in order to further 
understand some of the disparities noted between AA and Caucasians.  Understanding the role of 
IL-1 and IL-6 genes in the development of prostate cancer is of great public health significance 
because it will enable their possible use as biomarkers for early detection and prompt 
intervention, increase our understanding of the molecular biology of the disease, open up new 
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avenues for prevention and treatment, as well as explain some of the observed disparities in the 
disease. 
 
 
4.6 TABLES AND FIGURES 
Table 4.1 : General characteristics of CAPS subjects 
Attribute
Mean (SD) Mean (SD) p-value Mean (SD) Mean (SD) p-value Mean (SD) Mean (SD) p-value
Age  (yrs) 59.7 -7.7 61.1 -9.8 0.42 61 -6.5 61.1 -6.2 0.78 60.7 -6.8 61.1 -7.1 0.49
Height (cm) 177.3 -7.3 174.7 -5.3 0.04 176.1 (6.5)1 176.2 -6.3 0.84 176.3 (6.6)1 175.9 -6.1 0.44
Weight (kg) 93.8 -18.3 92 -17.1 0.58 87.8 (12.6)1 90.6 -15.5 0.04 89 (14.1)1 90.9 -15.8 0.14
BMI (kg/m2) 29.8 -5.2 30 -5 0.79 28.3 (3.5)1 29.1 -4.4 0.03 28.6 (4.0)1 29.3 -4.5 0.04
Hip BMD (gm/cm2) 1. 05 -0.16 1.08 -0.16 0.3276 1.01 -0.14 1.02 -0.14 0.1614 1.02 -0.14 1.04 -0.14 0.08
N (%) N (%) p-value N (%) N (%) p-value N (%) N (%) p-value
Father or brother with prostate 
cancer 9 -17 3 -5 0.05 41 -19 10 -4 <0.0001 50 -18 13 -5 <0.0001
Personal history of BPH or 
prostatitis 19 -35 10 -17 0.03 93 -43 128 -56 <0.01 112 -41 138 -48 0.09
Regular use of ASA or NSAIDS 16 -30 16 -27 0.73 101 -46 115 -51 0.36 117 -43 131 -46 0.51
1. Attribute information missing for one subject
N=54 N=59 N=218 N=227 N=272 N=286
Cases Controls Cases Controls Cases Controls
Black White All
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Chromosome Gene SNP identification number
Chr1 IL-6R rs4845617 rs6427641 rs11265610 rs12083537 rs1386821 rs4075015 rs4601580 rs4845618
rs7549338 rs7518199 rs4553185 rs4393147 rs4537545 rs4845626 rs28730736 rs11265618
rs10159236 rs4329505 rs4509570 rs2229238 rs4072391 rs4379670
Chr2 IL-1A rs3783590 rs2856836 rs17561 rs20540 rs2856838 rs1609682 rs3783526 rs2856837
Chr2 IL-1B rs1143643 rs1143634 rs1143633 rs3136558 rs1143630
Chr2 IL-1RN rs3181052 rs1794066 rs1794067 rs2071459 rs432014 rs380092 rs452204 rs4252019
rs315955 rs315951 rs9005
Chr7 IL-6 rs2069837 rs2069840 rs1554606 rs2069842 rs1548216 rs2069843 rs2069845
Genes are odered by chromosome.  SNPs are presented by position across the gene. SNPs (N=51) were selected from HapMap/Haploview
               using the Tagger approach, MAF > 0.8, r2 > 0.1 .  Two additional SNPs were selected from FastSNP
Chr - Chromosome; SNP - Single nucleotide polymorphism; IL-1A - Interleukin-1A; IL-1B - Interleukin-1B;
IL1RN - Interleukin-1 receptor antagonist; IL-6 - Interleukin-6; IL-6R - IL-6R
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Table 4.2 : SNPs included in genotyping analysis 
            Table 4.3 : Control subjects, number (N) with a personal history of BPH or prostatitis 
 
History of BPH or Prostatitis History of BPH or Prostatitis
No Yes No Yes
Locus % (N) % (N) Exact  p-value % (N) % (N) Exact p-value
IL1A
rs3783590 22.4 (49) 0.0 (10) 0.1827 0.0 (99) 0.8 (128) 1
rs2856836 40.8 (49) 30.0 (10) 0.7255 45.5 (99) 48.4 (128) 0.6899
rs17561 40.8 (49) 30.0 (10) 0.7225 45.5 (99) 48.4 (128) 0.6889
rs20540 12.2 (49) 0.0 (10) 0.5768 0.0 (99) 0.0 (128)
rs2856838 61.2 (49) 60.0 (10) 1 63.6 (99) 60.9 (128) 0.7827
rs1609682 34.7 (49) 50.0 (10) 0.477 55.1 (98) 56.7 (127) 0.8924
rs3783526 6.1 (49) 10.0 (10) 0.5345 54.5 (99) 56.3 (128) 0.8929
rs2856837 46.9 (49) 30.0 (10) 0.488 45.5 (99) 48.4 (128) 0.6889
IL1B
rs1143643 36.7 (49) 40.0 (10) 1 61.6 (99) 57.0 (128) 0.4996
rs1143634 32.7 (49) 20.0 (10) 0.708 32.7 (98) 40.2 (127) 0.2673
rs1143633 42.9 (49) 60.0 (10) 0.4881 61.6 (99) 57.5 (127) 0.5859
rs3136558 26.5 (49) 30.0 (10) 1 30.3 (99) 37.5 (128) 0.2642
rs1143630 46.9 (49) 50.0 (10) 1 17.2 (99) 8.6 (128) 0.0665
IL1RN
rs3181052 28.6 (49) 20.0 (10) 0.7128 12.2 (98) 16.4 (128) 0.4492
rs1794066 63.3 (49) 40.0 (10) 0.2892 61.6 (99) 66.1 (127) 0.8935
rs1794067 53.1 (49) 40.0 (10) 0.5062 52.5 (99) 53.9 (128)
rs2071459 30.6 (49) 20.0 (10) 0.708 12.1 (99) 16.7 (126) 0.4481
rs432014 38.8 (49) 20.0 (10) 0.4699 52.5 (99) 53.9 (128) 0.8935
rs380092 87.8 (49) 100.0 (10) 0.5768 44.4 (99) 50.4 (125) 0.4199
rs452204 77.1 (48) 40.0 (10) 0.0499 * 61.6 (99) 65.6 (128) 0.5784
rs4252019 67.3 (49) 30.0 (10) 0.0373 * 15.2 (99) 16.4 (128) 0.856
rs315955 25.0 (48) 30.0 (10) 0.7082 0.0 (99) 0.0 (128)
rs315951 63.3 (49) 70.0 (10) 1 39.8 (98) 44.1 (127) 0.5865
rs9005 46.9 (49) 10.0 (10) 0.0376 * 54.5 (99) 58.6 (128) 0.5897
Black White
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             Table 4.3 (continued)  
History of BPH or Prostatitis History of BPH or Prostatitis
No Yes No Yes
Locus % (N) % (N) Exact  p-value % (N) % (N) Exact p-value
IL6
rs2069837 20.4 (49) 50.0 (10) 0.1037 13.1 (99) 14.1 (128) 1
rs2069840 24.5 (49) 10.0 (10) 0.4324 52.5 (99) 59.1 (127) 0.3466
rs1554606 57.1 (49) 50.0 (10) 0.7365 73.7 (99) 66.4 (128) 0.2479
rs2069842 8.2 (49) 0.0 (10) 1 0.0 (99) 0.0 (126)
rs1548216 28.6 (49) 30.0 (10) 1 6.1 (99) 1.6 (128) 0.0817
rs2069843 18.4 (49) 10.0 (10) 1 6.1 (99) 1.6 (128) 0.0817
rs2069845 55.1 (49) 50.0 (10) 1 73.7 (99) 65.3 (124) 0.192
IL6R
rs4845617 62.5 (48) 70.0 (10) 0.7333 61.6 (99) 64.1 (128) 0.7818
rs6427641 89.8 (49) 100.0 (10) 0.5768 64.6 (99) 70.3 (128) 0.392
rs1126561046.8 (47) 40.0 (10) 0.7412 0.0 (93) 0.0 (121)
rs1208353744.9 (49) 50.0 (10) 1 35.4 (99) 35.2 (128) 1
rs1386821 20.4 (49) 10.0 (10) 0.6697 33.3 (99) 32.0 (128) 0.8868
rs4075015 22.4 (49) 20.0 (10) 1 64.6 (99) 68.8 (128) 0.57
rs4601580 74.5 (47) 100.0 (10) 0.0997 59.6 (99) 67.2 (125) 0.2642
rs4845618 75.5 (49) 90.0 (10) 0.4324 71.7 (99) 69.5 (128) 0.7702
rs7549338 49.0 (49) 70.0 (10) 0.3056 69.7 (99) 67.2 (128) 0.7739
rs7518199 36.7 (49) 10.0 (10) 0.1446 70.7 (99) 67.2 (128) 0.6652
rs4553185 85.4 (48) 90.0 (10) 1 71.7 (99) 68.8 (128) 0.6632
rs4393147 22.9 (48) 0.0 (10) 0.1824 70.7 (99) 67.2 (128) 0.6652
rs4537545 87.8 (49) 80.0 (10) 0.6126 67.7 (99) 69.5 (128) 0.7747
rs4845626 77.6 (49) 60.0 (10) 0.257 28.3 (99) 32.8 (128) 0.4734
rs2873073628.6 (49) 30.0 (10) 1 0.0 (99) 0.0 (126)
rs1126561867.3 (49) 60.0 (10) 0.7809 28.3 (99) 33.6 (128) 0.4704
rs1015923640.8 (49) 40.0 (10) 1 26.3 (99) 32.0 (128) 0.3806
rs4329505 67.3 (49) 60.0 (10) 0.7209 26.3 (99) 31.3 (128) 0.4625
rs4509570 73.5 (49) 80.0 (10) 1 44.4 (99) 42.2 (128) 0.7875
rs2229238 30.6 (49) 30.0 (10) 1 38.4 (99) 32.8 (128) 0.4033
rs4072391 42.9 (49) 40.0 (10) 1 38.4 (99) 32.8 (128) 0.4033
rs4379670 30.6 (49) 30.0 (10) 1 38.4 (99) 32.8 (128) 0.4033
1. Fisher's Exact test with asterisk (*) to indicate p<0.05
Black White
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Table 4.4 : Control subjects, number (N) with and without a family  
     history of prostate cancer 
 
Family history of prostate cancer Family history of prostate cancer
No Yes No Yes
Locus % (N) % (N)  p-value % (N) % (N)  p-value [1]
IL1A
rs3783590 17.9 (56) 33.3 (3) 0.468 0.5 (217) 0.0 (10) 1
rs2856836 39.3 (56) 33.3 (3) 1 47.9 (217) 30.0 (10) 0.341
rs17561 39.3 (56) 33.3 (3) 1 47.9 (217) 30.0 (10) 0.341
rs20540 10.7 (56) 0.0 (3) 1 0.0 (217) 0.0 (10)
rs2856838 58.9 (56) 100.0 (3) 0.2741 61.3 (217) 80.0 (10) 0.3258
rs1609682 37.5 (56) 33.3 (3) 1 56.3 (215) 50.0 (10) 0.7522
rs3783526 5.4 (56) 33.3 (3) 0.193 55.8 (217) 50.0 (10) 0.7544
rs2856837 44.6 (56) 33.3 (3) 1 47.9 (217) 30.0 (10) 0.341
IL1B
rs1143643 35.7 (56) 66.7 (3) 0.5493 57.6 (217) 90.0 (10) 0.0503 *
rs1143634 30.4 (56) 33.3 (3) 1 37.7 (215) 20.0 (10) 0.3306
rs1143633 44.6 (56) 66.7 (3) 0.5881 57.9 (216) 90.0 (10) 0.0511 *
rs3136558 26.8 (56) 33.3 (3) 1 35.0 (217) 20.0 (10) 0.5004
rs1143630 48.2 (56) 33.3 (3) 1 11.1 (217) 40.0 (10) 0.0233 *
IL1RN
rs3181052 26.8 (56) 33.3 (3) 1 15.3 (216) 0.0 (10) 0.3647
rs1794066 57.1 (56) 100.0 (3) 0.2636 64.4 (216) 60.0 (10) 0.7484
rs1794067 51.8 (56) 33.3 (3) 0.612 53.0 (217) 60.0 (10) 0.754
rs2071459 28.6 (56) 33.3 (3) 1 15.3 (215) 0.0 (10) 0.3648
rs432014 33.9 (56) 66.7 (3) 0.2864 53.0 (217) 60.0 (10) 0.754
rs380092 89.3 (56) 100.0 (3) 1 48.6 (214) 30.0 (10) 0.3376
rs452204 69.1 (55) 100.0 (3) 1 64.1 (217) 60.0 (10) 0.7503
rs4252019 60.7 (56) 66.7 (3) 1 16.1 (217) 10.0 (10) 1
rs315955 27.3 (55) 0.0 (3) 0.561 0.0 (217) 0.0 (10)
rs315951 62.5 (56) 100.0 (3) 0.5459 42.3 (215) 40.0 (10) 1
rs9005 41.1 (56) 33.3 (3) 1 57.1 (217) 50.0 (10) 0.7491
Black White
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Family history of prostate cancer Family history of prostate cancer
No Yes No Yes
Locus % (N) % (N)  p-value % (N) % (N)  p-value [1]
IL6
rs2069837 25.0 (56) 33.3 (3) 1 13.4 (217) 20.0 (10) 0.6304
rs2069840 21.4 (56) 33.3 (3) 0.5331 57.4 (216) 30.0 (10) 0.109
rs1554606 58.9 (56) 0.0 (3) 0.08 68.7 (217) 90.0 (10) 0.2895
rs2069842 7.1 (56) 0.0 (3) 1 0.0 (215) 0.0 (10)
rs1548216 30.4 (56) 0.0 (3) 0.5498 3.2 (217) 10.0 (10) 0.3067
rs2069843 17.9 (56) 0.0 (3) 1 3.2 (217) 10.0 (10) 0.3067
rs2069845 57.1 (56) 0.0 (3) 0.09 68.1 (213) 90.0 (10) 0.1799
IL6R
rs4845617 61.8 (55) 100.0 (3) 0.5467 63.6 (217) 50.0 (10) 0.5051
rs6427641 91.1 (56) 100.0 (3) 1 67.7 (217) 70.0 (10) 1
rs11265610 47.3 (55) 0.0 (2) 0.495 0.0 (204) 0.0 (10)
rs12083537 44.6 (56) 66.7 (3) 0.5881 35.0 (217) 40.0 (10) 0.7446
Black White
Table 4.4 (continued) 
rs1386821 17.9 (56) 33.3 (3) 0.468 32.7 (217) 30.0 (10) 1
rs4075015 21.4 (56) 33.3 (3) 0.5331 66.8 (217) 70.0 (10) 1
rs4601580 79.6 (54) 66.7 (3) 0.515 63.1 (214) 80.0 (10) 0.3356
rs4845618 78.6 (56) 66.7 (3) 0.5331 70.0 (217) 80.0 (10) 0.7272
rs7549338 51.8 (56) 66.7 (3) 1 67.7 (217) 80.0 (10) 0.5098
rs7518199 30.4 (56) 66.7 (3) 0.2402 69.1 (217) 60.0 (10) 0.5084
rs4553185 87.3 (55) 66.7 (3) 0.3648 69.6 (217) 80.0 (10) 0.7271
rs4393147 16.4 (55) 66.7 (3) 0.0891 69.1 (217) 60.0 (10) 0.5084
rs4537545 87.5 (56) 66.7 (3) 0.3594 69.1 (217) 60.0 (10) 0.5084
rs4845626 76.8 (56) 33.3 (3) 0.1561 30.9 (217) 30.0 (10) 1
rs28730736 30.4 (56) 0.0 (3) 0.5498 0.0 (215) 0.0 (10)
rs11265618 67.9 (56) 33.3 (3) 0.263 31.3 (217) 30.0 (10) 1
rs10159236 41.1 (56) 33.3 (3) 1 29.5 (217) 30.0 (10) 1
rs4329505 67.9 (56) 33.3 (3) 0.263 29.0 (217) 30.0 (10) 1
rs4509570 76.8 (56) 33.3 (3) 0.1561 43.3 (217) 40.0 (10) 1
rs2229238 30.4 (56) 33.3 (3) 1 35.0 (217) 40.0 (10) 0.7446
rs4072391 42.9 (56) 33.3 (3) 1 35.0 (217) 40.0 (10) 0.7446
rs4379670 30.4 (56) 33.3 (3) 1 35.0 (217) 40.0 (10) 0.7446
1. Fisher's Exact test with asterisk (*) to indicate p<0.05  
Table 4.5 : Single SNPs (ordered by gene and marker position) and prostate cancer in cases and controls 
Gene variant Rare Common Case Control Global Trend OR CI Case Control Global Trend OR CI
IL1A
rs3783590 A T 1/11/42 0/11/48 0.5540 0.5026 1.25 0.50-3.12 0/1/217 0/1/226 0.9771 0.9771 1.04 0.06-16.8
rs2856836 C T 3/12/39 4/19/36 0.4436 0.2737 0.60 0.27-1.33 23/86/109 19/88/120 0.6871 0.4186 1.12 0.77-1.63
rs17561 T G 3/12/39 4/19/36 0.4436 0.2737 0.60 0.27-1.33 22/87/109 19/88/120 0.7513 0.4600 1.12 0.77-1.63
rs20540 T C 0/7/47 0/6/53 0.6420 0.6420 1.32 0.41-4.19 0/0/218 0/0/227
rs2856838 T C 8/22/24 7/29/23 0.6606 0.8456 0.80 0.38-1.69 43/96/79 35/106/86 0.4889 0.3784 1.07 0.73-1.58
rs1609682 C A 3/13/38 2/20/37 0.4772 0.6085 0.71 0.32-1.56 14/91/110 25/101/99 0.1369 0.0554 0.75 0.52-1.09
rs3783526 A G 0/6/48 1/3/55 0.3232 0.6666 1.72 0.46-6.45 15/92/111 25/101/101 0.2008 0.0847 0.77 0.53-1.12
rs2856837 T C 4/15/35 4/22/33 0.5587 0.4831 0.69 0.32-1.47 22/87/109 19/88/120 0.7513 0.4600 1.12 0.77-1.63
IL1B
rs1143643 A G 1/19/34 1/21/37 0.9972 0.9924 0.99 0.46-2.12 29/102/87 20/114/93 0.3106 0.3707 1.05 0.72-1.53
rs1143634 T C 1/17/36 2/16/41 0.7914 0.8971 1.14 0.52-2.51 12/78/127 8/75/142 0.4605 0.2346 1.21 0.83-1.78
rs1143633 A G 2/21/31 1/26/32 0.7185 0.9107 0.88 0.42-1.85 27/101/87 19/115/92 0.3387 0.4763 1.01 0.69-1.48
rs3136558 C T 2/16/36 0/16/43 0.3006 0.2946 1.34 0.60-3.01 9/78/131 7/71/149 0.4596 0.2142 1.27 0.86-1.87
rs1143630 A C 2/22/30 6/22/31 0.4068 0.4206 0.89 0.42-1.86 3/24/191 1/27/199 0.5602 0.7755 1.00 0.57-1.77
IL1RN
rs3181052 A G 2/20/32 2/14/43 0.2929 0.1798 1.85 0.84-4.07 2/49/165 4/29/193 0.0206 0.0486 * 1.81 1.11-2.94
rs1794066 G A 6/26/22 11/24/24 0.4919 0.5652 1.00 0.47-2.11 34/104/79 35/110/81 0.9876 0.9533 0.98 0.66-1.44
rs1794067 A G 3/13/38 4/26/29 0.0647 0.0510 0.41 0.19-0.88 16/86/114 19/102/106 0.4410 0.2420 0.78 0.54-1.14
rs2071459 T C 3/20/30 2/15/42 0.2725 0.1209 1.89 0.87-4.14 1/48/165 4/29/192 0.0161 0.0891 * 1.73 1.06-2.81
rs432014 C T 0/8/46 3/18/38 0.0247 0.0067 * 0.31 0.13-0.79 16/86/114 19/102/106 0.4410 0.2420 0.78 0.54-1.14
rs380092 T A 22/21/10 30/23/6 0.3668 0.1794 0.49 0.16-1.45 21/88/105 16/91/117 0.5636 0.3420 1.14 0.78-1.65
rs452204 A G 10/25/19 16/25/17 0.5080 0.2847 0.76 0.35-1.69 32/105/81 35/110/82 0.9633 0.7852 0.96 0.65-1.41
rs4252019 T C 9/22/23 7/29/23 0.6091 0.9270 0.86 0.41-1.83 4/52/162 5/31/191 0.0221 0.0318 * 1.83 1.15-2.93
rs315955 C G 1/6/45 1/14/43 0.2314 0.1602 0.45 0.17-1.20 0/0/218 0/0/227
rs315951 C G 12/22/20 10/28/21 0.7025 0.7799 0.94 0.44-2.02 20/79/119 13/82/130 0.3836 0.2724 1.14 0.78-1.66
rs9005 A G 1/10/43 6/18/35 0.0394 0.0110 * 0.37 0.16-0.87 24/86/107 23/106/98 0.3205 0.4086 0.78 0.54-1.14
Black White
Alleles Frequencies [1] Statistical tests [2] Dominant model [3] Frequencies [1] Statistical tests [2] Dominant model [3]
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Gene var
IL6
rs206
rs206
rs155
rs206
rs154
rs206
rs206
IL6R
rs484
rs642
rs112
rs120
rs138
rs407
rs460
rs484
rs754
rs751
rs455
rs439
rs453
rs484
rs287
rs112
rs101
rs432
rs450
rs222
rs407
rs437
Legend: 
1. Num
2. P-values for
3. Risk
iant Rare Common Case Control Global Trend OR CI Case Control Global Trend OR CI
9837 G A 0/10/44 2/13/44 0.3372 0.2409 0.67 0.27-1.64 0/25/193 2/29/196 0.3433 0.3547 0.82 0.47-1.44
9840 G C 1/12/41 2/11/46 0.8010 0.9569 1.12 0.47-2.70 33/98/86 30/97/99 0.6444 0.3557 1.19 0.81-1.73
4606 T G 5/29/19 9/24/26 0.3029 0.8502 1.41 0.66-3.02 35/110/73 44/114/69 0.5982 0.3269 0.87 0.58-1.29
9842 A G 0/7/46 1/3/55 0.2134 0.4579 2.09 0.58-7.60 0/2/212 0/0/225 0.1461 0.1461 5.31 0.25-111.
8216 C G 3/15/36 3/14/42 0.8714 0.6482 1.24 0.56-2.74 0/9/209 0/8/219 0.7396 0.7396 1.18 0.45-3.11
9843 A G 1/11/42 1/9/49 0.7717 0.5219 1.40 0.55-3.57 0/13/205 0/8/219 0.2251 0.2251 1.74 0.71-4.27
9845 G A 5/29/19 9/23/27 0.2330 0.7482 1.51 0.71-3.23 35/106/72 44/110/69 0.6268 0.3556 0.88 0.59-1.31
5617 A G 3/26/25 7/30/21 0.3511 0.1633 0.66 0.31-1.40 34/107/77 31/112/84 0.8290 0.5737 1.08 0.73-1.58
7641 G A 19/29/6 29/25/5 0.3241 0.1711 0.74 0.21-2.58 39/117/62 38/116/73 0.6936 0.4488 1.19 0.80-1.79
65610 C T 5/21/26 5/21/31 0.9005 0.6771 1.19 0.56-2.53 0/3/203 0/0/214 0.0764 0.0764 7.38 0.38-144.
83537 G A 6/18/30 6/21/32 0.9636 0.9765 0.95 0.45-1.99 7/81/128 12/68/147 0.1745 0.5270 1.26 0.86-1.86
6821 C A 1/14/39 2/9/48 0.3440 0.4141 1.68 0.69-4.07 6/79/133 10/64/153 0.1502 0.3698 1.32 0.90-1.95
5015 A T 0/16/38 0/13/46 0.3558 0.3558 1.49 0.64-3.48 35/110/71 40/112/75 0.9103 0.8486 1.01 0.68-1.50
1580 T A 19/22/12 20/25/12 0.9648 0.9535 0.91 0.37-2.25 39/103/71 43/100/81 0.7331 0.7764 1.13 0.76-1.68
5618 G T 13/26/15 18/28/13 0.6691 0.3705 0.73 0.31-1.73 38/112/68 37/123/67 0.8379 0.9319 0.92 0.62-1.38
9338 C G 8/25/21 4/27/28 0.3340 0.1801 1.42 0.67-3.00 36/108/73 36/119/72 0.8543 0.8534 0.92 0.62-1.36
8199 C A 5/22/27 3/16/40 0.1529 0.0621 2.11 0.98-4.52 28/113/77 30/126/71 0.6578 0.4735 0.83 0.56-1.24
3185 C T 16/28/9 17/33/8 0.8718 0.8529 0.78 0.28-2.20 38/110/70 36/123/68 0.7310 0.9276 0.90 0.60-1.35
3147 T C 3/15/36 1/10/47 0.1902 0.0686 2.14 0.90-5.08 28/113/77 30/126/71 0.6578 0.4735 0.83 0.56-1.24
7545 T C 16/31/7 25/26/8 0.3224 0.3323 1.05 0.35-3.13 30/115/71 35/121/71 0.8763 0.6193 0.93 0.62-1.39
5626 T G 2/27/25 12/32/15 0.0072 0.0022 * 0.40 0.18-0.87 10/65/143 6/64/157 0.4772 0.2910 1.18 0.79-1.75
30736 A G 1/14/38 1/16/42 0.9940 0.9729 0.98 0.43-2.22 0/0/214 0/0/225
65618 T C 2/26/26 9/30/20 0.0702 0.0321 0.55 0.26-1.18 10/66/142 6/65/156 0.4762 0.2903 1.18 0.79-1.75
59236 A C 0/15/39 2/22/35 0.1896 0.0939 0.56 0.25-1.24 8/62/146 6/61/160 0.7183 0.4383 1.14 0.77-1.71
9505 C T 6/22/26 10/29/20 0.2826 0.1230 0.55 0.26-1.18 8/62/148 6/60/161 0.7105 0.4235 1.15 0.77-1.73
9570 G C 10/34/10 15/29/15 0.3362 1.0000 1.50 0.61-3.70 9/84/123 12/86/129 0.8513 0.8246 1.00 0.68-1.45
9238 T C 3/22/29 1/17/41 0.1752 0.0625 1.96 0.91-4.24 4/72/142 9/71/147 0.3995 0.6254 0.98 0.67-1.45
2391 T C 8/22/24 6/19/34 0.3657 0.1743 1.70 0.81-3.58 4/73/141 9/71/147 0.3878 0.6902 1.00 0.68-1.48
9670 T A 3/22/29 1/17/41 0.1752 0.0625 1.96 0.91-4.24 5/71/142 9/71/147 0.5922 0.6924 0.98 0.67-1.45
OR odds ratio; CI 95% confidence interval
ber with two copies of the rare allele/Number with one copy of the rare allele/Number with no copies of the rare allele
 global test and trend test with an asterisk (*) to indicate genotype test p-value < 0.05 and trend test p-value < 0.10
 group has one or two copies and the reference group no copies of the rare allele
Black White
Alleles Frequencies [1] Statistical tests [2] Dominant model [3] Frequencies [1] Statistical tests [2] Dominant model [3]
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IL‐1A
Frequency
Gene Block Haplotype Case Control P value 
IL-1A 1 TGTAGC 0.417 0.385 0.33
TGCCAC 0.278 0.333 0.07
CTCAGT 0.298 0.278 0.5
White
Frequency
Gene Block Haplotype Case Control P value 
IL-1A 1 TG 0.833 0.771 0.24
Black CT 0.167 0.229 0.24
2 TAC 0.352 0.364 0.84
CAT 0.213 0.254 0.46
CAC 0.259 0.178 0.14
CCC 0.176 0.203 0.6
 
Figure 4.1: Haplotype block organization of IL-1A in Blacks and Whites (left), and the corresponding case-
control haplotype frequencies (right). 
  
 
Figures 4-1 to 4-5 show haplotypes observed in five genes and case-control haplotype frequencies, by race. 
Analyses were completed in Haploview 4.1 (Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and 
visualization of LD and Haplotype maps. Bioinformatics 2005;21:263-265), with default confidence interval 
method used to define haplotype blocks (Gabriel SB, Schaffner SF, Nguyen H et al. The structure of 
Haplotype blocks in the human genome. Science 2002; 296:2225-2229). Haplotype maps show R-squared 
values. Haplotype maps use shades between pink and red to indicate magnitude of D-prime (LOD≥2) and pale 
blue to indicate D-prime =1, (LOD<2).  
 
IL‐1B
Frequency
Gene Block Haplotype Case Control P value 
White IL-1B 1 GCG 0.398 0.455 0.09
ACA 0.365 0.337 0.39
GTG 0.233 0.202 0.26
Black
 
Figure 4.2 : Haplotype block organization of IL-1B in Blacks and Whites (left), and the corresponding case-
control haplotype frequencies in Whites (right). 
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IL‐1RN
Frequency
Gene Block Haplotype Case Control P value
IL-1RN 1 GAGCT 0.06 0.603 0.94
GGACC 0.271 0.308 0.21
AGGTT 0.117 0.081 0.08
2 CGG 0.417 0.426 0.78
CGA 0.309 0.335 0.41
CCG 0.138 0.149 0.6572
TCG 0.136 0.09 0.03
White
Frequency
Gene Block Haplotype Case Control P value
IL-1RN 1 GA 0.648 0.61 0.55
Black GG 0.13 0.237 0.04
AG 0.222 0.153 0.18
2 GC 0.583 0.507 0.25
AT 0.37 0.364 0.93
AC 0.046 0.128 0.03
Figure 4.3 : Haplotype block organization of IL-1RN in Blacks and Whites (left), and the corresponding case-
control haplotype frequencies (right). 
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IL‐6
Frequency
Gene Block Haplotype Case Control P value 
IL-6 1 ACTG 0.413 0.445 0.33
AGGA 0.379 0.347 0.32
ACGA 0.15 0.133 0.45
White GCGA 0.057 0.073 0.35
Frequency
Black Gene Block Haplotype Case Control P value 
IL-6 1 GGGGA 0.554 0.601 0.47
TGGGG 0.186 0.179 0.89
TGCAG 0.12 0.093 0.51
TGCGG 0.064 0.075 0.73
GAGGA 0.066 0.042 0.43
Figure 4.4 : Haplotype block organization of IL-6 in Blacks and Whites (left), and the corresponding case-
control haplotype frequencies (right). 
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 IL‐6R
Frequency
Gene Block Haplotype Case Control P value 
IL-6R 1 AAAA 0.413 0.418 0.89
GAAT 0.225 0.223 0.94
GGCT 0.203 0.178 0.33
AAAT 0.134 0.156 0.35
White GGAT 0.014 0.017 0.68
2 CACCC 0.409 0.408 0.98
GCTTT 0.381 0.399 0.58
GATCC 0.18 0.16 0.42
GACCT 0.011 0.009 0.69
3 GCCTCCCA 0.58 0.597 0.61
GCCTGTTT 0.181 0.196 0.57
TTACCCCA 0.179 0.159 0.42
GCCTGCCA 0.037 0.037 0.98
TTCTGCCA 0.014 0.009 0.49
Frequency
Gene Block Haplotype Case Control P value 
IL-6R 1 AA 0.722 0.72 0.97
GA 0.13 0.169 0.4
GC 0.148 0.11 0.39
2 GCA 0.38 0.297 0.19
Black TGA 0.222 0.271 0.39
TGC 0.296 0.186 0.05
GGA 0.102 0.246 0
3 CC 0.568 0.578 0.88
TC 0.238 0.319 0.18
TT 0.194 0.103 0.05
4 CC 0.722 0.593 0.04
TA 0.139 0.22 0.11
TC 0.139 0.186 0.33
5 CCA 0.648 0.737 0.15
TTT 0.259 0.161 0.07
CTA 0.093 0.102 0.82
 
Figure 4.5 : Haplotype block organization of IL-6R in Blacks and Whites (left), and the corresponding case-
control haplotype frequencies (right). 
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5.1 ABSTRACT 
Objective: To evaluate the association between bone mineral density (BMD) – a possible 
surrogate of cumulative exposure to inflammatory cytokines – and prostate cancer in African 
Americans and Caucasians. 
Method: We conducted a case-control study of 591 African-American and Caucasian men (287 
recently diagnosed cases, and 304 controls with normal prostate specific antigen (PSA) levels, 
and no history of prostate cancer). In the current study, we included men, aged 40-80y, who 
enrolled in the Cancer and Prostate Study (CAPS) between 2001 and 2006. Controls were 
frequency matched by age and race to cases. BMD of the total hip was obtained using dual X-ray 
absorptiometry (DXA) scan. All prostate cancer cases were confirmed histologically. We 
evaluated the association between total hip BMD and prostate cancer.  
Results: Mean ages of cases and controls were 60.7 years (standard deviation (SD), 6.7) and 
61.2 years (SD, 7.1) respectively. Mean body mass index (BMI) of cases was lower than 
controls, 28.5 kg/m2 (SD, 3.9) and 29.3 kg/m2 (SD, 4.5) respectively (p = 0.036). Mean BMD was 
lower in cases than controls, 1.017 gm/cm2 (SD 0.130) vs. 1.036 gm/cm2 (SD 0.140) (p = 0.10). 
A statistically significant inverse association was noted between hip BMD (continuous) and 
prostate cancer in a conditional logistic regression model (both races) adjusting for age, race and 
marital status (OR = 0.28, 95% confidence interval (CI) = 0.08 – 0.97, p = 0.045). A marginally 
significant inverse association between hip BMD (continuous) and prostate cancer was noted 
among Caucasians (OR = 0.26, 95% CI = 0.06 – 1.08, p = 0.063), but not AA  (OR = 0.41, 95% 
CI = 0.39 – 4.22, p = 0.450), adjusting for age and marital status.   
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Conclusion: Hip BMD is inversely associated with prostate cancer in this case-control study of 
African-American and Caucasian men, ages 40-80 years.  
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5.2 INTRODUCTION 
Prostate cancer is a major public health problem in the United States. It is the most common non-
skin cancer, and the second leading cause of cancer-related death among men in the United 
States1. African Americans have higher incidence and mortality rates than Caucasians1. 
Socioeconomic and hormonal differences are thought to be contributory factors2-4. However, the 
roles of inflammatory cytokines and bone mineral density in these two populations have not been 
comprehensively examined as part explanation for these disparities.  
Chronic or recurrent inflammation is known to increase the incidence of malignancies of 
the bladder, colon, endometrium, esophagus, liver, lung and pancreas5-9. Evidence from 
epidemiologic, genetic, molecular biology and histopathology studies have suggested a 
compelling role of inflammation in the development of prostate cancer 10-13. The precise 
mechanism by which inflammation causes cancer is not clearly understood, but it is thought that 
chronic or recurrent inflammation, which may be a result of immunological conditions, recurrent 
microbial infections, or chemical irritation, trigger the production of inflammatory cytokine 
mediators and genotoxic reactive oxygen radicals that increase cell proliferation and promote 
tumorigenesis 14. The likelihood of developing cancer may then be dependent upon precise host 
response to this inflammatory cascade 15. 
The inflammatory cytokines interleukin-1 (IL-1) and IL-6 have been reported to influence 
the initiation and progression of prostate cancer23-25. Additionally, these cytokines have been 
shown to decrease bone mineral density by resorption of bone matrix via osteoclast activity 29-32. 
Furthermore, serum levels of IL-1 and IL-6 have been reported to be associated with bone loss 33, 
34. Serum sex steroid hormone levels have been reported by some studies to be associated with 
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prostate cancer59, 219, but not by others40, 289.  Additionally, some224, 225 but not all40, 290 
epidemiologic studies have reported an association between a shorter length of the androgen 
receptor gene CAG repeat sequence and an increased risk of prostate cancer. This gene mediates 
the effect of testosterone and dihydrotestosterone (DHT) in androgen-responsive tissues291. 
Shorter CAG repeats have been reported to result in an increased transactivational activity of the 
androgen receptor. African Americans have been reported by some studies to have a shorter 
mean CAG repeat length than Caucasians292, 293.   
Androgens and estrogen play a major role in bone health, including bone development 
and the attainment of peak bone mass 294. The sexual dimorphism of the skeleton noted during 
adolescence is attributable to androgens295. Additionally, sex steroid hormones are involved in 
age-related bone loss294.  Estrogen deficiency is a major cause of bone loss during menopause296, 
however, this process is prevented or reversed by estrogen replacement therapy29. Free 
testosterone levels below the median has been reported to be an independent predictor of 
osteoporosis-related fractures and x-ray verified vertebral fractures in elderly men 297. Besides 
estrogen and testosterone, other hormones such as parathyroid hormone (PTH) and insulin-like 
growth factor 1 (IGF-1) influence bone mineral density by regulating the bone resorption 
activities of IL-1 and IL-635-39. Moreover, these same factors, as well as others, such as calcium, 
and vitamin D, are considered risk factors for prostate cancer 35, 39-44.  
Several studies have documented an association between BMD and cancer of the 
breast298, 299, endometrium300, and prostate261, 262. These studies have primarily assessed BMD as 
a proxy measurement of a lifetime exposure of specific organs to sex-steroid hormones, among 
others. Bone health is influenced by a variety of hormones, including estrogen and testosterone, 
whose bone-building ability is counteracted by the bone resorption activities of the inflammatory 
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cytokines IL-1 and IL-6. To ascertain the long term effect of serum levels of IL-1 and IL-6 on 
the pathogenesis of prostate cancer, there is the need to obtain serial measurements over many 
years, but this has been difficult, resulting in discrepant findings by various epidemiologic 
studies 26-28, 45. The purpose of this study, therefore, is to evaluate the relationship between bone 
mineral density (BMD), a possible surrogate of cumulative exposure to inflammatory cytokines 
IL-1 and IL-6, and prostate cancer in African Americans and Caucasians. We hypothesized that 
high BMD would be associated with prostate cancer in both racial groups. 
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5.3 MATERIALS AND METHODS 
5.3.1 Study sample 
Participants in the current study were from an existing prostate cancer study known as the 
Cancer and Prostate Study (CAPS). Briefly, CAPS was a case-control study designed to assess 
the individual and joint roles of bone mineral density (BMD) and sex hormone gene 
polymorphisms in prostate cancer risk. Enrollment into CAPS started in December of 2001 and 
was completed in January of 2006, and included Caucasian and African American (AA) men 
aged 40 to 80 years. Cases were men with recently diagnosed prostate cancer (within 3 months 
of enrollment into the study; confirmed diagnosis based on pathology report). Controls were men 
without a history of prostate cancer. All participants in CAPS gave informed consent. The study 
was approved by the institutional review boards (IRB) of the University of Pittsburgh and the 
University of Alabama at Birmingham. 
Potential enrollees were excluded if they used glucocorticoids (>6 months); used 
testosterone (>3 months); had a history of hyper- or hypothyroidism, hyperparathyroidism, renal 
disease or bone disease. Other exclusion criteria included bilateral hip replacement; kidney 
transplant; previous diagnosis of prostate cancer or any other cancer besides basal and squamous 
cell skin cancer; evidence of bone metastases among prostate cancer cases; and PSA levels above 
3.0 ng/ml among controls. Controls were frequency matched to cases by age and race. 
Participants in CAPS were recruited from Pittsburgh and Alabama. In Pittsburgh, 
recruitment was conducted at two sites: The University of Pittsburgh Medical Center (UPMC), 
and the Veterans Administration Medical Center (VA). Recruitment in Alabama was conducted 
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at the University of Alabama in Birmingham (UAB) Medical Center. A total of 591 Caucasian 
and African American men who enrolled in CAPS are included in our analysis. There were a 
total of 242 cases recruited at UPMC, all of who were referrals from one institution-based 
urology practice. Patients at this practice were mostly community-based residents from 
Pittsburgh, many of who were referred for specialty care by their primary care physicians.  All 
recruited cases from this urology practice underwent radical prostatectomy within 3 months of 
diagnosis. The urologist personally informed potential subjects about the study for the first time 
during their second post-operative follow-up visit. Interested men were then referred to the 
CAPS research team at UPMC for further study details and enrollment information. Controls 
from Pittsburgh numbered 253, and were recruited from the local community, as well as from the 
University of Pittsburgh employees, by sending out flyers. Participants were signed up in 
particular age groups and race in the order they called until the group was filled. Majority of the 
controls were from the ongoing Prostate, Lung, Colorectal, and Ovarian study (PLCO). A total of 
10 participants were recruited from the VA Medical Center in Pittsburgh, comprising of 3 cases 
and 7 controls.  
In Alabama, information about the CAPS study was advertised in the UAB Reporter. 
Additionally, flyers were sent out to local residents and University of Alabama employees, and 
brochures were placed in waiting rooms of Birmingham area urologist offices. Urologists at three 
community-based urology practices informed potential case subjects about the study, and then 
referred interested parties to an on-site study recruiter from UAB Medical Center, who provided 
detailed information about the study. A total of 42 cases were enrolled at UAB Medical Center, 
which included 41 referrals from the three community-based urology practices and one subject 
who was referred by word of mouth from another study participant. Forty-four community-based 
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controls were enrolled at the UAB Medical center, majority of who were from the ongoing 
PLCO trial. Other control enrollees included UAB employees, as well as local Birmingham 
residents who responded to advertisements and flyers.  
5.3.2 Assessment of bone mineral density 
All enrollees underwent measurement of total hip bone mineral density by Dual-energy X-ray 
Absorptiometry (DXA) using a Hologic QDR-4500A bone densitometer (Hologic Inc., Waltham 
MA). Quality control was assessed by daily quality control scans with a phantom provided by the 
manufacturer. All DXA scans were interpreted by one radiologist, and all results were recorded 
on a standard study form.  
5.3.3 Data analysis 
We analyzed our data using the following variables: age (40-49y, 50-59y, 60-69y, 70y+),  race 
(African-American and Caucasian),  education (less than high school, high school graduate, 
technical training or college), marital status (currently married, never or previously married), 
history of benign prostatic hyperplasia or prostatitis (yes or no), father or brother with a history 
of prostate cancer (yes or no), history of regular nonsteroidal anti-inflammatory drugs (NSAIDS) 
or aspirin use (yes or no). Regular aspirin or NSAIDS use was defined as taking these drugs at 
least five to seven days per week for the past twelve months. Variable information was obtained 
via interviewer-administered standardized questionnaire. Other variables included height, weight 
and body mass index (BMI, measured in kg/m2). Height and weight were measured directly by 
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research staff. Weight was measured in kilograms using a standard beam balance, and without 
shoes or heavy clothing. Height was measured in centimeters using a wall- mounted Harpenden 
stadiometer, without shoes, and at the peak of deep inspiration. The height and beam balance 
weight information on eight participants were either missing or incomplete: these measurements 
were therefore imputed using DXA estimates.  
We calculated the 25th, 50th, and 75th percentile hip BMD cut points in controls by race, 
and for all subjects. We assessed associations between selected risk factors and hip BMD 
quartiles in controls by race, and for all controls, using a chi-squared test for categorical 
variables. These risk factors included age, level of education, marital status, history of benign 
prostatic hyperplasia (BPH) or prostatitis, father or brother with history of prostate cancer, 
history of regular aspirin or NSAIDS use, weight, height, and BMI.  
Additionally, we evaluated associations between risk factors and prostate cancer, by race, 
and for all subjects using conditional logistic regression. To examine the relation between hip 
BMD (continuous) and prostate cancer, we fitted age-adjusted and multiply adjusted conditional 
logistic regression models. We also used conditional logistic regression to assess the relation 
between hip BMD (quartiles) and prostate cancer. Our considerations for statistical significance 
were based on a two-sided p-value of 0.05 or less.  
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5.4 RESULTS 
The mean ages of cases (n = 287) and controls (n = 304) were 60.7 years (SD, 6.7) and 61.2 
years (SD, 7.1) respectively. Mean body mass index (BMI) of cases was lower than controls, 
28.5 kg/m2 (SD, 3.9) and 29.3 kg/m2 (SD, 4.5) respectively (p = 0.036). Race-specific 
associations between risk factors and hip BMD in control subjects are shown in Table 5.1. The 
25th, 50th and 75th percentile hip BMD cut points are shown for AA, Caucasians, and all subjects. 
African Americans had higher cut points (0.975 gm/cm2, 1.055 gm/cm2, 1.171 gm/cm2) than 
Caucasians (0.932 gm/cm2, 1.023 gm/cm2, 1.113 gm/cm2). Marital status (currently married vs. 
never / previously married) was significantly associated with hip BMD in the race-combined 
group (p < 0.001), and in Caucasians (p < 0.001), but not in AA (p = 0.148). Hip BMD was 
significantly associated with weight (p=0.0029, AA, and p<0.0001, Caucasians) and BMI 
(p=0.0011, AA, and p<0.0001, Caucasians), but height was not (p= 0.1227 vs. p =0.0774 in AA 
and Caucasians respectively). Hip BMD appeared unrelated to age, education, history of BPH or 
prostatitis, father or brother with history of prostate cancer and aspirin or NSAID use in either 
racial group.   
Table 5.2 shows race-specific associations between risk factors and prostate cancer. 
Significant associations were noted between each of the following risk factors and prostate 
cancer in the race-combined group: marital status (p<.0001), father or brother with a history of 
prostate cancer (p<.0001), weight (p=0.0079), and BMI (p=0.0074). Similar associations were 
noted in Caucasians, but not in AA: marital status (p<.0001 vs. 0.2781), father or brother with a 
history of prostate cancer (p<.0001 vs. p= 0.0228), weight (p=0.0066 vs. p=0.0792), BMI 
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(p=0.0357 vs. p=0.1147). Mean BMD was lower in cases than controls, 1.017 gm/cm2 (SD, 
0.130) vs. 1.036 gm/cm2 (SD, 0.140) (p = 0.10).        
The relationship between hip BMD and prostate cancer was assessed using conditional 
logistic regression. Covariates in our multiply-adjusted model included age, race, educational 
level, marital status, history of BPH or prostatitis, father or brother with history of prostate 
cancer, body weight, height, BMI, and aspirin or NSAIDS use (Table 5.3). Separate models were 
fitted with hip BMD entered as a continuous, and as a categorical (quartile) variable. A 
statistically significant inverse association was noted between hip BMD and prostate cancer (all 
subjects), in the model in which hip BMD was entered as a continuous variable, adjusting for 
age, race, and marital status (OR = 0.28, 95% CI = 0.08 – 0.97, p = 0.045). The strengths of 
association between hip BMD (continuous) and prostate cancer (both races) were similar among 
older men (70 years or older, OR = 0.32, 95% CI = 0.01-8.63, p = 0.496) and younger men (<70 
years old, OR = 0.28, 95% CI = 0.07-1.06, p = 0.060), adjusting for race and marital status. 
Results in Caucasians were similar to those of both races combined among subjects in the 
highest hip BMD quartile after adjusting for marital-status (OR = 0.57, 95% CI = 0.33 -0.97, p 
=0.2254; vs. OR = 0.58, 95% CI = 0.36 – 0.93, p = 0.1061) respectively. Results were also 
similar in models in which hip BMD was entered as a continuous variable (OR = 0.25, 95% CI = 
0.06 – 1.08, p =0.0628; vs. OR = 0.28, 95% CI = 0.08 – 0.97, p = 0.0454) among Caucasians and 
both races combined respectively. The magnitude of association was different for AA, but the 
direction of association was the same. 
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5.5 DISCUSSION 
Our analyses suggest an inverse association between hip BMD and prostate cancer among 
participants in this case-control study of African-American and Caucasian men, ages 40-80 
years. However, statistical significance was only noted in the parsimonious model (all 
participants) in which BMD was entered as a continuous variable, adjusting for race, age, and 
marital status.  
Our results are consistent with the findings of Nelson et al., who reported an inverse 
association between BMD and prostate cancer risk in 2,769 men followed prospectively in the 
First National Health and Nutrition Examination Survey (NHANES I) Epidemiologic follow-up 
Study (NHEFS), but this association was not statistically significant 263. BMD of the hand was 
measured at a mean age of 49 years, after which participants were followed for approximately 19 
years for diagnosis of prostate cancer. Mean age at diagnosis of prostate cancer was not reported. 
There were 94 incident cases of prostate cancer, and the rate ratio for men in the highest quartile 
compared to the lowest was 0.72 (95% CI 0.38-1.38, P trend = 0.37) 263. Farhat et al. reported a 
statistically significant inverse association between BMD and prostate cancer in a cohort study of 
4,597 men aged 65 years and older, with no prior history of prostate cancer that were followed 
for an average of 5.2 years264. 
Contrary to these findings, Bunker et al reported an increased risk of prostate cancer with 
increasing BMD quartiles among men ages 60-79 years in a cross-sectional study of 1,725 Afro-
Caribbean men who were being screened for cancer in the Tobago Prostate Survey 261. In this 
study, prostate cancer risk among participants in the highest quartile of BMD was double that of 
those in the lowest quartile, independent of age and body mass index (OR 2.12, 95% CI 1.21-
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3.71, P for trend = 0.004)261. These results were consistent with the findings of Zhang et al, in a 
cohort study which assessed the relationship of bone mass and subsequent prostate cancer risk in 
1,012 Caucasian men in the Framingham study 262. There were 100 incident cases in the 
Framingham study, most of which were diagnosed at an older age (median age 75.2 years). 
Cortical bone mineral densities of the metacarpal bones were obtained at a mean participant age 
of 61 years. They reported an increased incidence of prostate cancer in the two higher age-
specific quartiles compared to the lowest quartile. The risk ratio for men in the highest quartile 
compared to the lowest was 1.6 (95% CI 0.9-3.0, P for trend =0.06) 262. McGlynn et al reported a 
significantly decreased risk of prostate cancer (standardized incident ratio [SIR] = 0.74 95% CI = 
0.54-0.98) in a cohort of 3,055 Danish men hospitalized with a diagnosis of osteoporosis301. 
Notably, subgroup analysis showed that the association was only significant in men 70 years or 
older (SIR = 0.62, 95% CI = 0.41-0.91), but not in men 69 years or younger (SIR = 0.97, 95% CI 
= 0.59-1.50)301. 
The cohort in NHANES was enrolled at a much younger age (mean age 49 years), 
bringing the mean age at the end of the 19 year follow-up period to approximately 68 years.  
Even though the median age at prostate cancer diagnosis was not reported in NHANES, it 
appears likely to be considerably less than the median age of 75.2 years reported by the 
Framingham study. Age is an important risk factor in prostate cancer development, as well as 
BMD determination; as one ages the risk of developing prostate cancer increases, but BMD 
decreases. Therefore, there is the possibility that the observed relation between BMD and 
prostate cancer risk reverses as one transitions from a younger to an older age group, which may 
represent shifting androgen to cytokine ratio with age.  
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Previous studies261, 262, 301 appear to suggest an association between high testosterone 
levels and prostate cancer risk, because men with higher BMD, as reported by these studies, are 
also likely to have higher testosterone levels. An association between high levels of testosterone 
and prostate cancer has been reported by some studies59, 219, 225, but not others40, 302. Testosterone 
and estrogen maintain bone homeostasis by counteracting the bone resorption activities of 
inflammatory cytokines such as IL-1 and IL-6.  The major factor driving low BMD is an 
imbalance in bone resorption which exceeds bone formation; this occurs due to excessive bone 
resorption activity of osteoclasts 30. The inflammatory cytokines IL-1 and IL-6 play a central role 
in bone turnover by stimulating osteoclastogenesis30 266. The bioactivity of IL-1 and IL-6 may be 
potentially modified by sex-steroid hormones29. For example, decreasing BMD in aging men due 
to subnormal testosterone levels can be reversed with testosterone treatment303. Similarly, the 
accelerated rate of bone loss in aging women can be decelerated by administration of estrogen 29.  
The reversal of bone loss in these instances are likely a direct result of the counteractive effect of 
these sex-steroid hormones on the bone resorption activities of inflammatory cytokines such as 
IL-1 and IL-629, 30, among other factors. Furthermore, several studies have reported an 
association of sequence variants of these inflammatory cytokines and bone mineral density38, 257, 
265, 267. Besides their roles in bone resorption, IL-1 and IL-6 have been reported to influence the 
initiation and progression of prostate cancer23-25. These cytokines mediate the rapid development 
of prostate cancer, which starts as an androgen-dependent disease initially responsive to 
androgen ablation therapy, but which invariably progresses to an androgen-independent disease, 
which is refractory to treatment, and is characterized by recurrent growth and metastasis, 
predominantly to bone25, 114. 
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We report an inverse association between hip BMD (continuous) and prostate cancer in 
our case control study of African-American and Caucasian men ages 40-80 years. Our results did 
not change considerably when we examined the relation of hip BMD and prostate cancer in 
advanced age (70 years and older) versus younger age (69 years and younger), suggesting that 
sex-hormone levels may not be the dominating etiologic factor of prostate cancer in our sample. 
After adjusting for race, age and marital-status, we obtained results in the combined racial groups 
which approximated the results in Caucasians (BMD quartiles and continuous), implying that our 
overall results were possibly driven by Caucasians. Even though the magnitude of association 
was different in the two racial groups, the direction of association was the same, suggesting a 
transcendent commonality in the causative factors of prostate cancer in both Caucasians and AA 
in this study. 
 Besides the increasing bone resorption activities of IL-1 and IL-6 with age, another 
possible explanation for the inverse association between BMD and prostate cancer observed in 
this study may be vitamin D deficiency. Vitamin D is essential for bone health, and has also been 
associated with prostate cancer304. Low levels of vitamin D have been reported to be associated 
with a decrease in BMD305, as well as increase the risk of prostate cancer44.  Levels are reported 
to decrease with age306, 307, and are lower in AA compared to Caucasians305. We did not measure 
Vitamin D levels in our subjects, but it might be reasonable to speculate that the vitamin D levels 
in our AA and Caucasian subjects of mean age approximately 61 years, will be lower that the 
levels in the general population. The possibility exists that the rate of change of BMD over time 
(or “BMD velocity/deceleration”) may be a better predictor of the risk of disease, rather than an 
instantaneous measurement. A prospective study which assesses serial measurements of BMD, 
hormones such as androgen and estrogen, and cytokines will help elucidate this relationship, as 
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well as serve an important public health purpose to further help in identifying those at increased 
risk, in order to initiate early intervention.  
This study has several limitations. First, we relied on self-reporting of race in spite of the 
fact that 7-20% of African Americans have Caucasian admixture. Furthermore, a 
disproportionately higher number of Caucasians participated in the study compared to African 
Americans (79% versus 21%); therefore our statistical analysis for African Americans in this 
population may be underpowered. Our analysis was based on hip BMD; it is possible that BMD 
of other sites may provide a different outcome in regard to the association between BMD and 
prostate cancer. Among our cases, approximately 85% were married, and nearly 76% had a 
technical training or college background. A combination of these factors is likely to result in an 
increase in doctor visits due to availability of health insurance, or pressure from spouses to get 
medical check-up, which may lead to prostate cancer detection. This group is also apt to self 
select into ongoing research studies due to the likelihood of being more informed. 
There are also several strengths. The mean race-specific hip BMD measurements in our 
controls were similar to those reported by Leder et al308, thereby validating our sample 
externally. Additionally, all our case diagnoses were based on pathology report, reducing the 
likelihood of misclassification. Furthermore, case recruitment was restricted to those with early 
diagnosed prostate cancer (within 3 months of diagnosis) thereby limiting the likelihood of bone 
metastasis. Age and race frequency matching of cases to controls improved the comparability of 
the two groups.  
In conclusion we found an inverse association between hip BMD and prostate cancer in 
our case control study of African-American and Caucasian men ages 40-80 years. With a few 
exceptions, this finding was consistent in both races and across all models; however, statistical 
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significance was observed only in the age-, race- and marital status-adjusted parsimonious model 
(combined races) in which hip BMD was entered as a continuous variable. The long term effect 
of inflammatory cytokines on bone during the aging process needs to be carefully studied along 
with vitamin D status and hormonal factors in order to fully understand the relation between 
bone mineral density and prostate cancer. 
 
5.6 TABLES AND FIGURES 
Table 5.1 : Race-specific associations between risk factors and hip BMD in controls 
Attribute N
25th   
p-tile
50th   
p-tile
75th   
p-tile p-value N
25th   
p-tile
50th   
p-tile
75th   
p-tile p-value N
25th   
p-tile
50th   
p-tile
75th   
p-tile p-value
ALL 66 0.975 1.055 1.171 238 0.932 1.023 1.113 304 0.939 1.031 1.123
Age (years) 0.5197 0.6933 0.2582
40-49 8 1.031 1.119 1.206 7 1.006 1.048 1.090 15 1.006 1.065 1.171
50-59 18 0.956 1.044 1.094 89 0.956 1.023 1.094 107 0.956 1.023 1.094
60-69 31 0.959 1.061 1.199 121 0.921 1.031 1.134 152 0.923 1.037 1.141
70+ 9 0.983 1.005 1.181 21 0.904 1.001 1.101 30 0.923 1.003 1.135
Education 0.8413 0.4457 0.8349
Less than high school 9 0.990 1.005 1.058 5 0.929 0.932 0.972 14 0.959 0.993 1.058
High school graduate 14 0.974 1.052 1.129 39 0.893 1.044 1.135 53 0.919 1.044 1.131
Technical training or college 43 0.972 1.074 1.181 194 0.936 1.023 1.110 237 0.947 1.031 1.122
Marital status 0.148 <0.001 <0.001
Married 41 0.996 1.074 1.199 179 0.958 1.044 1.131 220 0.969 1.045 1.141
Other (never/previously married) 25 0.972 1.042 1.096 59 0.890 0.956 1.042 84 0.911 0.985 1.069
Note: p-value (Kruskall-Wallis)
Height missing for N=1 black control, weight missing  for N=1 black control, BMI missing for N=1 black control
The height and weight estimates of 3 controls with missing data points were based on DXA measurements 
Race-specific height quartile cut-points, blacks: 171.1, 174.1, 178.5 cm, white: 172.1, 176.2, 180.0 cm
Race-specific weight quartile cut-points, blacks:  78.4, 91.35, 102.5 kg, whites:  77.5, 89.35, 100. 0 kg
Black White All races
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Table 5.1 (continued) 
 
Attribute N
25th   
p-tile
50th   
p-tile
75th   
p-tile p-value N
25th   
p-tile
50th   
p-tile
75th   
p-tile p-value N
25th   
p-tile
50th   
p-tile
75th   
p-tile p-value
ALL 66 0.975 1.055 1.171 238 0.932 1.023 1.113 304 0.939 1.031 1.123
History of BPH or prostatitis 0.1123 0.5737 0.6849
Yes 12 1.030 1.109 1.264 132 0.936 1.023 1.124 144 0.937 1.033 1.132
No 54 0.974 1.044 1.156 106 0.931 1.023 1.108 160 0.951 1.029 1.113
Father or brother with prostate cancer 0.4357 0.8824 0.5866
Yes 4 1.029 1.079 1.228 11 0.929 1.045 1.094 15 0.936 1.045 1.096
No 62 0.974 1.049 1.171 227 0.932 1.023 1.116 289 0.940 1.028 1.124
Height 0.1227 0.0774 0.0110
Quartile 1 (low) 14 0.954 0.0.993 1.074 59 0.881 0.987 1.072 73 0.886 0.990 1.072
Quartile 2 18 1.016 1.093 1.290 61 0.925 1.032 1.131 79 0.951 1.052 1.139
Quartile 3 17 0.972 1.065 1.156 59 0.953 1.039 1.103 76 0.955 1.039 1.107
Quartile 4 (high) 17 0.997 1.046 1.171 59 0.975 1.025 1.139 76 0.976 1.039 1.149
Weight 0.0029 <.0001 <.0001
Quartile 1 (low) 18 0.901 0.978 1.022 59 0.867 0.938 1.041 77 0.876 0.951 1.037
Quartile 2 14 1.042 1.102 1.186 60 0.920 1.015 1.072 74 0.929 1.031 1.101
Quartile 3 17 0.974 1.065 1.156 59 0.975 1.032 1.139 76 0.975 1.046 1.141
Quartile 4 (high) 17 1.020 1.082 1.253 60 1.014 1.106 1.178 77 1.018 1.102 1.193
Body mass index (kg/m2) 0.0011 <.0001 <.0001
Normal (18.5-24.9) 12 0.900 0.964 0.999 43 0.875 0.951 1.041 55 0.878 0.956 1.021
Overweight (25.0-29.9) 21 0.996 1.084 1.199 110 0.922 1.016 1.079 131 0.929 1.025 1.097
Obese (30.0+) 33 1.016 1.082 1.171 85 0.988 1.068 1.169 118 0.997 1.072 1.171
Aspirin or NSAIDS 0.8685 0.6612 0.9384
   Yes 18 0.974 1.018 1.199 120 0.934 1.032 1.118 138 0.947 1.024 1.125
   No 48 0.987 1.063 1.164 118 0.931 1.016 1.108 166 0.938 1.038 1.121
Note: p-value (Kruskall-Wallis)
Height missing for N=1 black control, weight missing  for N=1 black control, BMI missing for N=1 black control
The height and weight estimates of 3 controls with missing data points were based on DXA measurements 
Race-specific height quartile cut-points, blacks: 171.1, 174.1, 178.5 cm, white: 172.1, 176.2, 180.0 cm
Race-specific weight quartile cut-points, blacks:  78.4, 91.35, 102.5 kg, whites:  77.5, 89.35, 100. 0 kg
Black White All races
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Attribute N % N % p-value N % N % p-value N % N % p-value
ALL 56 100.0 66 100.0 231 100.0 238 100.0 287 100.0 304 100.0
Age (years) 0.3579 0.9998 0.8900
40-49 5 8.9 8 12.1 7 3.0 7 2.9 12 4.2 15 4.9
50-59 22 39.3 18 27.3 86 37.2 89 37.4 108 37.6 107 35.2
60-69 19 33.9 31 47.0 118 51.1 121 50.8 137 47.7 152 50.0
70+ 10 17.9 9 13.6 20 8.7 21 8.8 30 10.5 30 9.9
Education 0.6088 0.9287 0.7952
Less than high school 8 14.3 9 13.6 4 1.7 5 2.1 12 4.2 14 4.6
High school graduate 16 28.6 14 21.2 40 17.3 39 16.4 56 19.5 53 17.4
Technical training or college 32 57.1 43 65.2 187 81.0 194 81.5 219 76.3 237 78.0
Marital status 0.2781 <.0001 <.0001
Married 40 71.4 41 62.1 208 90.0 179 75.2 248 86.4 220 72.4
Other (never/previously married) 16 28.6 25 37.9 23 10.0 59 24.8 39 13.6 84 27.6
History of BPH or prostatitis 0.0283 0.0026 0.0889
Yes 20 35.7 12 18.2 96 41.6 132 55.5 116 40.4 144 47.4
No 36 64.3 54 81.8 135 58.4 106 44.5 171 59.6 160 52.6
Father or brother with prostate cancer 0.0228 <.0001 <.0001
Yes 11 19.6 4 6.1 44 19.0 11 4.6 55 19.2 15 4.9
No 45 80.4 62 93.9 187 81.0 227 95.4 232 80.8 289 95.1
Height 0.0439 0.6240 0.2021
Quartile 1 (low) 13 23.2 14 21.2 63 27.3 59 24.8 76 26.5 73 24.0
Quartile 2 5 8.9 18 27.3 55 23.8 61 25.6 60 20.9 79 26.0
Quartile 3 14 25.0 17 25.8 48 20.8 59 24.8 62 21.6 76 25.0
Quartile 4 (high) 24 42.9 17 25.8 65 28.1 59 24.8 89 31.0 76 25.0
Weight 0.9390 0.0059 0.0064
Quartile 1 (low) 12 21.4 18 27.3 46 19.9 59 24.8 58 20.2 77 25.3
Quartile 2 17 30.4 14 21.2 91 39.4 60 25.2 108 37.6 74 24.3
Quartile 3 6 10.7 17 25.8 55 23.8 59 24.8 61 21.3 76 25.0
Quartile 4 (high) 21 37.5 17 25.8 39 16.9 60 25.2 60 20.9 77 25.3
Body mass index (kg/m2) 0.1230 0.0352 0.0053
Normal (18.5-24.9) 7 12.5 12 18.2 38 16.5 43 18.1 45 15.7 55 18.1
Overweight (25.0-29.9) 28 50.0 21 31.8 133 57.6 110 46.2 161 56.1 131 43.1
Obese (30.0+) 21 37.5 33 50.0 60 26.0 85 35.7 81 28.2 118 38.8
Total hip bone mineral density 0.1680 0.3666 0.2524
Quartile 1 (low) 19 33.9 16 24.2 66 28.6 59 24.8 85 29.6 75 24.7
Quartile 2 6 10.7 17 25.8 59 25.5 59 24.8 65 22.6 76 25.0
Quartile 3 17 30.4 16 24.2 63 27.3 60 25.2 80 27.9 76 25.0
Quartile 4 (high) 14 25.0 17 25.8 43 18.6 60 25.2 57 19.9 77 25.3
Aspirin or NSAIDS 0.7074 0.427 0.6527
   Yes 17 30.4 18 27.3 108 46.8 120 50.4 125 43.6 138 45.4
   No 39 69.6 48 72.7 123 53.2 118 49.6 162 56.4 166 54.6
Note: p-value (Wald test)
Uses conditional logistic regression
Blacks Whites All races
Cases Controls Cases Controls Cases Controls
Table 5.2 : Race-specific associations between risk factors and prostate cancer 
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Table 5.3 : Unadjusted and adjusted associations of hip BMD (quartiles and continuous) and prostate cancer, by race, and for 
     all subjects  
 
OR 95% CI OR 95% CI OR 95% CI  p-value OR 95% CI p-value
Blacks  (19/16)  (6/17) (17/16) (14/17)
Age-adjusted  0.26 0.08 - 0.82 1.08 0.41 - 2.86 0.78 0.29 - 2.08 0.0950 0.57 0.06 - 5.57 0.6248
Marital status-adjusted 0.24 0.07 - 0.78 1.13 0.42 - 3.03 0.63 0.22 - 1.76 0.0670 0.41 0.39 - 4.22 0.4504
Multiply adjusted  0.20 0.05 - 0.77 1.12 0.35-3.58 0.54 0.17 - 1.72 0.0611 0.11 0.01 - 2.09 0.1422
White (66/59)  (59/59) (63/60) (43/60)
Age-adjusted  0.89 0.54 - 1.48 0.94 0.57 - 1.55 0.64 0.38 - 1.09 0.3727 0.38 0.09 - 1.55 0.1748
Marital status-adjusted 0.82 0.49 - 1.38 0.8 0.47 - 1.34 0.57 0.33 - 0.97 0.2254 0.25 0.06 - 1.08 0.0628
Multiply adjusted  0.89 0.51 - 1.56 0.90 0.51 - 1.57 0.73 0.40 - 1.34 0.7930 0.45 0.09 - 2.32 0.3361
Both races (85/75)  (65/76) (80/76) (57/77)
Age-adjusted  0.74 0.47 -1.16 0.95 0.61 - 1.49 0.67 0.42 - 1.06 0.2435 0.42 0.13 - 1.40 0.1582
Marital status-adjusted 0.68 0.42 - 1.08 0.86 0.55 - 1.37 0.58 0.36 - 0.93 0.1061 0.28 0.08 - 0.97 0.0454
Multiply adjusted  0.66 0.40 - 1.08 0.90 0.55 - 1.44 0.64 0.38 - 1.07 0.2123 0.35 0.09 - 1.38 0.1341
Notes 
Hip BMD quartile cut-point are 0.975, 1.055, and 1.171 gm/cm2 for b lacks and 0.932, 1.023, and 1.113 gm/cm2 for whites. 
p-value -- statistical significance of Hip BMD quartile in logistic regression model (Wald test)
ORs  for analyses that model hip BMD as a continuous variable represent the relative odds of prostate cancer per one gm/cm2 chang in hip BMD
Uses conditional logistic regression
Age adjusment considers age in four categories (40-49, 50-59, 60-69, and 70+ year of age)
Multiply adjusted models adjusts for, education (three categories), marital status (two categories), history of BPH (two categories), 
history of prostatitis (two categories), 
family h istory of prostate cancer (two categories), body weight (continuous), height (continuous),
body mass index (continuous ) 
Hip BMD (gm/cm2)
Hip BMD quartile
Q1 Reference
Q2 Q3 Q4
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6.0  GENERAL DISUSSION 
We examined allele frequency distributions of polymorphisms in IL-1A, IL-1B, IL-1RN, IL-6 and 
IL-6 genes in African Americans and Caucasians. We also assessed the associations of genotypes 
of these inflammatory genes and the risk of prostate cancer in the two racial groups. 
Additionally, we evaluated the associations of bone mineral density and prostate cancer in our 
case control study of AA and Caucasian men ages 40 to 80 years old. The current study was 
undertaken because recent studies have reported mounting evidence for potential associations of 
sequence variants of these inflammatory genes and prostate cancer21, 24 . Furthermore, there have 
been recent reports of an association of BMD with prostate cancer; and IL-1 and IL-6 are known 
to decrease BMD by inducing osteoclasts to resorb bone. Prostate cancer incidence and mortality 
rates have been consistently higher among AA than Caucasians for several decades1, 54. 
Furthermore, racial differences in immune modulating genes are well documented 277, and it has 
been suggested that such differences may influence disparities in clinical outcome between AA 
and Caucasians274. We sought to determine if genotypes of IL-1A, IL-1B, IL-1RN, IL-6 and IL-6R 
were associated with prostate cancer risk, as well as with selected risk factors, in the two racial 
groups. We found racial differences in MAFs, as well as in the associations of SNPs of 
inflammatory genes IL-1 and IL-6 and prostate cancer. We also found an inverse association of 
BMD and prostate cancer in both racial groups. Our findings support a growing body of evidence 
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that chronic or recurrent inflammation play an important role in prostate carcinogenesis10-13, and 
the possibility of ethnic based differences in susceptibility.  
6.1 PAPER #1 
In our first aim we assessed allele frequencies of inflammatory cytokines IL-1 and IL6 
gene polymorphisms to determine if there were differences between African American and 
Caucasian men without prostate cancer. We compared MAFs of inflammatory gene markers 
between AA and Caucasian controls. We found 50% or greater significant differences in the 
distribution of variant alleles in IL-1A, IL-1B, IL-1RN, IL-6 and IL-6R genes between the two 
racial groups. We also made race-specific comparisons of MAF of IL-1 and IL-6 gene markers 
between observed and HapMap reference groups and found that approximately 12% of MAFs 
were significantly different in our Black comparison group, but none in our White comparison 
group. These differences may reflect greater admixture in the African American population 
compared to Caucasians, and is an important consideration in disease susceptibility275, 276. 
Cytokine gene polymorphisms have been reported to influence disease susceptibility, severity 
and clinical outcome184, 277. Racial differences in the distribution of inflammatory marker allele 
frequencies have been reported to influence allograft rejection, and in rheumatoid arthritis 
development and response to treatment 274, 278-280.  Inter-ethnicity differences in the frequencies 
of cytokine gene variants are well document, and the extent to which these differences 
influenced disease in our subjects is unclear, but they may, to some degree, have served as a 
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basis for some of the differences in marker-disease and marker-risk factor associations we 
observed in our second specific aim.    
6.2 PAPER #2 
This part of our project examined the associations of IL-1 and IL-6 gene polymorphisms and the 
risk of prostate cancer in AA and Caucasians. We found racial differences in the associations of 
SNPs of pro-inflammatory genes IL-1 and IL-6 and prostate cancer, as well as with selected risk 
factors. Two IL-1RN markers (rs432014 and rs9005), and one IL-6R marker (rs4845626) were 
associated with prostate cancer in AA, but to these markers provided a protective effect against 
prostate cancer in African Americans homozygous or heterozygous for the variant allele. On the 
other hand, the markers that were significantly associated with prostate cancer in Caucasians (IL-
1RN-rs3181052, IL-1RN-rs2071459 and IL-1RN-rs4252019) all increased prostate cancer risk in 
this racial group. We observed that two of these SNPs (IL-1RN-rs3181052 and IL-1RN-
rs2071459) were associated with a higher risk of prostate cancer among AA than Caucasians; 
however, there were no statistically significant differences between AA individuals homozygous 
and heterozygous for the variant allele compared to non-carriers. 
 The overarching theme of markers of disease association in this study is that IL-1RN 
plays an important in the development of prostate cancer among our subjects. Of the six SNPs 
that were significantly associated with prostate cancer in our subjects five (83%) were IL-1RN 
SNPs. This underscores the important role of inflammation in prostate cancer development 
because IL-1RN is the natural inhibitor of the pro-inflammatory genes IL-1A and IL-1B188, and 
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therefore certain polymorphisms in the gene which may impair its normal activities may result in 
disease. Polymorphisms in IL-1RN have been reported to be associated with bladder cancer309, 
BPH310 and several other cancers311. Additionally, IL-1RN has been used to treat melanoma311.  
In our specific first specific aim (paper one) we reported that MAFs of approximately 63% of IL-
1RN markers were significantly different between AA and Caucasians. There is a possibility that 
these differences partly explain the differences in disease associations observed in our second 
specific aim. We also observed an association of one IL-6R SNP with prostate cancer in AA, 
while several other IL-6R markers were significantly associated with BMD in Caucasians 
controls.  
6.3 PAPER #3 
In our third aim, we assessed the association of BMD and prostate cancer in our subjects. Our 
analyses suggested an inverse association of hip BMD and prostate cancer in our participants. 
Even though several of our results were not statistically significant, the inverse association was 
consistent across all our models. An inverse association of BMD and prostate cancer has been 
reported by some263, 264, but not all261, 262 epidemiologic studies. A possible explanation for the 
inverse association between BMD and prostate cancer observed in this study may be due to 
increased bone resorption activity of IL-1 and IL-6 which exceeds bone formation in our sample. 
In the current study nine IL-6 and IL-6R markers showed significant associations with BMD in 
Caucasian controls. One of these SNPs showed the strongest association with prostate cancer in 
AA individuals homozygous or heterozygous for the variant allele (IL-6R-rs4845625, Ptrend 
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=0.0022). This relationship underscores the important role of these inflammatory markers in 
BMD as well as prostate cancer. Another possible explanation could be vitamin D deficiency. 
Vitamin D is essential for bone health, and has also been associated with prostate cancer304. Low 
levels of vitamin D have been reported to be associated with a decrease in BMD305, as well as 
increase the risk of prostate cancer44.   
6.4 CONCLUSION 
In conclusion, the aggregate findings of these papers suggest that inflammation plays an 
important role in prostate cancer, and that differences in allele frequencies between AA and 
Caucasians may be partly influencing the observed disparities in prostate cancer rates between 
these two racial groups. These findings suggest differences in response to inflammation which 
may be ethnic or race based. Limitations of this study include relying on self reporting of race, 
even though there is an approximately 7-20% admixture among African Americans, which may 
tend to decrease our observed race-specific associations. Our tag SNP panel was based on Phase 
II of the International HapMap project, and may not have captured a more comprehensive set of 
tag SNPs as provided in Phase III of the HapMap project. In spite of our best efforts to include a 
comprehensive set of markers in our study, there is always the possibility of excluding markers 
of true association. Also, our analysis of BMD was based on hip BMD; it is possible that BMD 
of other sites may provide a different outcome in regard to the association between BMD and 
prostate cancer. Among our cases, approximately 85% were married, and nearly 76% had a 
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technical training or college background. This group is also apt to self select into ongoing 
research studies due to the likelihood of being more informed. 
In spite of these limitations, our study has several strengths. It is one of the first to 
directly assess prostate cancer risk in AA and Caucasian men within the context of a 
comprehensive set of inflammatory cytokines.  It evaluated the associations of the inflammatory 
cytokines and commonly reported risk factors of prostate cancer in the two racial groups. It 
identified two putative functional SNPs (IL-1A-rs20540 and IL-6R- rs28730736) in which variant 
alleles were observed in African Americans, but not Caucasians. We report race-specific mean 
hip BMD in our controls that corroborate those reported by Leder et. al.308, therefore our sample 
is validated externally. Additionally, all our case diagnoses were based on pathology report 
confirmed by one pathologist, there reducing the likelihood of misclassification. Furthermore, 
case recruitment was restricted to those with early diagnosed prostate cancer (within 3 months of 
diagnosis) thereby limiting the likelihood of bone metastasis. Age and race frequency matching 
of cases to controls improved the comparability of the two groups.  
6.5 FUTURE DIRECTIONS 
Future studies may want to closely examine the IL-1RN, as well as the IL-6R including its alpha- 
(gp80) and beta- (gp130) subunits in order to further understand some of the disparities noted 
between AA and Caucasians. Also, a prospective study which assesses serial measurements of 
BMD, hormones, and cytokines will help elucidate the role of inflammation in disease 
disparities. Understanding the role of IL-1 and IL-6 genes in the development of prostate cancer 
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is of great public health significance because it will enable their possible use as biomarkers for 
early detection and prompt intervention, increase our understanding of the molecular biology of 
the disease, open up new avenues for prevention and treatment, as well as explain some of the 
observed disparities in the disease.  
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  APPENDIX  
ASSOCIATIONS OF IL-1A, IL-1B, IL-1RN, IL-6 AND IL-6R POLYMORPHISMS AND 
SELECTED RISK FACTORS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subjects included Subjects excluded 
        (n = 558)         (n=35)
Attribute Mean SD Mean SD p-value
Age 60.9 6.9 61.7 6.8 0.5295
Height (cm) 176.1 6.4 176.4 6.7 0.7631
Weight (kg) 89.9 87.4 87.4 14.8 0.3313
BMI (kg/m2) 29.0 4.3 28.0 4.0 0.1806
Father or brother with history of prostate cancer,  n (%)
   Yes 63 90.0 7 10.0 0.1214
   No 495 94.7 28 5.4
Personal medical history of BPH or prostatitis, n(%)
   Yes 250 95.8 11 4.2 0.1221
   No 308 92.8 24 7.2
Note: Subject exclusion was based on poor sample quality or lack of sufficient samples for genotyping  
Table A1.1: Characteristics of subjects included and those excluded from genotyping analysis 
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Table A1.2 : Control subjects with and without a variant allele, number (N) and age 
                   (years, mean and standard deviation – SD), by locus and race 
 
Locus N Mean SD N Mean SD N Mean SD N Mean SD
IL1A
rs3783590 11 60.1 11.8 48 61.3 9.4 0.7175 1 80.0 226 61.1 6.1
rs2856836 23 61.4 9.9 36 60.9 9.9 0.8415 107 60.5 5.7 120 61.7 6.6 0.1455
rs17561 23 61.4 9.9 36 60.9 9.9 0.8415 107 60.5 5.7 120 61.7 6.6 0.1455
rs20540 6 54.7 8.1 53 61.8 9.8 0.0917
rs2856838 36 61.9 9.7 23 59.8 10.1 0.4257 141 61.5 6.2 86 60.6 6.2 0.3130
rs1609682 22 59.4 11.2 37 62.1 8.9 0.3206 126 60.9 6.0 99 61.4 6.4 0.5232
rs3783526 4 61.5 11.8 55 61.0 9.8 0.9282 126 60.9 6.1 101 61.4 6.4 0.5357
rs2856837 26 62.2 9.6 33 60.2 10.0 0.4549 107 60.5 5.7 120 61.7 6.6 0.1455
IL1B
rs1143643 22 64.1 9.5 37 59.2 9.6 0.0632 134 61.2 6.2 93 61.0 6.3 0.8128
rs1143634 18 62.2 9.2 41 60.6 10.1 0.5536 83 61.0 5.8 142 61.3 6.4 0.6915
rs1143633 27 63.4 9.8 32 59.1 9.5 0.0873 134 61.4 6.4 92 60.8 6.0 0.4863
rs3136558 16 63.5 8.4 43 60.2 10.2 0.2485 78 60.4 5.7 149 61.5 6.4 0.1871
rs1143630 28 61.0 9.9 31 61.2 9.9 0.9394 28 63.4 7.6 199 60.8 5.9 0.0442 *
IL1RN
rs3181052 16 60.3 9.3 43 61.4 10.1 0.6995 33 61.3 5.8 193 61.1 6.3 0.8926
rs1794066 35 60.5 10.1 24 62.0 9.5 0.5680 145 61.0 6.2 81 61.4 6.2 0.6334
rs1794067 30 62.2 9.4 29 59.9 10.3 0.3859 121 61.0 6.3 106 61.4 6.1 0.6063
rs2071459 17 60.8 9.3 42 61.2 10.1 0.8815 33 61.3 5.8 192 61.2 6.3 0.9212
rs432014 21 60.6 10.9 38 61.3 9.3 0.7964 121 61.0 6.3 106 61.4 6.1 0.6063
rs380092 53 60.9 9.8 6 62.5 10.3 0.7093 107 61.3 5.6 117 61.1 6.8 0.7831
rs452204 41 60.5 10.7 17 62.9 7.1 0.3958 145 61.0 6.2 82 61.4 6.2 0.6779
rs4252019 36 60.0 10.9 23 62.7 7.7 0.3122 36 60.9 6.4 191 61.2 6.2 0.7618
rs315955 15 61.1 9.8 43 61.0 10.0 0.9946
rs315951 38 60.4 9.5 21 62.2 10.5 0.5003 95 61.1 6.1 130 61.1 6.3 0.9686
rs9005 24 62.1 10.8 35 60.4 9.2 0.5147 129 60.9 6.1 98 61.5 6.3 0.4343
Controls with 
variant allele
Controls without 
variant allele
p-value [1] p-value [1]
Black White
Age Age Age Age
Controls with 
variant allele
Controls without 
variant allele
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Table A1.2 (continued) 
Locus N Mean SD N Mean SD N Mean SD N Mean SD
IL6
rs2069837 15 60.8 11.7 44 61.2 9.2 0.9038 31 61.0 6.2 196 61.2 6.2 0.9100
rs2069840 13 60.6 10.8 46 61.2 9.6 0.8524 127 61.4 5.8 99 60.8 6.8 0.4548
rs1554606 33 59.9 9.7 26 62.5 10.0 0.3106 158 61.1 6.4 69 61.3 5.9 0.7516
rs2069842 4 59.5 8.2 55 61.2 10.0 0.7436
rs1548216 17 62.4 9.6 42 60.5 9.9 0.5077 8 58.9 5.9 219 61.2 6.2 0.2924
rs2069843 10 61.6 10.2 49 61.0 9.8 0.8525 8 58.9 5.9 219 61.2 6.2 0.2924
rs2069845 32 60.2 9.6 27 62.1 10.1 0.4738 154 61.1 6.4 69 61.3 5.9 0.8050
IL6R
rs4845617 37 60.4 10.1 21 62.9 9.3 0.3529 143 61.4 6.4 84 60.7 5.8 0.3700
rs6427641 54 60.8 10.0 5 64.2 7.9 0.4601 154 61.4 6.3 73 60.6 6.0 0.3864
rs11265610 26 62.5 10.0 31 60.8 9.3 0.5279
rs12083537 27 61.0 9.6 32 61.1 10.1 0.9826 80 60.2 5.7 147 61.7 6.4 0.0934
rs1386821 11 56.3 11.1 48 62.2 9.3 0.0718 74 60.1 5.7 153 61.7 6.4 0.0787
rs4075015 13 65.2 5.7 46 59.9 10.4 0.0889 152 61.1 6.1 75 61.3 6.5 0.7898
rs4601580 45 61.9 10.0 12 59.6 9.3 0.4741 143 61.4 6.1 81 60.6 6.5 0.3608
rs4845618 46 60.7 10.4 13 62.2 7.8 0.6323 160 61.2 6.2 67 61.1 6.3 0.9064
rs7549338 31 61.6 10.2 28 60.5 9.5 0.6763 155 61.3 6.3 72 60.9 6.1 0.7007
rs7518199 19 58.7 10.1 40 62.2 9.6 0.2007 156 61.3 6.5 71 60.9 5.6 0.6353
rs4553185 50 61.5 10.2 8 59.8 6.9 0.6425 159 61.2 6.2 68 61.1 6.2 0.8856
rs4393147 11 58.0 9.8 47 62.0 9.7 0.2226 156 61.3 6.5 71 60.9 5.6 0.6353
rs4537545 51 61.1 10.0 8 60.9 9.2 0.9529 156 61.3 6.4 71 60.9 5.7 0.7022
rs4845626 44 60.5 9.9 15 62.6 9.7 0.4882 70 60.7 6.1 157 61.4 6.3 0.4259
rs28730736 17 64.3 8.9 42 59.8 9.9 0.1084
rs11265618 39 60.9 10.2 20 61.5 9.3 0.8324 71 60.6 6.1 156 61.4 6.3 0.4125
rs10159236 24 60.6 10.5 35 61.4 9.4 0.7563 67 60.8 6.2 160 61.3 6.2 0.5585
rs4329505 39 60.4 10.6 20 62.3 8.1 0.4942 66 60.8 6.2 161 61.3 6.2 0.5750
rs4509570 44 61.9 9.4 15 58.6 10.8 0.2626 98 61.4 5.7 129 60.9 6.6 0.5280
rs2229238 18 61.8 10.2 41 60.7 9.7 0.6947 80 61.4 5.8 147 61.0 6.4 0.6076
rs4072391 25 61.4 9.1 34 60.8 10.4 0.8050 80 61.4 5.8 147 61.0 6.4 0.6076
rs4379670 18 61.8 10.2 41 60.7 9.7 0.6947 80 61.4 5.8 147 61.0 6.4 0.6076
1. t-test with asterisk (*) to indicate p<0.05
Controls with 
variant allele
Controls without 
variant allele
p-value [1] p-value [1]
Black White
Age Age Age Age
Controls with 
variant allele
Controls without 
variant allele
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  Table A1.3 : Control subjects with and without a variant allele, number (N) and  
                    height (cm, mean and standard deviation – SD), by locus and race 
 
Locus N Mean SD N Mean SD N Mean SD N Mean SD
IL1A
rs3783590 10 174.8 5.9 46 174.4 4.9 0.8104 1 175.5 226 176.2 6.3
rs2856836 23 173.8 3.2 33 174.9 6.0 0.4517 107 176.0 5.9 120 176.3 6.6 0.7226
rs17561 23 173.8 3.2 33 174.9 6.0 0.4517 107 176.0 5.9 120 176.3 6.6 0.7226
rs20540 6 172.1 1.9 50 174.7 5.3 0.2294
rs2856838 34 174.2 5.6 22 174.8 4.2 0.7143 141 175.9 6.6 86 176.6 5.7 0.4006
rs1609682 20 175.6 5.3 36 173.8 4.9 0.2150 126 176.4 6.1 99 175.8 6.6 0.4453
rs3783526 4 175.4 2.6 52 174.4 5.2 0.7074 126 176.5 6.1 101 175.8 6.5 0.3701
rs2856837 26 173.5 3.3 30 175.3 6.1 0.1977 107 176.0 5.9 120 176.3 6.6 0.7226
IL1B
rs1143643 21 173.5 6.1 35 175.0 4.3 0.2711 134 176.3 6.9 93 176.0 5.3 0.7510
rs1143634 18 173.5 3.4 38 174.9 5.7 0.3230 83 176.1 5.7 142 176.3 6.6 0.8264
rs1143633 26 173.6 5.7 30 175.2 4.4 0.2570 134 176.5 6.9 92 175.8 5.3 0.4298
rs3136558 16 172.7 3.5 40 175.1 5.5 0.1060 78 176.0 6.0 149 176.3 6.4 0.6875
rs1143630 25 174.9 5.0 31 174.1 5.1 0.5352 28 175.4 5.5 199 176.3 6.4 0.4819
IL1RN
rs3181052 15 174.9 4.9 41 174.3 5.2 0.7051 33 175.3 6.2 193 176.4 6.3 0.3469
rs1794066 34 174.6 4.9 22 174.3 5.5 0.8213 145 176.2 5.8 81 176.1 7.1 0.9092
rs1794067 29 175.3 5.7 27 173.5 4.2 0.1826 121 176.4 5.7 106 176.0 6.9 0.6160
rs2071459 16 174.3 5.3 40 174.5 5.0 0.8939 33 175.3 6.2 192 176.4 6.3 0.3389
rs432014 21 175.0 5.1 35 174.1 5.1 0.5663 121 176.4 5.7 106 176.0 6.9 0.6160
rs380092 50 174.7 5.2 6 172.6 3.0 0.3489 107 176.5 6.8 117 176.0 5.8 0.5019
rs452204 40 174.3 4.8 15 174.9 6.0 0.6961 145 176.2 5.8 82 176.1 7.1 0.8597
rs4252019 35 174.7 5.0 21 174.1 5.3 0.6790 36 175.6 6.4 191 176.3 6.3 0.5732
rs315955 14 173.8 6.2 41 174.4 4.6 0.6996
rs315951 37 174.6 4.4 19 174.2 6.3 0.8261 95 176.2 6.9 130 176.1 5.8 0.9824
rs9005 23 174.3 5.2 33 174.5 5.1 0.9013 129 176.4 5.7 98 176.0 7.0 0.6481
Controls without 
variant allele
p-value [1] p-value [1]
Black White
Height Height Height Height
Controls with 
variant allele
Controls without 
variant allele
Controls with 
variant allele
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        Table A1.3 (continued) 
Locus N Mean SD N Mean SD N Mean SD N Mean SD
IL6
rs2069837 13 175.8 4.0 43 174.0 5.3 0.2700 31 177.6 6.4 196 176.0 6.2 0.1893
rs2069840 13 172.9 3.8 43 174.9 5.3 0.2025 127 176.3 6.5 99 176.2 5.9 0.9227
rs1554606 31 174.0 5.2 25 175.0 4.9 0.4779 158 176.4 6.2 69 175.8 6.4 0.5518
rs2069842 4 172.1 3.6 52 174.6 5.1 0.3510
rs1548216 15 173.9 6.7 41 174.6 4.4 0.6308 8 178.6 5.4 219 176.1 6.3 0.2635
rs2069843 9 173.6 7.2 47 174.6 4.6 0.5953 8 178.6 5.4 219 176.1 6.3 0.2635
rs2069845 30 174.1 5.3 26 174.9 4.8 0.5485 154 176.5 6.2 69 175.8 6.4 0.4749
IL6R
rs4845617 35 175.0 5.2 20 173.6 4.9 0.3498 143 176.0 6.2 84 176.5 6.3 0.5611
rs6427641 51 174.5 5.2 5 174.2 3.5 0.9174 154 176.0 6.2 73 176.6 6.5 0.5190
rs11265610 24 173.4 5.4 30 175.2 4.8 0.2154
rs12083537 26 174.1 5.7 30 174.7 4.6 0.6689 80 176.6 6.4 147 176.0 6.2 0.4929
rs1386821 11 174.9 6.3 45 174.3 4.8 0.7321 74 176.6 6.6 153 176.0 6.1 0.4445
rs4075015 13 174.0 4.4 43 174.6 5.3 0.7245 152 176.0 6.4 75 176.7 6.0 0.4326
rs4601580 42 175.0 5.4 12 172.8 3.6 0.1843 143 176.0 6.5 81 176.5 6.0 0.5888
rs4845618 44 174.4 4.6 12 174.6 6.8 0.8923 160 176.2 6.1 67 176.0 6.8 0.8160
rs7549338 29 174.4 3.8 27 174.5 6.2 0.9573 155 176.1 6.1 72 176.3 6.6 0.8522
rs7518199 19 173.7 4.4 37 174.8 5.4 0.4603 156 176.4 6.4 71 175.7 5.9 0.4267
rs4553185 48 174.2 4.7 7 176.6 7.6 0.2503 159 176.2 6.1 68 176.0 6.7 0.8153
rs4393147 11 174.5 5.0 44 174.5 5.2 0.9911 156 176.4 6.4 71 175.7 5.9 0.4267
rs4537545 48 174.7 5.3 8 172.8 3.3 0.3337 156 176.4 6.5 71 175.7 5.8 0.4109
rs4845626 43 174.8 5.1 13 173.3 4.9 0.3737 70 176.2 6.6 157 176.2 6.1 0.9688
rs28730736 15 172.3 6.0 41 175.2 4.5 0.0564
rs11265618 38 174.6 5.4 18 174.1 4.4 0.7587 71 176.2 6.6 156 176.2 6.1 0.9764
rs10159236 23 173.9 5.3 33 174.8 4.9 0.5217 67 175.9 6.6 160 176.3 6.1 0.6931
rs4329505 36 173.6 4.9 20 176.0 5.1 0.0977 66 175.9 6.7 161 176.3 6.1 0.6409
rs4509570 42 174.1 4.8 14 175.6 5.7 0.3178 98 177.0 6.1 129 175.6 6.4 0.1013
rs2229238 16 173.1 3.5 40 175.0 5.5 0.2161 80 177.2 6.0 147 175.7 6.4 0.0810
rs4072391 22 173.6 4.7 34 175.0 5.3 0.3299 80 177.2 6.0 147 175.7 6.4 0.0810
rs4379670 16 173.1 3.5 40 175.0 5.5 0.2161 80 177.2 6.0 147 175.7 6.4 0.0810
1. t-test with asterisk (*) to indicate p<0.05
Controls without 
variant allele
p-value [1] p-value [1]
Black White
Height Height Height Height
Controls with 
variant allele
Controls without 
variant allele
Controls with 
variant allele
 
 
 
 
 
 
 
 
 
 
147 
 
Table A1.4 : Control subjects with and without a variant allele, number (N) and  
     weight (kg, mean and standard deviation – SD), by locus and race 
 
Locus N Mean SD N Mean SD N Mean SD N Mean SD
IL1A
rs3783590 10 93.0 14.3 46 92.7 18.0 0.9654 1 80.8 226 90.6 15.6
rs2856836 23 92.8 15.5 33 92.7 18.7 0.9838 107 89.5 15.6 120 91.5 15.5 0.3343
rs17561 23 92.8 15.5 33 92.7 18.7 0.9838 107 89.5 15.6 120 91.5 15.5 0.3343
rs20540 6 77.8 6.8 50 94.6 17.3 0.0239 *
rs2856838 33 93.3 18.3 23 92.1 16.1 0.8093 141 90.9 15.8 86 90.0 15.2 0.6717
rs1609682 21 94.8 14.7 35 91.6 18.8 0.4981 126 90.6 14.6 99 90.5 16.9 0.9439
rs3783526 4 90.0 7.1 52 93.0 17.9 0.7420 126 90.6 14.6 101 90.5 16.7 0.9696
rs2856837 25 93.0 15.5 31 92.6 18.9 0.9189 107 89.5 15.6 120 91.5 15.5 0.3343
IL1B
rs1143643 20 91.0 20.8 36 93.8 15.2 0.5640 134 90.8 15.9 93 90.2 15.1 0.7822
rs1143634 18 93.2 14.0 38 92.6 18.8 0.8985 83 89.9 15.0 142 91.0 15.7 0.5938
rs1143633 25 91.5 20.7 31 93.8 14.3 0.6133 134 90.8 15.7 92 90.0 15.3 0.6857
rs3136558 15 94.1 19.5 41 92.3 16.7 0.7286 78 89.7 15.8 149 91.0 15.4 0.5464
rs1143630 26 93.2 14.0 30 92.5 20.0 0.8815 28 90.9 17.4 199 90.5 15.3 0.9044
IL1RN
rs3181052 14 88.9 15.5 42 94.1 17.9 0.3371 33 90.2 17.0 193 90.7 15.3 0.8562
rs1794066 33 90.8 15.4 23 95.7 19.7 0.3015 145 90.9 15.8 81 90.2 15.2 0.7561
rs1794067 29 96.2 16.8 27 89.1 17.4 0.1263 121 90.6 15.1 106 90.6 16.1 0.9983
rs2071459 15 87.6 15.7 41 94.7 17.7 0.1788 33 90.2 17.0 192 90.6 15.2 0.8656
rs432014 20 93.7 15.4 36 92.3 18.5 0.7643 121 90.6 15.1 106 90.6 16.1 0.9983
rs380092 50 92.7 18.1 6 93.5 8.8 0.9116 107 91.9 16.2 117 89.4 14.7 0.2250
rs452204 39 90.7 15.2 16 99.3 20.5 0.0933 145 90.6 15.7 82 90.5 15.3 0.9375
rs4252019 34 89.9 16.3 22 97.2 18.3 0.1219 36 89.8 17.5 191 90.7 15.2 0.7593
rs315955 15 93.6 18.6 40 92.9 17.0 0.8944
rs315951 37 92.7 18.9 19 93.0 14.1 0.9469 95 90.8 16.8 130 90.0 14.4 0.6823
rs9005 22 90.8 15.2 34 94.1 18.7 0.4857 129 91.4 14.9 98 89.5 16.4 0.3445
Controls without 
variant allele
p-value [1] p-value [1]
Black White
Weight Weight Weight Weight
Controls with 
variant allele
Controls without 
variant allele
Controls with 
variant allele
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        Table A1.4 (continued) 
Locus N Mean SD N Mean SD N Mean SD N Mean SD
IL6
rs2069837 13 95.3 15.8 43 92.0 17.8 0.5592 31 93.8 17.4 196 90.1 15.2 0.2107
rs2069840 13 86.5 15.2 43 94.7 17.6 0.1347 127 90.1 14.7 99 91.4 16.6 0.5213
rs1554606 31 90.3 15.7 25 95.8 19.0 0.2379 158 91.7 15.9 69 88.0 14.4 0.0943
rs2069842 4 81.9 19.9 52 93.6 17.0 0.1945
rs1548216 15 91.2 17.9 41 93.4 17.3 0.6855 8 83.9 16.9 219 90.8 15.5 0.2180
rs2069843 9 92.2 22.5 47 92.9 16.4 0.9069 8 83.9 16.9 219 90.8 15.5 0.2180
rs2069845 30 89.9 15.9 26 96.1 18.6 0.1894 154 91.8 15.9 69 88.0 14.4 0.0856
IL6R
rs4845617 35 96.4 18.9 20 86.0 12.3 0.0319 * 143 91.4 15.9 84 89.2 14.9 0.2998
rs6427641 51 92.8 18.0 5 92.9 9.1 0.9917 154 91.5 15.6 73 88.7 15.4 0.1995
rs11265610 25 85.7 16.5 29 98.7 15.8 0.0047 *
rs12083537 26 92.8 19.3 30 92.8 15.7 0.9907 80 93.3 15.5 147 89.1 15.4 0.0540
rs1386821 10 92.6 23.7 46 92.8 15.9 0.9759 74 93.1 16.0 153 89.3 15.2 0.0834
rs4075015 13 96.5 18.2 43 91.7 17.1 0.3876 152 89.9 15.7 75 91.9 15.1 0.3560
rs4601580 42 95.1 17.7 12 86.2 14.0 0.1164 143 89.3 15.0 81 92.7 16.4 0.1215
rs4845618 43 93.5 17.3 13 90.4 18.0 0.5784 160 89.7 15.2 67 92.7 16.3 0.1850
rs7549338 28 94.8 17.5 28 90.8 17.2 0.3845 155 89.4 15.2 72 93.0 16.1 0.1077
rs7518199 19 87.5 13.8 37 95.5 18.4 0.0997 156 91.4 15.8 71 88.8 14.9 0.2537
rs4553185 47 92.8 17.0 8 91.7 21.3 0.8712 159 89.6 15.1 68 92.8 16.4 0.1679
rs4393147 11 89.9 13.8 44 93.3 18.3 0.5606 156 91.4 15.8 71 88.8 14.9 0.2537
rs4537545 49 91.5 16.5 7 102.1 21.5 0.1308 156 91.1 15.6 71 89.4 15.4 0.4567
rs4845626 43 91.9 17.1 13 95.6 18.3 0.5137 70 92.4 14.9 157 89.8 15.8 0.2512
rs28730736 16 87.1 17.7 40 95.1 16.8 0.1179
rs11265618 38 91.7 17.7 18 95.1 16.7 0.4881 71 92.2 14.9 156 89.8 15.8 0.2841
rs10159236 23 93.1 18.0 33 92.6 17.1 0.9111 67 91.9 15.1 160 90.0 15.7 0.4047
rs4329505 37 90.4 17.2 19 97.5 17.0 0.1440 66 92.0 15.2 161 90.0 15.7 0.3628
rs4509570 41 92.1 16.6 15 94.5 19.5 0.6549 98 90.5 16.1 129 90.6 15.1 0.9786
rs2229238 15 89.7 17.3 41 93.9 17.4 0.4212 80 90.5 16.2 147 90.6 15.2 0.9326
rs4072391 22 91.0 18.6 34 93.9 16.6 0.5382 80 90.5 16.2 147 90.6 15.2 0.9326
rs4379670 15 89.7 17.3 41 93.9 17.4 0.4212 80 90.5 16.2 147 90.6 15.2 0.9326
1. t-test with asterisk (*) to indicate p<0.05
Controls without 
variant allele
p-value [1] p-value [1]
Black White
Weight Weight Weight Weight
Controls with 
variant allele
Controls without 
variant allele
Controls with 
variant allele
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Table A1.5 : Control subjects with and without a variant allele, number (N) and body mass index  
                  (BMI, kg/m2, mean and standard deviation – SD), by locus and race 
 
Locus N Mean SD N Mean SD N Mean SD N Mean SD
IL1A
rs3783590 10 30.3 3.6 45 30.1 5.2 0.9065 1 26.2 226 29.1 4.4
rs2856836 23 30.7 4.9 32 29.8 5.0 0.5030 107 28.8 4.2 120 29.4 4.5 0.3072
rs17561 23 30.7 4.9 32 29.8 5.0 0.5030 107 28.8 4.2 120 29.4 4.5 0.3072
rs20540 6 26.3 2.6 49 30.6 4.9 0.0412 *
rs2856838 33 30.5 5.3 22 29.6 4.3 0.4932 141 29.3 4.5 86 28.8 4.2 0.3553
rs1609682 20 30.2 3.8 35 30.1 5.5 0.9530 126 29.1 4.2 99 29.2 4.6 0.8368
rs3783526 4 29.2 1.5 51 30.2 5.1 0.6958 126 29.0 4.2 101 29.2 4.6 0.7551
rs2856837 25 30.8 4.9 30 29.6 5.0 0.3936 107 28.8 4.2 120 29.4 4.5 0.3072
IL1B
rs1143643 20 30.0 6.0 35 30.3 4.2 0.8401 134 29.2 4.4 93 29.1 4.3 0.8652
rs1143634 18 30.9 4.3 37 29.8 5.2 0.4229 83 28.9 4.0 142 29.3 4.6 0.5693
rs1143633 25 30.1 6.0 30 30.2 4.0 0.9457 134 29.1 4.4 92 29.0 4.3 0.9128
rs3136558 15 31.3 5.9 40 29.7 4.5 0.2808 78 28.9 4.2 149 29.2 4.5 0.5407
rs1143630 25 30.0 3.7 30 30.3 5.8 0.8157 28 29.5 5.2 199 29.1 4.3 0.6118
IL1RN
rs3181052 14 28.9 4.8 41 30.6 4.9 0.2623 33 29.3 4.7 193 29.1 4.3 0.8418
rs1794066 33 29.7 4.8 22 30.9 5.1 0.3701 145 29.2 4.4 81 29.1 4.4 0.8307
rs1794067 28 30.8 4.9 27 29.5 5.0 0.3106 121 29.0 4.2 106 29.2 4.6 0.7889
rs2071459 15 28.6 4.7 40 30.7 4.9 0.1630 33 29.3 4.7 192 29.1 4.3 0.8245
rs432014 20 30.5 4.8 35 30.0 5.0 0.7458 121 29.0 4.2 106 29.2 4.6 0.7889
rs380092 49 30.0 5.1 6 31.4 3.1 0.5128 107 29.4 4.5 117 28.8 4.2 0.3010
rs452204 39 29.8 4.7 15 31.7 5.2 0.1976 145 29.1 4.3 82 29.2 4.5 0.9312
rs4252019 34 29.3 5.0 21 31.5 4.7 0.1144 36 29.0 4.8 191 29.1 4.3 0.8842
rs315955 14 30.1 4.5 40 30.4 5.0 0.8492
rs315951 36 30.0 5.5 19 30.6 3.8 0.6647 95 29.2 4.6 130 29.0 4.2 0.7191
rs9005 22 29.7 4.7 33 30.5 5.1 0.5832 129 29.3 4.2 98 28.8 4.6 0.3774
Controls with 
variant allele
Controls without 
variant allele
p-value [1] p-value [1]
Black White
BMI BMI BMI BMI
Controls with 
variant allele
Controls without 
variant allele
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Table A1.5 (continued) 
Locus N Mean SD N Mean SD N Mean SD N Mean SD
IL6
rs2069837 13 30.8 4.6 42 30.0 5.1 0.6158 31 29.7 4.8 196 29.0 4.3 0.4383
rs2069840 13 28.9 4.5 42 30.6 5.0 0.2832 127 29.0 4.1 99 29.4 4.7 0.4678
rs1554606 30 29.3 4.6 25 31.1 5.2 0.1774 158 29.4 4.5 69 28.4 4.0 0.1001
rs2069842 4 27.6 6.4 51 30.4 4.8 0.2857
rs1548216 14 29.2 5.0 41 30.5 4.9 0.3920 8 26.2 4.0 219 29.2 4.4 0.0507
rs2069843 8 28.8 6.0 47 30.4 4.8 0.4068 8 26.2 4.0 219 29.2 4.4 0.0507
rs2069845 29 29.2 4.6 26 31.3 5.1 0.1169 154 29.4 4.5 69 28.4 4.0 0.1005
IL6R
rs4845617 34 31.0 5.3 20 28.5 3.9 0.0725 143 29.4 4.5 84 28.6 4.2 0.1558
rs6427641 50 30.1 5.1 5 30.6 3.0 0.8358 154 29.5 4.3 73 28.4 4.4 0.0831
rs11265610 24 27.9 4.3 29 32.0 4.7 0.0016 *
rs12083537 25 29.9 5.2 30 30.4 4.8 0.7482 80 29.8 4.2 147 28.7 4.4 0.0674
rs1386821 10 29.8 6.6 45 30.2 4.5 0.7903 74 29.8 4.3 153 28.8 4.4 0.1228
rs4075015 13 31.8 5.3 42 29.7 4.8 0.1754 152 29.0 4.4 75 29.4 4.3 0.4748
rs4601580 41 30.6 4.9 12 28.9 4.5 0.2734 143 28.8 4.2 81 29.7 4.7 0.1318
rs4845618 43 30.6 5.1 12 28.6 4.2 0.2210 160 28.8 4.3 67 29.8 4.5 0.1136
rs7549338 28 31.0 5.1 27 29.3 4.7 0.2092 155 28.8 4.3 72 29.9 4.5 0.0861
rs7518199 19 28.9 4.2 36 30.8 5.2 0.1845 156 29.3 4.4 71 28.7 4.3 0.3723
rs4553185 47 30.4 4.9 7 27.7 4.5 0.1764 159 28.8 4.3 68 29.9 4.6 0.0967
rs4393147 11 29.5 4.2 43 30.2 5.1 0.6640 156 29.3 4.4 71 28.7 4.3 0.3723
rs4537545 48 29.6 4.5 7 33.8 6.4 0.0373 * 156 29.2 4.4 71 28.9 4.4 0.6460
rs4845626 43 30.0 5.0 12 30.7 4.8 0.6568 70 29.7 4.2 157 28.9 4.5 0.1820
rs28730736 15 28.3 3.9 40 30.9 5.1 0.0879
rs11265618 38 30.0 5.1 17 30.6 4.5 0.6689 71 29.6 4.2 156 28.9 4.5 0.2224
rs10159236 23 30.7 5.5 32 29.8 4.5 0.4830 67 29.6 4.3 160 28.9 4.4 0.2470
rs4329505 36 29.6 5.0 19 31.3 4.8 0.2358 66 29.7 4.3 161 28.9 4.4 0.2025
rs4509570 41 30.3 4.8 14 29.9 5.4 0.7874 98 28.9 4.6 129 29.3 4.2 0.4294
rs2229238 15 29.7 5.1 40 30.3 4.9 0.6799 80 28.8 4.7 147 29.3 4.2 0.3825
rs4072391 21 29.4 4.8 34 30.6 5.0 0.3790 80 28.8 4.7 147 29.3 4.2 0.3825
rs4379670 15 29.7 5.1 40 30.3 4.9 0.6799 80 28.8 4.7 147 29.3 4.2 0.3825
1. t-test with asterisk (*) to indicate p<0.05
Controls with 
variant allele
Controls without 
variant allele
p-value [1] p-value [1]
Black White
BMI BMI BMI BMI
Controls with 
variant allele
Controls without 
variant allele
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Table A1.6 : Control s ubjects with and wi thout a va riant allele, number (N) and hip b one min eral densi ty 
(BMD, gm/cm2, mean and standard deviation – SD), by locus and race 
 
Locus N Mean SD N Mean SD N Mean SD N Mean SD
IL1A
rs3783590 11 1.08 0.10 48 1.08 0.17 0.9419 1 1.10 226 1.02 0.14 0.5773
rs2856836 23 1.08 0.18 36 1.08 0.15 0.9351 107 1.03 0.14 120 1.02 0.13 0.8505
rs17561 23 1.08 0.18 36 1.08 0.15 0.9351 107 1.03 0.14 120 1.02 0.13 0.8505
rs20540 6 1.03 0.13 53 1.09 0.16 0.4024
rs2856838 36 1.09 0.16 23 1.06 0.17 0.5113 141 1.01 0.14 86 1.05 0.13 0.0136 *
rs1609682 22 1.10 0.18 37 1.07 0.15 0.4384 126 1.03 0.13 99 1.01 0.15 0.3014
rs3783526 4 1.20 0.11 55 1.07 0.16 0.1321 126 1.03 0.13 101 1.01 0.15 0.2970
rs2856837 26 1.08 0.17 33 1.08 0.15 0.9379 107 1.03 0.14 120 1.02 0.13 0.8505
IL1B
rs1143643 22 1.10 0.18 37 1.07 0.15 0.5610 134 1.02 0.14 93 1.04 0.14 0.3550
rs1143634 18 1.06 0.16 41 1.09 0.16 0.4693 83 1.02 0.14 142 1.03 0.13 0.4790
rs1143633 27 1.07 0.18 32 1.08 0.15 0.8361 134 1.02 0.13 92 1.04 0.14 0.3290
rs3136558 16 1.05 0.14 43 1.09 0.17 0.4717 78 1.01 0.15 149 1.03 0.13 0.3962
rs1143630 28 1.10 0.15 31 1.06 0.17 0.4098 28 1.02 0.15 199 1.03 0.13 0.7290
IL1RN
rs3181052 16 1.02 0.15 43 1.10 0.16 0.0837 33 1.04 0.13 193 1.02 0.14 0.4790
rs1794066 35 1.07 0.16 24 1.10 0.16 0.4314 145 1.02 0.14 81 1.02 0.14 0.9872
rs1794067 30 1.08 0.16 29 1.07 0.17 0.7826 121 1.02 0.14 106 1.03 0.14 0.9768
rs2071459 17 1.03 0.15 42 1.10 0.16 0.1395 33 1.04 0.13 192 1.02 0.14 0.4843
rs432014 21 1.07 0.18 38 1.09 0.15 0.6628 121 1.02 0.14 106 1.03 0.14 0.9768
rs380092 53 1.09 0.16 6 1.02 0.14 0.3155 107 1.03 0.14 117 1.02 0.14 0.9135
rs452204 41 1.07 0.15 17 1.11 0.19 0.3524 145 1.02 0.14 82 1.03 0.14 0.9251
rs4252019 36 1.07 0.14 23 1.10 0.19 0.5155 36 1.03 0.13 191 1.02 0.14 0.7817
rs315955 15 1.09 0.10 43 1.08 0.18 0.8121
rs315951 38 1.09 0.18 21 1.05 0.12 0.3223 95 1.02 0.14 130 1.03 0.13 0.9878
rs9005 24 1.07 0.17 35 1.09 0.16 0.7122 129 1.03 0.13 98 1.02 0.14 0.7328
Controls without 
variant allele
p-value [1] p-value [1]
Black White
BMD BMD BMD BMD
Controls with 
variant allele
Controls without 
variant allele
Controls with 
variant allele
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Table A1.6 (continued) 
Locus N Mean SD N Mean SD N Mean SD N Mean SD
IL6
rs2069837 15 1.10 0.20 44 1.07 0.15 0.5069 31 1.04 0.14 196 1.02 0.14 0.5803
rs2069840 13 1.01 0.12 46 1.10 0.16 0.0667 127 1.02 0.13 99 1.03 0.14 0.3511
rs1554606 33 1.07 0.14 26 1.09 0.19 0.6230 158 1.04 0.13 69 1.00 0.14 0.0402 *
rs2069842 4 1.05 0.15 55 1.08 0.16 0.7135
rs1548216 17 1.07 0.15 42 1.08 0.16 0.8302 8 1.03 0.12 219 1.02 0.14 0.9421
rs2069843 10 1.10 0.17 49 1.07 0.16 0.6049 8 1.03 0.12 219 1.02 0.14 0.9421
rs2069845 32 1.07 0.14 27 1.09 0.18 0.6557 154 1.04 0.14 69 1.00 0.14 0.0425 *
IL6R
rs4845617 37 1.08 0.17 21 1.07 0.15 0.8154 143 1.03 0.14 84 1.01 0.13 0.2397
rs6427641 54 1.09 0.16 5 0.99 0.15 0.1883 154 1.03 0.14 73 1.01 0.13 0.1991
rs11265610 26 1.06 0.14 31 1.10 0.17 0.3645
rs12083537 27 1.09 0.15 32 1.07 0.17 0.6697 80 1.04 0.14 147 1.02 0.13 0.3436
rs1386821 11 1.09 0.14 48 1.08 0.17 0.7487 74 1.03 0.14 153 1.02 0.13 0.5086
rs4075015 13 1.14 0.21 46 1.06 0.14 0.1494 152 1.02 0.13 75 1.04 0.14 0.1398
rs4601580 45 1.09 0.17 12 1.06 0.12 0.5690 143 1.02 0.14 81 1.03 0.13 0.8321
rs4845618 46 1.09 0.17 13 1.04 0.12 0.2916 160 1.01 0.13 67 1.07 0.14 0.0022 *
rs7549338 31 1.10 0.18 28 1.06 0.13 0.4050 155 1.01 0.13 72 1.07 0.13 0.0022 *
rs7518199 19 1.03 0.12 40 1.10 0.17 0.0949 156 1.03 0.14 71 1.01 0.14 0.4475
rs4553185 50 1.08 0.17 8 1.10 0.14 0.7580 159 1.01 0.13 68 1.07 0.14 0.0017 *
rs4393147 11 1.03 0.16 47 1.09 0.16 0.2534 156 1.03 0.14 71 1.01 0.14 0.4475
rs4537545 51 1.06 0.14 8 1.21 0.23 0.0114 * 156 1.03 0.14 71 1.02 0.14 0.9153
rs4845626 44 1.08 0.13 15 1.08 0.23 0.9450 70 1.05 0.14 157 1.01 0.14 0.0409 *
rs28730736 17 1.06 0.15 42 1.09 0.16 0.4819
rs11265618 39 1.08 0.12 20 1.08 0.22 0.9086 71 1.05 0.13 156 1.01 0.14 0.0402 *
rs10159236 24 1.06 0.13 35 1.09 0.18 0.5247 67 1.05 0.14 160 1.01 0.13 0.0351 *
rs4329505 39 1.06 0.14 20 1.12 0.20 0.1697 66 1.05 0.14 161 1.01 0.13 0.0356 *
rs4509570 44 1.09 0.16 15 1.05 0.17 0.3564 98 1.01 0.14 129 1.04 0.13 0.0760
rs2229238 18 1.07 0.20 41 1.09 0.14 0.6752 80 1.00 0.14 147 1.04 0.13 0.1009
rs4072391 25 1.05 0.19 34 1.10 0.13 0.2153 80 1.00 0.14 147 1.04 0.13 0.1009
rs4379670 18 1.07 0.20 41 1.09 0.14 0.6752 80 1.00 0.14 147 1.04 0.13 0.1009
1. t-test with asterisk (*) to indicate p<0.05
Controls without 
variant allele
p-value [1] p-value [1]
Black White
BMD BMD BMD BMD
Controls with 
variant allele
Controls without 
variant allele
Controls with 
variant allele
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